Biological models of colorectal cancer metastasis and tumor suppression provide mechanistic insights to guide personalized care of the colorectal cancer patient by Smith, Jesse Joshua
BIOLOGICAL MODELS OF COLORECTAL CANCER METASTASIS AND TUMOR SUPPRESSION 
PROVIDE MECHANISTIC INSIGHTS TO GUIDE PERSONALIZED CARE OF THE COLORECTAL 
CANCER PATIENT 
By 
Jesse Joshua Smith 
 
Dissertation 
Submitted to the Faculty of the 
Graduate School of Vanderbilt University 
In partial fulfillment of the requirements 
For the degree of 
DOCTOR OF PHILOSOPHY 
In 
Cell and Developmental Biology 
May, 2010 
Nashville, Tennessee 
 
Approved: 
Professor R. Daniel Beauchamp 
Professor Robert J. Coffey 
Professor Mark deCaestecker 
Professor Ethan Lee 
Professor Steven K. Hanks 
  
 
 
 
 
 
 
 
 
Copyright  2010 by Jesse Joshua Smith
All Rights Reserved 
ii 
To my grandparents, Gladys and A.L. Lyth and Juanda Ruth and J.E. Smith, 
fully supportive and never in doubt.  To my amazing and enduring parents, Rebecca Lyth and Jesse 
E. Smith, Jr., always there for me. . . . .my sure foundation.  To Jeannine, Bill and Reagan for 
encouragement, patience, love, trust and a solid backing.  To Granny George and Shawn for loving 
support and care. 
And 
To my beautiful wife, Kelly, 
My heart, soul and great love, 
Infinitely supportive, patient and graceful. 
 
 
 
 
 
 
 iii
ACKNOWLEDGEMENTS 
 
    This work would not have been possible without the financial support of the Vanderbilt Medical 
Scientist Training Program through the Clinical and Translational Science Award (Clinical Investigator 
Track), the Society of University Surgeons-Ethicon Scholarship Fund and the Surgical Oncology T32 
grant and the Vanderbilt Medical Center Section of Surgical Sciences and the Department of Surgical 
Oncology.  I am especially indebted to Drs. R. Daniel Beauchamp, Chairman of the Section of 
Surgical Sciences, Dr. James R. Goldenring, Vice Chairman of Research of the Department of 
Surgery, Dr. Naji N. Abumrad, Chairman of the Department of Surgery and Dr. John L. Tarpley, 
Program Director and Professor of the Department of Surgery for constant support, encouragement 
and guidance.  I would especially like to thank Mrs. Donna Putnam, Dr. Natasha G. Deane, Associate 
Research Professor, Department of Surgical Oncology, Dr. Nancy J. Brown, Director, Department of 
Clinical Pharmacology, Dr. Yu Shyr, Professor and Chief, Department of Cancer Biostatistics and Dr. 
Terence Dermody, Professor and Director of the Vanderbilt Medical Scientist Training Program, who 
have supported my career goals and who worked tirelessly to provide me with the resources, 
protected time and encouragement to pursue my dreams and goals.  I would also like to thank two 
individuals who have been taken from us, Niki Carey and Dr. Neville Grant, who provided measures 
of heroism and inspiration during my early residency and graduate training.  I am thankful to Fei Wu, 
M.D., Ph.D. for getting the 34-gene story off to a great start.  I thank Drs. J. Chad Johnson, Carl 
Schmidt, Nipun B. Merchant, Steven Eschrich, Timothy J. Yeatman and Martin J. Heslin for initial 
efforts to organize and secure the colorectal tissues used  for the microarray analysis in this work.  
     I am grateful to all of those with whom I have had the pleasure to work during the last 4 years in 
the laboratory.  Each of my Dissertation Committee members has provided excellent professional 
 iv
guidance and spurred me on to pursue science and research at a new level.  Notably, Drs. Mark de 
Caestecker and Ethan Lee had tremendous roles in my development as a scientist.  I am thankful for 
their guidance, time, patience and generosity with reagents.  I would especially like to thank Dr. Bob 
Coffey and Dr. Steve Hanks who have exemplified a steady hand in my graduate school career and 
who have provided me with much wisdom and encouragement. 
    I would like to thank my medical school mentors, Drs. Hazim J. Safi, Charles C. Miller and Anthony 
L. Estrera for continued support and encouragement in my studies, my life and my career.  Dr. Safi 
has been a stalwart and was the first to introduce me to the wonderful world of medicine and science.  
I am forever grateful for his inspiration and encouragement.  Dr. Miller taught me how to think like a 
clinical scientist and kept me sane during medical school.  Dr. Estrera encouraged me during my 
pursuit of surgical residency and taught me how to round on patients as a first year medical student.  I 
am thankful to R. Daniel Beauchamp, M.D. and Maximilian Buja, M.D. for giving me a chance. 
 Nothing has been more important to me than my faith and my family as a bedrock of support 
during my training.  My mom and dad, in-laws, my brother Nate and extended family have provided 
much grace and love to Kelly and myself.  Most importantly, I wish to thank my dear wife Kelly and 
our yet unknown children for unending love, support and help during my training. 
    This work was supported by the following grants from the National Institutes of Health:  1) CA69457; 
DK52334; CA068485; CA077839 (R. Daniel Beauchamp, M.D.); 2) TL1 RR024978; CA106183 (Institutional 
support for J. Joshua Smith); 3) CA46413; CA95103; CA084239 (R. J. Coffey, M.D.); 4) CA112215 (Timothy J. 
Yeatman, M.D.); 5) CA126588; CA128323 (Natasha G. Deane, Ph.D.); Other sources of funding:  Society of 
University Surgeons-Ethicon Scholarship Award (J.J.S.). 
 
 
 
 v 
TABLE OF CONTENTS 
 
Page 
DEDICATION........................................................................................................................................ ii 
ACKNOWLEDGEMENTS .....................................................................................................................iii 
LIST OF TABLES................................................................................................................................. ix 
LIST OF FIGURES ............................................................................................................................... x 
LIST OF ABBREVIATIONS..................................................................................................................xii 
Chapter 
I.  INTRODUCTION TO THE PROBLEM OF COLORECTAL CANCER...............................................1 
    Epidemiology and Pathogenesis.......................................................................................................1 
    Genomic Instability............................................................................................................................2 
    Mutational Inactivation of Tumor-Suppressor Genes........................................................................2 
    Oncogenic Pathway Activation..........................................................................................................3 
    Developmental Biology and Carcinogenesis in Intestinal Epithelial Cells .........................................5 
         Overview of Prominent Signaling Pathways.................................................................................5 
         Metastasis and Epithelial-Mesenchymal Transition (EMT):  Parallels in Developmental  
         Biology and Cancer......................................................................................................................5 
         Transforming Growth Factor- (TGF) Superfamily Signaling in Epithelial Biology .....................7 
              TGF and Smad4 in Gastrointestinal Homeostasis and Cancer.............................................9 
              Bone Morphogenetic Proteins in the Intestinal Tract.............................................................11 
              TGF Superfamily Signaling and EMT..................................................................................12 
         Wnt Signaling in Intestinal Growth, Differentiation and Colorectal Cancer.................................13 
              Adherens junctions, Wnt and EMT........................................................................................15 
              Tumor Biology at the Invasive Front......................................................................................17           
    Other Contributing Pathways in the Pathogenesis of Colorectal Cancer ........................................18 
    Predictive and Prognostic Markers and Molecular Detection in Colorectal Cancer.........................20 
    Biological Models of Colorectal Cancer...........................................................................................21 
    Summary.........................................................................................................................................23 
 
 
II.  AN EXPERIMENTALLY DERIVED METASTASIS GENE EXPRESSION PROFILE 
     PREDICTS RECURRENCE AND DEATH IN COLON CANCER PATIENTS ................................25 
      
    Abstract...........................................................................................................................................25 
    Introduction .....................................................................................................................................26     
    Materials and Methods....................................................................................................................27 
 vi
         Cell Culture and Mouse Model Overview...................................................................................27 
              Detailed Cell Culture and Mouse Methods............................................................................28 
         Human Tissue and Microarray Platforms...................................................................................30 
         Statistical Methods and Identification of VMC High-Risk Patients..............................................30 
         Clinical Outcomes and Testing of the 34-gene Based Metastasis Score...................................32 
              Vanderbilt Cox Model (Training Dataset) ..............................................................................32 
              Moffitt Cox Model (Test Dataset)...........................................................................................33 
                   Distribution of Re-Sampling Wald Tests with the 34-Gene Recurrence Classifier ...........34 
                   Cox Modeling of Disease-specific Survival for Relative Risk According 
                   to Percentile Score...........................................................................................................34 
              Histologic Analysis and Microsatellite Instability in Association with Metastasis Score.........34 
         Pathway Analysis.......................................................................................................................35 
Results................................................................................................................................................36 
    Development of an Immunocompetent Mouse Model of Colon Cancer Metastasis........................36 
    Discovery of a Gene Expression Profile Associated with Metastasis:  Mouse to Man ....................39 
    The Recurrence Classifier Identifies Poor Outcome Colon Cancer Patients in an 
    Independent Colon Cancer Dataset................................................................................................42 
         High-risk Characteristics and the Metastasis Score...................................................................46 
         Microsatellite Instability and the Recurrence Classifier ..............................................................47 
    A High Recurrence Score Predicts Recurrence and Survival in Univariate and  
    Multivariate Models .........................................................................................................................48 
    The 34-gene Based Metastasis Score is Associated with Patient Benefit and  
    Adjuvant Chemotherapy in Stage III Colon Cancer Patients...........................................................50 
    Pathway Analysis of the 34-gene Based Recurrence Score...........................................................51 
         Ingenuity Pathways Analysis and the Recurrence Classifier......................................................52 
Discussion and Future Directions .......................................................................................................55 
 
III.  SMAD4 INHIBITS WNT SIGNALING IN EPITHELIAL CELLS BY  
      TRANSCRIPTIONAL REPRESSION OF -CATENIN ..................................................................59 
    Abstract...........................................................................................................................................59 
    Introduction .....................................................................................................................................60 
    Materials and Methods....................................................................................................................62 
         Primers.......................................................................................................................................62 
         Reverse Transcriptase-Polymerase Chain Reaction (RT-PCR).................................................62 
         Quantitative Real-time PCR.......................................................................................................63 
              RNA Collection......................................................................................................................63 
              mRNA Stability......................................................................................................................64 
              Data Analysis ........................................................................................................................64 
         Flow Cytometry ..........................................................................................................................64 
         Chromatin Immunoprecipitation Assay.......................................................................................65 
         Transcription Assays..................................................................................................................66 
         Microarray Experiments: Human Tissues, Cell lines and Platform.............................................67 
         Wnt Target List...........................................................................................................................67 
         Wnt Conditioned Medium...........................................................................................................68 
         Immunodetection .......................................................................................................................68 
              Immunoblots .........................................................................................................................68 
 vii
              Immunofluorescence.............................................................................................................69 
              Immunohistochemistry ..........................................................................................................69 
         Functional Assays......................................................................................................................70 
              Matrigel Invasion Assay ........................................................................................................70 
              Athymic (nude) Mouse Tumorigenicity Assay .......................................................................70 
         Gene Set Analysis......................................................................................................................71 
         Statistical analysis......................................................................................................................71 
Results................................................................................................................................................73 
         Smad4 Expression Reduces Transcription of -catenin mRNA.................................................73 
         Smad4 Repression of Wnt Activated Transcription is Independent of APC mutation 
         and Occurs in a Dose-Dependent Manner.................................................................................77 
         Smad4 Inhibition of TOPflash Activity is -catenin Dependent ..................................................77 
         Smad4 Inhibits Wnt Target Gene Expression While Reversing EMT.........................................82 
              Smad4 Inhibition of Wnt Target Gene Expression ................................................................82 
              Smad4 Expression is Associated with Reversal of EMT in Colon Cancer Cells ...................85 
         Smad4 and -catenin Levels Demonstrate Significant Inverse Expression Patterns 
         In Human Colorectal Cancer Specimens ...................................................................................92 
         A Smad4-Modulated Wnt Target Gene Expression Pattern is Correlated with Outcome 
         in Colorectal Cancer Patients.....................................................................................................98  
    Discussion and Future Directions .................................................................................................102 
 
IV.  SUMMARY OF FINDINGS AND FUTURE DIRECTIONS ..........................................................105 
    Brief Review..................................................................................................................................105 
    Future Directions for the 34-gene Classifier Work ........................................................................106 
         Validation and Optimization of the 34-gene Classifier in Clinical Samples...............................106 
         Determination of the Primary Drivers of the 34-gene Classifier ...............................................108 
         Identification of Central Transcriptional Regulators in the 34-gene Classifier ..........................109 
    Differences and Overlap Between the 34-gene Classifier and Recently Published 
    High-risk Gene Signatures for Colorectal Cancer Patients ...........................................................110 
    Interactions Amongst the 34-gene Classifier and the Smad4-expression Profile..........................114 
    Future Dissection of the Mechanism of Smad4 Inhibition of Wnt/-catenin Signaling...................116 
    Summary.......................................................................................................................................119 
 
Appendix 
 
     Figure 8.  Functional Genomic Clustering of the 300-gene Metastatic Signature ........................121 
 
    Table 3:  300 Gene Metastatic Signature......................................................................................122 
 
    Figure 10.  Distribution of 10,000-permutation Wald tests for the 177 MCC 
    Patients with the 34-gene Metastasis Score .................................................................................132 
 
    Table 7:  The Metastasis Score is an Independent Predictor 
    of Recurrence Risk .......................................................................................................................133 
 
 
 viii
    Table 8:  The Metastasis Score Associates With Increased Risk 
    of Cancer-Related Death ..............................................................................................................133 
 
    Table 9:  The Metastasis Score is an Independent Predictor 
    of Cancer-Related Death ..............................................................................................................134 
 
    Figure 18.  
         (A) Ctnnb1 Promoter/enhancer Minimal Smad Binding Elements Schematic..........................135 
         (B) Smad4 Restoration in SW480 Cells Does Not Affect -catenin mRNA Stability.................135 
 
    Table 11:  Global Gene Expression Analysis of SW480vector 
    Versus SW480Smad4 Colon Cancer Cells.......................................................................................136 
 
    Table 12:  Wnt Target List Gene Identifiers...................................................................................178 
 
    Figure 22.   
         (A) Smad4 Colon Cancer Cell Expression Profile Determination:  Flow Diagram....................182 
         (B) Schema for Determination of Wnt Target Gene Enrichment in the Smad4 Profile .............182  
 
    Table 13:  Smad4-Modulated, Wnt Enriched Targets ...................................................................183 
 
    Figure 32.  Derivation of Epithelial Specific Smad4 Targets 
    and Determination of Wnt Enrichment. .........................................................................................187 
 
    Table 17:  Primers.........................................................................................................................188 
 
REFERENCES .................................................................................................................................189 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 ix
LIST OF TABLES 
 
 
 
 
Table 1:  Quantification of Lung Nodules from MC-38 Parental and MC-38Inv Cells..........................37 
 
Table 2:  Hepatic and Lung Metastases (Splenic and Tail Vein Models):  Quantified 
Necropsy Results................................................................................................................................38 
 
Table 3:  See Appendix.....................................................................................................................122 
 
Table 4:  The 34-gene Recurrence Classifier......................................................................................41 
 
Table 5:  Study Demographics............................................................................................................44 
 
Table 6:  The 34-gene Metastasis Score Associates with Increased 
Risk of Recurrence .............................................................................................................................49 
 
Table 7: See Appendix......................................................................................................................133 
 
Table 8: See Appendix......................................................................................................................133 
 
Table 9: See Appendix......................................................................................................................134 
 
Table 10:  Metastasis Score Associates with Patient Benefit and Adjuvant 
Chemotherapy in Patients with Stage III Colon Cancer from the MCC Dataset..................................51 
 
Table 11:  See Appendix...................................................................................................................136 
 
Table 12:  See Appendix...................................................................................................................178 
 
Table 13:  See Appendix...................................................................................................................183 
 
Table 14:  Microarray Study Demographics........................................................................................93 
 
Table 15:  Smad4-Modulated KEGG Signaling Pathways ..................................................................98 
 
Table 16:  Smad4-Modulated, Epithelial Specific Wnt Target Genes 
In Colorectal Cancer Patients .............................................................................................................99 
 
Table 17:  Primers.............................................................................................................................188 
 
 
 
 
 x 
LIST OF FIGURES 
 
 
 
 
Figure 1.  Pathogenesis of Colorectal Cancer.......................................................................................4 
 
Figure 2.  Schematic of an Epithelial-Mesenchymal Transition.............................................................6 
 
Figure 3.  Overview of TGF signaling..................................................................................................8 
 
Figure 4.  Canonical Wnt Signaling Pathway ......................................................................................15 
 
Figure 5.  Cell Culture and Mouse Model:  Murine Model of Metastasis, in vivo Monitoring 
and ex vivo Proof of Metastases.........................................................................................................37 
 
Figure 6.  MC-38 Parental and MC-38met Gross and Histopathology in Tail Vein 
and Splenic Assays.............................................................................................................................38 
 
Figure 7.  Recurrence Classifier Development and Functional Genomic Cluster 
Analysis of the 34-gene Recurrence Classifier ...................................................................................40 
 
Figure 8.  See Appendix....................................................................................................................121 
 
Figure 9. The 34-gene Recurrence Classifier as Tested in the Moffitt Cancer Center (MCC)  
Dataset Across All Stages...................................................................................................................44 
 
Figure 10.  See Appendix..................................................................................................................132 
 
Figure 11.  Kaplan-Meier Estimates from 114 Colon Cancer (stages II and III) Patients 
Under Study at MCC Analyzed with the 34-gene Based Metastasis Score ........................................45 
 
Figure 12.  Cox Model Hazard Ratios. ................................................................................................49 
 
Figure 13. Functional Enrichment of the Up-regulated Genes in the Recurrence Classifier. ..............52 
 
Figure 14. Functional Enrichment of the Down-regulated Genes in the Recurrence Classifier...........53 
 
Figure 15.  Smad4 Expression Represses Transcription of -catenin mRNA. ....................................75 
 
Figure 16.  Smad4 Restoration in SW480 cells is Associated with Transcriptional 
Down-regulation and Binding to the ctnnb1 Promoter/enhancer.........................................................75 
 
Figure 17.  Smad4 Restoration in SW480 cells is associated with down-regulation of 
-catenin mRNA which is reflected at the protein level .......................................................................76 
 
 xi
Figure 18.  See Appendix..................................................................................................................135 
 
Figure 19.  Smad4 Expression Represses TOPflash Activity in an APC Independent Manner ..........78 
 
Figure 20.  Smad4 Inhibition of TOPflash Activity is -catenin Dependent .........................................80 
 
Figure 21.  Smad4 Cannot Suppress TOPflash Independently of -catenin.......................................81 
 
Figure 22.  See Appendix..................................................................................................................182 
  
Figure 23.  A Smad4-specific Gene Expression Profile Reflects Down-regulation 
of Wnt Signaling.............................................................................................................................83-84 
 
Figure 24.  Smad4 Expression Restores an Epithelial Cell Phenotype in Colon Cancer Cells. ..........86 
  
Figure 25.  Smad4 Expression is Associated with Membrane Localization of -catenin 
and E-cadherin in Colon Cancer Cells ................................................................................................87 
 
Figure 26.  Smad4 Expression is Associated with Membrane Localization of p120 catenin 
 and -catenin in Colon Cancer Cells..................................................................................................89 
 
Figure 27.  Smad4 Expression Significantly Decreases Colon Cancer Cell Invasion .........................91 
 
Figure 28.  Smad4 Expression Significantly Decreases Tumorigenicity in a Nude Mouse Model.......91 
 
Figure 29.   
    (A) Smad4 Expression is Significantly Down-regulated in Colorectal Cancer 
   Patient Tumors Compared with Normal Adjacent Mucosal Specimens ...........................................94 
   (B) -catenin Expression is Significantly Up-regulated in Colorectal Cancer 
  Patient Tumors Compared with Normal Adjacent Mucosal Specimens ............................................94 
 
Figure 30.  Smad4 and -catenin Demonstrate Significant Inverse Expression Patterns 
in Colorectal Cancer Patients..............................................................................................................95 
 
Figure 31.  Smad4 and -catenin Levels Show Inverse Expression in Colorectal 
Cancer Tumors ..............................................................................................................................96-97 
 
Figure 32.  See Appendix..................................................................................................................187 
 
Figure 33.  Smad4-Modulated Wnt Target Genes Are Significantly Associated with 
Better Survival in Colorectal Cancer Patients ...................................................................................101 
 
 
 
 
 
 
 xii
LIST OF ABBREVIATIONS 
 
 
 
APC = Adenomatous polyposis coli 
TGF = Transforming Growth Factor-beta 
MAPK = mitogen-activated protein kinase 
PI3K = Phosphatidylinositol 3-Kinase 
PTEN = phosphatase and tensin homolog 
EMT = epithelial-mesenchymal transition 
TCF = T cell-specific transcription factor 
MET = mesenchymal-epithelial-transition 
BMP = Bone Morphogenetic Protein 
GDF = Growth and Differentiation Factor 
MIS = Muellerian Inhibiting Substance 
KCP = kielin-chordin like protein 
TRII = Transforming Growth Factor-beta receptor type II 
BMP-2 = Bone Morphogenetic Protein-2 
BMPR1A = Bone Morphogenetic Protein receptor IA (also known as Alk3) 
FAP = familial adenomatous polyposis 
JPS = juvenile polyposis syndrome 
-SMA = alpha smooth muscle actin 
BMP-7 = Bone Morphogenetic Protein-7 
LEF1 = lymphoid enhancer-binding factor 1 
GSK3 = glycogen synthase kinase 3-beta 
CK1 = casein kinase 1-alpha 
PP2A = protein phosphatase 2A 
-TrCP = beta-transducin repeat containing  
LRP = LDL-receptor related protein 
Dsh = Dishevelled 
sFRP = secreted Frizzled-related protein 
DKK = Dickkopf 
bHLH = basic-helix-loop-helix 
SLUG = snail homolog 2 (also known as SNAI2) 
siRNA = small interfering RNA 
pT3 = pathologic stage T3 rectal tumor 
COX-2 = cyclooxygenase-2 
PGE2 = prostaglandin E2 
EGFR  = epidermal growth factor receptor 
HBEGF = heparin-binding Epidermal Growth Factor-like growth factor 
VEGF  = Vascular endothelial growth factor 
CD133 = prominin 1 
CD44 = CD44 molecule (Indian blood group) 
BRAF = B-Raf proto-oncogene serine/threonine-protein kinase 
MSH2 = MutS homolog 2, colon cancer, nonpolyposis type 1 
MSI-H = microsatellite-high 
 xiii
VMC = Vanderbilt Medical Center 
MCC = Moffitt Cancer Center 
UAB = University of Alabama-Birmingham 
HR = hazard ratio 
CI = confidence interval 
DMEM = dulbecco’s modified eagle medium 
ATCC = American Type Culture Collection 
BLI = bioluminescence imaging 
PBSA = phosphate buffered saline A 
AJCC = American Joint Commission on Cancer 
FDR = False discovery rate 
OS = overall survival 
DSS = disease-specific survival 
DFS = disease-free survival 
Cox PH = Cox Proportional Hazard 
CIMP = CpG island methylator phenotype 
MSS = microsatellite stable 
CTX = adjuvant chemotherapy 
IPA = Ingenuity Pathways Analysis 
TNF = tumor necrosis factor  
IL-1 = interleukin-1 
PCR = polymerase chain reaction 
RT-PCR = reverse transcriptase polymerase chain reaction 
qPCR = quantitative real time polymerase chain reaction 
DRB = 5,6-Dichlorobenzimidazole, 1--D-ribofuranoside 
GFP = green fluorescent protein 
ChIP = chromatin immunoprecipitation 
EDTA = ethylenediaminetetraacetic acid 
CCD = charge-coupled device 
KEGG = Kyoto Encyclopedia of Genes and Genomes   
RMA = Robust MultiChip Averaging  
ANOVA = analysis of variance 
POL2RA = RNA polymerase II 
SAMP = Ser-Ala-Met-Pro 
 
 1 
 
CHAPTER I 
 
 
 
INTRODUCTION TO THE PROBLEM OF COLORECTAL CANCER 
 
 
 
Epidemiology and Pathogenesis 
 
Colorectal adenocarcinoma is the second leading cause of cancer-related death in the United 
States.  Currently, there are an estimated 148,000 new colorectal cancer cases and ~50,000 deaths 
due to this disease annually (Jemal et al. 2009).  Colorectal cancer is thought to progress through a 
series of steps involving mutational inactivation of tumor suppressor genes, activation of oncogenes 
and eventual progression to metastatic lesions (Fearon and Vogelstein 1990).  While localized tumor 
growth may cause significant organ dysfunction and even death, metastases cause the vast majority 
(~90%) of human cancer deaths (Hanahan and Weinberg 2000).  The ability to metastasize is linked 
with the ability of cancer cells to invade adjacent tissues, to gain access to vascular or lymphatic 
channels and to survive transit through the bloodstream so that they may extravasate, then reside 
and colonize heterologous organs or tissues. Cancer cells acquire the capacity of invasion and 
metastasis through regulated processes related to tissue development and homeostasis.  Many steps 
in this process resemble a developmental program known as an ‘epithelial-mesenchymal transition’ 
as the epithelial cells travel from a primary cancer site to a new site of distant metastasis.  
Identification of the key regulators of the processes of metastasis and tumor suppression may provide 
valuable prognostic information to patients with colorectal cancer as well as opportunities for optimal, 
personalized intervention.     
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Genomic Instability 
 
     Chromosomal instability is the most common type of genomic instability in colorectal cancer and 
leads to changes in chromosomal number and structure (Lengauer, Kinzler, and Vogelstein 1997; 
Markowitz and Bertagnolli 2009).  Chromosomal instability can lead to loss of wild-type copies of 
tumor suppressor genes (e.g. APC or Smad4), which normally prevent malignant progression (Hahn 
et al. Dpc4, a candidate tumor suppressor gene at human chromosome 18q21.1 1996; Morin et al. 
1997).  Interestingly, colorectal cancer is not characterized by gene amplification or gene 
rearrangement (Leary et al. 2008); however, DNA-repair defects can occur and can even be 
inherited.  Patients with hereditary nonpolyposis colon cancer have germ-line defects in mismatch-
repair genes and this confers an 80% lifetime risk of colorectal cancer (Lynch et al. 2008).    Loss of 
mismatch-repair function and epigenetic silencing of genes are important in a proportion of patients 
with colorectal cancer, but fall outside the scope of this dissertation (Ionov et al. 1993; Issa 2004) and 
will not be discussed in detail. 
 
Mutational Inactivation of Tumor-Suppressor Genes 
    Wnt signaling pathway activation is considered the initiating event in sporadic colorectal cancer 
formation (Goss and Groden 2000).  The most common mutation in colorectal cancer inactivates the 
adenomatous polyposis coli gene (APC, see Fig. 1).  APC is a key component of a cellular protein 
complex, which normally regulates the degradation of -catenin.  -catenin is the central mediator of 
Wnt signaling and has important roles both developmentally and in carcinogenesis.  Inactivation of 
APC leads to inappropriate nuclear translocation of -catenin where it activates transcription of target 
genes such as cyclin D1 or c-MYC to promote proliferation and de-differentiation.  The second key 
genetic step in colorectal cancer development is inactivation of the p53 pathway via mutation of TP53 
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((Markowitz and Bertagnolli 2009), also see Fig. 1).  Usually both TP53 alleles are lost by a missense 
mutation and loss of chromosome 17p (Baker et al. 1989).  TP53 mediates cell-cycle arrest and the 
cell-death checkpoint (Vazquez et al. 2008) and inactivation is thought to parallel the adenoma to 
invasive carcinoma sequence (Baker et al. 1990).  A potential role of p53 in the 34-gene recurrence 
classifier will be discussed in Chapter II.  A third step in the colorectal cancer progression sequence is 
inactivation of the Transforming Growth Factor- (TGF) pathway.  Approximately half of colorectal 
cancers have a defect at the level of the receptor (e.g., TRII) (Grady et al. 1999; Markowitz et al. 
1995) or downstream at the level of the common mediator of TGF signaling, Smad4, or its partner 
transcription factors (e.g., Smad2 or Smad3) (Takagi et al. 1996; Thiagalingam et al. 1996).  
Inactivation in the TGF pathway is thought to be coincident with the adenoma to dysplasia or 
carcinoma transition (Also see Fig. 1).  Wnt signaling and TGF superfamily signaling will be 
discussed in extensive detail below and in Chapter III.   
 
Oncogenic Pathway Activation 
    Oncogenic mutations of RAS or BRAF (also see Fig. 1) activate the mitogen-activated protein 
kinase (MAPK) signaling pathway in ~30% of colorectal cancers (Bos et al. 1987; Davies et al. 2002) 
and this can potentiate defects in the Wnt or TGF pathways.  For example, recent observations have 
been made in regard to cooperative regulation between oncogenic Ras and TGF signaling in the 
process of metastatic behavior (Janda et al. 2002; Kanies et al. 2008).  Also, approximately one-third 
of colorectal cancers have mutations in the Phosphatidylinositol 3-Kinase pathway (e.g. PI3KA) and a 
smaller percentage include activation of other downstream mediators of PI3K signaling and loss of 
PTEN which is an inhibitor of PI3K signaling (Parsons et al. 2005).  Although these pathways play 
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Figure 1.  Pathogenesis of colorectal cancer.  The initiating event in the development of colorectal 
cancer is thought to be mutation of APC as shown.  Genetic loss of TP53 and pathway 
components of TGF signaling are thought to follow.  Other contributing pathways and processes 
thought to be involved in the progression of colorectal cancer are shown (e.g., MSI, MSH2, CIN, 
KRAS, BRAF, PI3K and PTEN).  A schematic of an epithelial-mesenchymal transition (EMT) is 
shown along the bottom and is thought to parallel this progression in a developmentally conserved 
program of events that regulate the transition from an epithelial cell to a more motile metastatic 
phenotype.  The question mark indicates yet unknown factors.  Key:  APC (adenomatous 
polyposis coli); MSI (microsatellite-instability); MSH2 (MutS homolog 2, colon cancer MutS 
homolog 2, colon cancer, nonpolyposis type 1); ACF (aberrant crypt foci); CIN (chromosomal 
instability); BRAF (B-Raf proto-oncogene serine/threonine-protein kinase ); PI3K 
(Phosphatidylinositol 3-Kinase); PTEN (phosphatase and tensin homolog).  Adapted with 
permission from Fearon ER and Vogelstein B, Cell. 1990 Jun 1;61(5):759-67 and Kalluri R, 
Weinberg RA.  The basics of epithelial-mesenchymal transition.  J Clin Invest. 2009 
Jun;119(6):1420-8. 
important roles in the pathogenesis of colorectal cancer they are outside the scope of this work and 
will not be discussed in further detail. 
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Developmental Biology and Carcinogenesis in Intestinal Epithelial Cells 
 
Overview of Prominent Signaling Pathways 
 
         Two major signaling pathways are critical for the development and maintenance of homeostasis 
in the gastrointestinal tract: the TGF superfamily and Wnt/-catenin/TCF (T cell-specific transcription 
factor) signaling pathways.  These pathways contribute to the development, differentiation and 
maintenance of homeostasis in intestinal epithelium, whereas mutations or aberrant regulation of 
these pathways contribute to tumor initiation and progression in the intestine (reviewed in (Radtke 
and Clevers 2005)).  In this section, emphasis will be placed on interactions of the TGF superfamily 
and Wnt pathways and their potential roles in colorectal cancer cell invasiveness and metastatic 
potential.  It is well recognized that other genetic alterations, signaling pathways and processes such 
as angiogenesis are also important contributors of carcinogenesis, tumor progression and metastasis, 
but these will only be mentioned briefly. 
 
Metastasis and Epithelial-Mesenchymal Transition:  Parallels in Developmental Biology and Cancer 
 
         Most solid human tumors are carcinomas that originate in epithelial cells.  In order for these 
cells to invade adjacent layers they become motile and lose cell-cell adhesion then must activate a 
highly conserved program known as epithelial-mesenchymal transition (EMT) (Thiery 2002).  The 
conversion of epithelial cells into mesenchymal cells was defined in the 1980s when epithelial cells 
from embryonic and adult lens were cultured in 3D collagen (Greenburg and Hay 1982).  The reverse 
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process of MET can occur and is best described in nephronic epithelium of the developing kidney 
(Davies 1996).  EMT is tightly controlled, reversible and required for embryonic development, tissue 
reorganization and wound healing (Yang and Weinberg 2008).  During EMT, cells lose epithelial 
polarity and acquire a mesenchymal phenotype (see Fig. 2) with invasive characteristics (Thiery 
2003).  Cell-cell junctions are disrupted in EMT by mechanisms involving loss of expression of the 
adherens junction protein and the key gatekeeper of the epithelial state, E-Cadherin (Kang and 
Massague 2004).  Tight junctions lose polarity and function, and the cells undergoing EMT express 
mesenchymal markers such as vimentin and -smooth muscle actin (-SMA).  Also, multiple 
transcription factors can induce EMT and have been associated with tumor invasion and metastasis.  
For example, Twist1 is essential for metastasis of a mouse breast cancer line to the lung (Yang et al. 
2004).  In colorectal cancer, nuclear localization of -catenin has been noted at the invasive front of 
tumor invasion and the cells appear to have undergone EMT as noted by loss of E-cadherin and gain 
of mesenchymal markers such as fibronectin (Fodde and Brabletz 2007).  In many cases, cellular 
transformation recapitulates a molecular environment favoring EMT, which in turn disrupts normal 
epithelial cell polarity and results in the acquisition of invasive and metastatic potential.  Thus, a 
growing body of evidence implicates EMT in tumor cell migration, invasiveness and metastatic 
behavior (Cui et al. 1996; Kalluri 2009).  
 
 
 
 
 
 Figure 2.  Schematic of an epithelial-mesenchymal transition.  Epithelial cells marked by expression of E-
cadherin undergo a highly conserved developmental program where a loss of epithelial markers is 
associated with gain of mesenchymal markers (e.g., N-cadherin vimentin, LEF-1).  Adapted with 
permission from Kalluri R, Weinberg RA.  The basics of epithelial-mesenchymal transition.  J Clin Invest. 
2009 Jun;119(6):1420-8. 
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TGF Superfamily Signaling in Epithelial Biology 
 
    The TGF superfamily is made up of two subfamilies of cytokines:  1) the TGF/Activin/Nodal 
subfamily and 2) the Bone Morphogenetic Protein (BMP) / Growth and Differentiation Factor (GDF) / 
Muellerian Inhibiting Substance (MIS) subfamily (Shi and Massague 2003).  For purposes of this 
work, the accessory receptors (e.g., Betaglycan, Cripto, or Endoglin), interactions with inhibin, GDFs, 
or the Mullerian subfamily (AMH/MIS) and their associations in the TGF superfamily will not be 
further discussed.  Specific TGF and BMP-related cytokines and their shared signaling 
intermediates function as critical developmental regulators, cell growth inhibitors and tumor 
suppressors in normal tissue.  Germline loss of certain components of the signaling intermediates for 
these cytokines often results in embryonic lethality due to their critical roles in development.  On the 
other hand, somatic cell mutations or acquired loss of function may contribute to the development or 
progression of cancer (Massague 2008).  
         The TGF family of ligands  (e.g., TGF, BMP, Activin) bind and signal through a heteromeric 
complex of ligand-specific type I (Alk 1-7) and type II serine/threonine kinase receptors (Shi and 
Massague 2003).  Ligand access to the serine/threonine kinase receptors is regulated by a family of 
proteins known as ligand traps, proteins that selectively bind to specific TGF superfamily ligands, 
thereby blocking access to the receptors (Neilson 2005; Shi and Massague 2003).  For example, the 
ligand trap protein, Noggin, inhibits receptor activation of the BMP cytokines 2, 4, and 7 (Fig. 3).  
Other proteins, like kielin-chordin like protein (see Fig. 3) have been noted to enhance BMP signaling 
to promote a more epithelial phenotype (Lin et al. 2007).  A type II receptor is necessary for specific 
ligand binding.  Following binding of ligand to type II receptors, the ligand-bound type II receptor 
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Figure 3.  Overview of TGF signaling.  Ligand interaction with type II receptors leads to activation of 
type I receptors.  Type I receptors phosphorylate the receptor-associated Smads which complex with 
Smad4 and translocate to the nucleus to induce target gene transcripts.  Ligand traps (e.g., Noggin) or 
agonists (e.g. KCP) can inhibit or potentiate signaling responses.  Key:  TGF = transforming growth 
factor beta; BMP=bone morphogenetic protein; P=phosphorylation event; RII = receptor type II; RI = 
receptor type I; R-Smads=receptor-associated Smads (Smads 1, 2, 3, 5 or 8); KCP: kielin-chordin like 
protein.  Adapted and re-drawn with permission from Ming Zhao M.D., Ph.D., Vanderbilt Medical 
Center. 
forms an oligomeric complex with the type I receptor, resulting in type I receptor phosphorylation.  
Information from the tissue microenvironment to the cell nucleus by these growth inhibitors is then 
transmitted by specific receptor-associated Smad proteins (R-Smads) associated with the growth 
factor (type II) receptors.  Eight members of the vertebrate TGF family intracellular signaling 
pathways have been identified, and by consensus are now referred to as Smad1 through Smad8 (Shi 
and Massague 2003).  As a general rule, Smads1, 5, and 8 are R-Smads  
that function to transduce signals from the bone morphogenetic proteins (BMPs) and their specific 
type II (BMPR-II, ActR-II/B) and type I (Alk3, Alk6, Alk2) receptors (see Fig. 3).  
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Smads2 and 3 are important R-Smad substrates of Alk5 that may be activated by either activin 
(through the type II ActR-IIB receptor) or by TGF selective type II receptors.  Inhibitory Smads 6 and 
7 (I-Smads) inhibit the signaling function of the receptor-activated Smads (not shown in Fig. 3). 
Smad6 preferentially inhibits BMP signaling, whereas Smad7 can inhibit both TGF and BMP 
signaling by preventing receptor-mediated phosphorylation of the receptor-activated Smad proteins 
(Shi and Massague 2003).  When phosphorylated by the type I receptor, R-Smads associate with the 
common signaling intermediate, Smad4 (co-Smad4), which translocates the entire R-Smad:Co-Smad 
complex to the nucleus, where it associates with one or more of a number of DNA-binding partners 
and activates the transcription of specific target genes important for both growth inhibition and EMT.  
Steady-state levels of Smad proteins are regulated through the ubiquitin-proteasome degradation 
pathway (Massague, Seoane, and Wotton 2005). 
TGF and Smad4 in Gastrointestinal Homeostasis and Cancer  
         The TGF family of peptides has a growth inhibitory role in intestinal epithelium.  Kurokowa and 
colleagues (Kurokowa, Lynch, and Podolsky 1987) were the first to report that TGF was an inhibitor 
of cultured rat intestinal epithelial cells.  It was subsequently determined that inhibition of cultured 
intestinal epithelial cell proliferation after TGF treatment results from mid-to-late G1 cell cycle arrest 
associated with down-regulation of cyclin D1 (Ko et al. 1995) and inhibition of Cdk4-associated 
retinoblastoma kinase activity (Ko et al. 1998).  In vivo, there is increased expression of both TGF1 
and type II TGF receptor (TRII) in intestinal epithelial cells as they migrate from the proliferative 
compartment toward the lumen in both the small intestine and the colon (Barnard et al. 1989; 
Barnard, Warwick, and Gold 1993; Winesett, Ramsey, and Barnard 1996).  This pattern of expression 
is inversely correlated with the mitotic activity in the gut epithelium (Zhang et al. 1997). Taken 
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together, these findings suggest that TGF plays a regulatory role in intestinal cell proliferation, and 
perhaps differentiation. 
         TGF regulation of epithelial cell proliferation is altered by cellular transformation. TGF inhibits 
growth of non-tumorigenic human colonic adenoma cells in culture; however, conversion of adenoma 
to a tumorigenic adenocarcinoma is associated with a decreased response to the inhibitory actions of 
TGF (Manning et al. 1991).  Studies in human colon carcinoma cell lines have demonstrated a 
correlation between the differentiation state of tumors and sensitivity to the anti-proliferative and 
differentiation-promoting effects of TGF (Hoosein et al. 1989).  Thus, loss of growth-inhibitory 
responses to TGF appears to be a common and important event that attends malignant 
transformation of epithelial cells. 
         One of the mechanisms by which tumor cells become resistant to the growth inhibitory actions 
of TGF may be through down-regulation or mutation of the TRII.  Several studies have suggested 
that a decrease in expression of TRII is a key step for the neoplastic transformation of epithelial cells 
(Arteaga et al. 1988; Kimchi et al. 1988; Sun et al. 1994).  Inactivation of the TRII has been detected 
in a subgroup of colorectal carcinomas associated with the microsatellite instability or replication error 
phenotype found in approximately 13% of all colorectal cancers (Markowitz et al. 1995).  Mutations of 
TRII have also been identified in 15% of microsatellite stable colorectal cancers (Grady et al. 1999).  
Of potential importance are the observations that the subset of colorectal cancers that exhibit 
microsatellite instability (and TRII mutations) tend to be proximal colon cancers and have a better 
prognosis (stage for stage) than the majority of sporadic colorectal cancers that do not share these 
genetic defects (Gryfe et al. 2000; Thibodeau, Bren, and Schaid 1993).  
         In addition to loss of the normal growth inhibitory processes mediated from mutations of the 
TRII, mutations or epigenetic loss of expression of Smad signal transduction proteins also 
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contributes to tumorigenesis and tumor progression in the GI tract (Elliott and Blobe 2005).  Mutations 
of Smad3 have not been identified in human cancers, but 37% of gastric carcinomas exhibit 
decreased Smad3 immunoreactivity and when Smad3 deficient gastric cancer cells are forced to 
express ectopic Smad3, TGF responsiveness is restored and xenograft growth in nude mice is 
suppressed in Smad3 transfected gastric cancer cells versus controls (Han et al. 2004).  Smad2 
mutations have been identified in a small subset (under 10%) of colorectal cancers (Eppert et al. 
1996; Ohtaki et al. 2001). 
    The most commonly disrupted Smad mediator in cancers, including colorectal cancer, is Smad4.  
Mutations of Smad4 have been identified in 50% of pancreatic cancers (Hahn et al. Homozygous 
deletion map at 18q21.1 in pancreatic cancer 1996), 20-30% of colorectal cancer (Riggins et al. 1997; 
Riggins et al. 1996; Thiagalingam et al. 1996) and in 10-20% of small bowel adenocarcinomas (Blaker 
et al. 2004). Loss of Smad4 expression is correlated with loss of E-cadherin expression (Reinacher-
Schick et al. 2004), liver metastasis and poor prognosis in colon cancer (Alazzouzi et al. 2005; Miyaki 
et al. 1999).  Loss of Smad4 expression and deletion of chromosome 18q have recently been 
associated with increased incidence of lymph node metastasis in colorectal cancer (Tanaka et al. 
2008).  These reports indicate that loss of Smad4 expression is an important contributing factor for 
tumorigenesis in colorectal cancer. 
Bone Morphogenetic Proteins in the Intestinal Tract  
         The role of BMP subfamily ligands and receptors in the GI tract are less well known than that of 
the TGF subfamily, though recent experimental observations indicate their activity in growth, 
development and cancer.  BMP-2 and its receptors are expressed in the mouse and human colon, 
predominantly in mature colonocytes at the epithelial surface. BMP-2 promotes apoptosis and growth 
inhibition in cultured colon cancer cells (Hardwick et al. 2004).  Howe and colleagues have identified 
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germline mutations in the gene encoding the BMP receptor 1A in Juvenile Polyposis Syndrome (JPS) 
(Howe et al. 2001; Sayed et al. 2002).  Of note, previous studies also implicated Smad4 mutations in 
a significant subset of JPS patients (Howe et al. 1998).  Villin promoter-directed expression of 
Noggin, a natural BMP antagonist, in the intestine of mice as well as targeted disruption of the BMP 
signaling pathway through conditional inactivation of the Bmpr1a gene in mice resulted in similar 
histopathology as is seen in JPS (Haramis et al. 2004; He et al. 2004).  Similarly, BMP-2 expression 
was found to be decreased in microadenomas of familial adenomatous polyposis (FAP) patients 
(Hardwick et al. 2004). These studies indicate that BMP signaling is critical for homeostasis in the 
intestinal tract, and loss of this function leads to pre-cancerous conditions such as JPS and FAP. 
TGF Superfamily Signaling and EMT 
         In contrast with the tumor suppressive effects of Smad4 intrinsic to TGF and BMP signaling, 
additional data demonstrate that Smad4 may also regulate EMT, perhaps through TGF and/or BMP 
mediated signaling interactions with Ras/MAPK, PI3K or Wnt signaling pathways (Valcourt et al. 
2005).  Others have reported that TGF and BMP ligands and their respective ligand trap peptides 
have homeostatic opposing effects on EMT in some systems, with TGF promoting and BMPs 
inhibiting EMT (Zeisberg et al. 2003) and (reviewed in (Neilson 2005)).  The balance between a 
differentiated epithelial phenotype and the more aggressive and invasive mesenchymal phenotype is 
also influenced by the abundance and activity of locally produced cytokines.  Rees and colleagues 
recently reported evidence of EMT at the leading invasive front of esophageal adenocarcinomas that 
consisted of loss of membrane E-cadherin expression, increased -SMA and vimentin, along with 
diffuse stromal TGF-1 immunostaining (Rees et al. 2006).  In contrast, BMP-7 immunostaining was 
absent at the invasive front with occasional cells showing increased immunoreactivity in the central 
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tumor areas.  These data suggest an intricate balance in the epithelial cell microenvironment amongst 
members of the TGF superfamily to either prevent or promote EMT. 
 
Wnt Signaling in Intestinal Growth, Differentiation and Colorectal Cancer 
    Wnt signaling is a critical regulator of embryonic development. The foundation for characterization 
of canonical Wnt signaling was laid by the discovery that the Drosophila segment polarity gene 
Wingless and the murine proto-oncogene Int-1 were of a common origin (Wg + Int-1 = Wnt) (Nusse 
and Varmus 1982; Rijsewijk et al. 1987).  -catenin-mediated canonical Wnt signaling is critical for 
maintenance of the intestinal epithelial stem cell compartment (Reya and Clevers 2005).  In adult 
organisms, Wnt signaling regulates intestinal crypt progenitor cell compartments and the control of 
cell fate along the intestinal crypt-villus axis (Radtke and Clevers 2005).  This pathway is highly 
conserved from invertebrates to vertebrate organisms and intracellular levels of the key signaling 
mediator, -catenin, are tightly controlled. The differentiated epithelial cell goes to great lengths to 
restrict the levels of cytosolic -catenin. The Wnt pathway is normally activated by Wnt ligand and 
receptor interactions in an embryologic or stem cell microenvironment and it is widely held that the 
central event in canonical Wnt signaling is cytoplasmic accumulation of -catenin and its subsequent 
nuclear translocation and activity (Gordon and Nusse 2006).  Although the non-canonical/Planar Cell 
Poloarity Wnt pathway may play an important role in epithelial pathobiology and cell movement in 
gastrulation (Veeman, Axelrod, and Moon 2003), it will not be discussed further in this work.  
When Wnt signaling is activated, -catenin levels transiently increase intracellularly and -
catenin translocates to the nucleus where it forms a transcriptional regulatory complex with the T cell-
specific transcription factor/lymphoid enhancer-binding factor 1 (TCF/LEF) to activate transcription of 
cyclin D1, c-MYC and other downstream target genes (He et al. 1998; Tetsu and McCormick 1999).  
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In the absence of Wnt signaling, -catenin levels in the cytoplasm are exceedingly low and the -
catenin pools are localized to the adherens junctions in a complex with E-cadherin (see Fig. 4, left 
panel).  Normally, in the absence of a Wnt ligand, low cytoplasmic concentrations of -catenin are 
maintained by the scaffold protein Axin.  Axin coordinates the formation of a protein complex that 
consists of casein kinase 1 (CK1), glycogen synthase kinase 3 (GSK3), the tumor suppressor 
adenomatous polyposis coli (APC) and protein phosphatase 2A (PP2A) (Fig. 4, left panel, CK1 and 
PP2A not shown).  Together, components of this complex act to constitutively phosphorylate -
catenin, leading to its recognition by the beta-transducin repeat containing (-TrCP) subunit of the 
SCF ubiquitin ligase complex (SCF-TrCP), catalytic transfer of polyubiquitin chains to -catenin and its 
rapid degradation by the 26S proteasome (Aberle et al. 1997; Ikeda et al. 1998; Kishida et al. 1998; 
Maniatis 1999). 
Inactivating mutations in the APC (adenomatous polyposis coli) gene or activating mutations in 
the -catenin gene (ctnnb1) result in failure to phosphorylate -catenin with stabilization and 
accumulation of -catenin in the cytoplasm and aberrant activation of Wnt signaling (Fig. 4, right 
panel).   Hypophosphorylation of -catenin leads to accumulation in the cytoplasm and translocation 
to the nucleus with resultant regulation of target gene expression with the TCF/LEF family of 
transcription factors (Gordon and Nusse 2006).  The significance of the role of APC in colorectal 
epithelial homeostasis is revealed by the fact that over 80% of sporadic colorectal cancer cases have 
truncating mutations in the APC gene, which has often been considered the gatekeeper in the 
genesis of colorectal cancer because it is the earliest detectable genetic lesion in most premalignant 
colorectal adenomas.  Aberrant stabilization of -catenin in colorectal cancer can result either from 
inactivating APC mutation or stabilizing mutations in -catenin (found in 10% of sporadic colon 
cancers). 
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Figure 4.  Canonical Wnt signaling pathway.  In the absence of Wnt ligand, E-cadherin binds and 
sequesters -catenin to the plasma cell membrane at the adherens junction (with p120 and alpha-
catenin), rendering it unavailable for transcriptional activity (left panel).  Wnt ligand interaction with the 
LRP receptor complex (Frizzled + LRP 5/6) can activate the pathway (right panel) and free cytoplasmic 
-catenin levels increase.  -catenin translocates to the nucleus where it forms a transcriptional 
regulatory complex with TCF/LEF1 (TCF) to activate transcription of downstream targets (e.g., c-MYC). 
Key:  LRP (LDL-receptor related protein), Dsh (Dishevelled), TCF/LEF1 (T-cell factor/lymphoid enhancer 
factor), sFRP (secreted Frizzled-related protein), DKK (Dickkopf), and GSK3 (glycogen synthase kinase 
3).  Adapted with permission from the publisher from Logan CY, Nusse R.  The Wnt signaling pathway in development and disease.  Annu Rev 
Cell Dev Biol.  2004; 20:781-810. 
 
 
 
 
 
 
Adherens Junctions, Wnt Signaling and EMT 
         Adherens junctions are specialized forms of cadherin-based adhesive contacts important for 
tissue organization in developing and adult organisms.  E-cadherin is an epithelium-specific cadherin 
that forms protein complexes with cytoplasmic proteins (catenins) that convert the specific, 
homophilic-binding capacity of the extracellular domain into stable cell adhesion.  Critical proteins  
found at the adherens junction include E-cadherin, -catenin, -catenin and p120 catenin (see Fig. 4, 
left panel).  E-cadherin is a calcium-dependent adhesion protein.  It is the major component of the 
adherens junction that facilitates cell-cell communication, and E-cadherin also functions as a tumor 
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suppressor (Christofori and Semb 1999)  Junctional proteins may also serve important roles other 
than as structural components of intercellular junctions.  E-cadherin binds and sequesters 
cytoplasmic -catenin, rendering -catenin unavailable for signaling in the canonical Wnt/-
catenin/TCF signaling cascade (Nelson and Nusse 2004).  Therefore, E-cadherin like the APC protein 
is an important tumor suppressor protein. Both E-cadherin and APC have essential roles in 
preventing accumulation of cytoplasmic -catenin, and thereby prevent inappropriate activation of the 
Wnt pathway (Christofori and Semb 1999). 
Loss of E-cadherin in epithelial malignancies is associated with invasion, metastasis, and 
worse prognosis (Brabletz et al. 2001; Ikeguchi, Makino, and Kaibara 2001; Ikeguchi et al. 2000; 
Kanazawa et al. E-cadherin expression in the primary tumors and metastatic lymph nodes of poorly 
differentiated types of rectal cancer 2002; Kanazawa et al. Poorly differentiated adenocarcinoma and 
mucinous carcinoma of the colon and rectum show higher rates of loss of heterozygosity and loss of 
e-cadherin expression due to methylation of promoter region 2002).  Loss of normal expression of E-
cadherin may occur by any of several well-described mechanisms. These mechanisms may include 
transcriptional and post-translational regulation of E-cadherin membrane localization and stability.  
Reynolds and colleagues demonstrated that p120 catenin interaction with E-cadherin is essential for 
maintenance of E-cadherin stability and function as a tumor suppressor in epidermoid and colorectal 
cancer cells (Davis, Ireton, and Reynolds 2003; Ireton et al. 2002).  Transcriptional repression is also 
a prominent regulatory mechanism by which E-cadherin expression may be suppressed in epithelial 
and colorectal cancer cells (Batlle et al. 2000).  Two basic-helix-loop-helix (bHLH) proteins, E12/E47 
(Perez-Moreno et al. 2001) and Twist (Yang et al. 2004) have been identified as interacting with the 
E-cadherin promoter E-box region to repress E-cadherin expression and to induce the EMT 
phenotype (Kang and Massague 2004).  Even though it is known that E-cadherin can regulate -
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catenin levels and that E-cadherin itself is regulated via a transcriptional mechanism, the 
transcriptional regulation of -catenin as it relates to colorectal cancer, Smad4 and EMT has not been 
described, but will be discussed in Chapter III. 
Alteration of E-cadherin expression in experimental models has profound effects on the 
invasive and metastatic potential of human cancer cells.  E-cadherin expression in human MDA MB 
231 breast cancer cells suppressed the development of bone metastases in athymic (nude) mice 
(Mbalaviele et al. 1996).  E-cadherin may interact with other Wnt target genes such as EphrinB2 to 
modulate tumorigenesis (Batlle et al. 2002; Cortina et al. 2007) and interestingly, we found EphrinB2 
to be down-regulated in the metastatic gene expression profile found in Chapter II of this work.  
Suppression of the transcriptional repressor, SLUG (or SNAI2) by siRNA restores E-cadherin 
expression and partially reverts the transformed phenotype in Ras transformed rat intestinal epithelial 
cells (Schmidt et al. 2005).  Recent work has shown that restoration of Smad4 in Smad4-deficient 
SW480 colon cancer cells induced E-cadherin expression while reducing total -catenin protein 
levels, and these effects were accompanied by a marked decrease in -catenin/TCF activity (Shiou et 
al. 2007).  These data implicate Smad4 as a key modulator of both EMT and Wnt signaling in colon 
cancer cells and will be expanded upon further in Chapter III. 
Tumor Biology at the Invasive Front 
         Increased nuclear -catenin localization and Wnt signaling have been demonstrated at the 
tumor-stromal interface of the leading invasive edge of tumors and is associated with localized 
evidence of EMT (loss of E-cadherin at the cell membrane) and disruption of cell polarity (Brabletz et 
al. 2001).  This group recently showed that well-to-moderately differentiated pT3 rectal 
adenocarcinomas express basement membrane proteins, but breakdown of the basement membrane 
in many of the rectal cancers occurs in discrete regions adjacent to cancer cells at the invasive front 
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of tumors (Spaderna et al. 2006).  A provocative observation from this report was that the basement 
membrane was rebuilt in both lymph node and distant metastases, accompanied by the same 
glandular morphology observed in the majority of the primary tumor, including the predominance of 
the epithelial phenotype, but that the entire process was recapitulated in the invasive regions of the 
metastatic lesions. These observations support the notion that in most cases, EMT is a dynamic, 
regulated and reversible process.  The notion that -catenin may also play a prominent role at the 
invasive front of colorectal cancers will be introduced in Chapter III. 
 
Other Contributing Pathways in the Pathogenesis of Colorectal Cancer 
 
    The Notch signaling cascade plays a role in intestinal homeostasis, cell fate decisions and 
differentiation (Radtke and Clevers 2005).  This pathway contributes heavily to the development and 
maintenance of secretory and enteroendocrine lineages important for regulation of the intestinal 
epithelial milieu (Jenny et al. 2002; Jensen et al. 2000; Yang et al. 2001).  Interestingly, a major target 
of the Notch signaling pathway, Hes1, is up-regulated in the 34-gene classifier as discussed in 
Chapter II.  Other important growth factor pathways contribute to colorectal cancer and are worthy of 
mention.  Activation of prostaglandins is an early step in the development of an adenoma (Markowitz 
2007) and this response can be induced by inflammation or up-regulation of cyclooxygenase-2 (COX-
2) that spurs the production of prostaglandin E2  (PGE2) and this action is strongly associated with 
colorectal cancer (Cha and DuBois 2007).  Loss of 15-prostaglandin dehydrogenase promotes 
activity of PGE2 and has been noted in the majority of colorectal adenomas and cancers (Yan et al. 
2004).  Interestingly, COX-2 is a Wnt target gene (Howe et al. 1999) and clinical trials have shown the 
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benefits of COX-2 inhibition in prevention and regression of adenomas (Bertagnolli et al. 2006).  The 
potential role of inflammation in the metastatic process will be discussed further in Chapter II.   
    Epidermal growth factor has been noted to play an important role via the epidermal growth factor 
receptor (EGFR) in a subset of colorectal cancer patients (Saltz et al. 2004).  Activation of EGFR can 
mediate up-regulation of prostaglandins (Coffey et al. 1997) in addition to up-regulation of MAPK and 
PI3K signaling pathways, all of which may play a role in lack of response to anti-EGFR therapies in 
advanced colorectal cancers (Wong and Cunningham 2008).  Notably, prominent members of this 
pathway, EGFR and HBEGF were implicated in the metastasis-associated signature as described in 
Chapter II.  Additionally, Vascular endothelial growth factor (VEGF) and its critical role in normal and 
transformative angiogenesis in tumor development and colorectal cancer pathogenesis have been 
well described (Ellis and Hicklin 2008).  The role of anti-VEGF treatment appears promising even 
though patient selection by reliable molecular markers for this treatment remains difficult (Hurwitz et 
al. 2004).  Finally, cancer stem cells play a prominent role in the development of colorectal cancer 
(O'Brien et al. 2007) and eventual metastasis (Boman and Huang 2008).  Although the isolation of 
individual colon cancer stem cells is not currently feasible, certain cell-surface proteins hold promise 
as markers (e.g. CD133, CD44) (Yeung and Mortensen 2009; Zeilstra et al. 2008).  The molecular 
mechanisms of colon cancer stem cell biology and treatment possibilities that would exist once these 
cells are readily identifiable hold great potential for the treatment and prevention of colorectal cancer.  
It is recognized that these additional pathways play important roles in the pathogenesis of colorectal 
cancer and may interact with molecules implicated in our 34-gene classifier and in the Wnt and TGF 
pathways; however, these topics are beyond the scope of this work and will not be addressed further.  
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Predictive and Prognostic Markers and Molecular Detection in Colorectal Cancer 
 
    An immense challenge to clinicians and biologists worldwide is the translation of colorectal cancer 
genomic data into a clinically useful and applicable prognostic test.  As mentioned above, the 
complexities of EGFR signaling via RAS and BRAF along with anti-EGFR therapy have been applied 
with individual patient genomic status in mind and have led to the strong recommendation to have all 
patients with colorectal cancer genotyped for KRAS mutations (Wong and Cunningham 2008).  Only 
a few markers can identify high-risk patients on a consistent basis and thereby be used to guide 
treatment decisions for colorectal cancer patients (e.g., APC, MSH2).  Many other markers have not 
been tested prospectively and have unconfirmed utility as prognostic markers.  It is well established 
that patients with microsatellite-high (MSI-H), sporadic colorectal cancer typically have favorable 
outcome (Samowitz et al. 2001) and recently loss of p27 has been associated with poor outcome in 
stage III colon cancers (Bertagnolli et al. 2009).  Currently, loss of heterozygosity at chromosome 18q 
(Watanabe et al. 2001) is being evaluated prospectively in stage II and stage III patients for its value 
in selection of high-risk stage II and III colorectal cancers at resection.   
    Determination of high-risk colorectal cancers at the earliest stage possible is a primary goal for 
clinicians worldwide (e.g., at surgical resection or in a surveillance assay).  Untargeted adjuvant 
chemotherapy in stage II patients produces a small absolute reduction in death at 5 years (Quasar 
Collaborative et al. 2007), but recent meta-analysis indicates that a sub-group of ‘high-risk’ stage II 
patients do benefit from such treatment (Figueredo, Coombes, and Mukherjee 2008).  Conversely, 
40-45% of stage III patients will not recur after surgical resection of their cancer (Ragnhammar et al. 
2001), whereas 55-60% of stage III patients would die without adjuvant chemotherapy.  Therefore, 
objective identification of high-risk stage II patients who would benefit from adjuvant chemotherapy 
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and selection of low-risk stage III patients who could be spared the cost, morbidity and potential 
mortality of systemic chemotherapy could prevent thousands of deaths each year in the US.  To this 
end, use of molecular detection tools for aberrant DNA methylation in fecal DNA, plasma cell-free 
DNA and in resected tissues with RNA profiling are under intense investigation to uncover reliable 
‘high-risk’ biomarkers (Imperiale et al. 2004; Jorissen et al. 2009; Li et al. 2009).  
 
Biological Models of Colorectal Cancer 
 
  Multiple mouse models of colorectal cancer are in use and have been successful in aiding our 
understanding of colorectal cancer pathogenesis.  For example, since it is known that inappropriate 
activation of the Wnt pathway is the key event in initiation of colonic polyps, the APCMin mouse has 
been particularly informative on its own and with introduction of additional genetic lesions that 
potentiate the development of adenomas and/or adenocarcinomas (Moser, Pitot, and Dove 1990; Su 
et al. 1992; Takaku et al. 1998).  Transplantation models (e.g. xenografts) are an important 
methodology to inform the biology of colon cancer cell tumorigenicity and metastasis and were used 
prior to the development of genetic mouse models (Heijstek, Kranenburg, and Borel Rinkes 2005; 
Kobaek-Larsen et al. 2000).  There are few (if any) genetic mouse models of spontaneous tumor 
development that invade and then metastasize (Taketo and Edelmann 2009).  The development of 
such a model is critical since metastasis is responsible for most of the mortality in colorectal cancer.  
In the meantime, xenograft models and colon cancer cell lines derived from mouse colon cancers 
(Corbett et al. 1975; Franks and Hemmings 1978) in addition to genetic mouse models are the 
workhorses for discovery in the biology and progression of colorectal cancers.   
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    In this body of work, we demonstrate novel, in vitro and in vivo translational application to human 
disease in a mouse colon cancer cell line to the process of metastasis (see Chapter II) in addition to 
testing of human colon cancer cell lines in a xenograft model to compliment in vitro findings in 
exploring the process of tumor suppression (see Chapter III).  Use of these biological models can still 
allow important discoveries even though a spontaneous model of colorectal tumorigenicity and 
metastasis is on the horizon.  For example, we describe two strategies based upon biological models 
that may prove useful in detection of high-risk colorectal cancer patients with use of tissue available 
upon surgical resection to inform treatment decisions and guide novel biologic therapies in Chapters 
II and III of this work.  First, we used a mouse model of colorectal cancer founded on the biology of 
metastasis to identify a gene expression signature that when applied to resected tumor tissues from 
colon cancer patients selected high-risk stage II patients and low-risk stage III patients.  Secondly, we 
used an in vitro model of epithelial cells to uncover a novel mechanism whereby Smad4 represses 
the transcriptional activity of -catenin and downstream Wnt signaling activity.  This program of 
transcriptional repression by Smad4 led to the discovery of a gene expression signature that 
identified an additional subset of high-risk colorectal cancer patients.   
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Summary 
 
    Colorectal cancer is the second most lethal, non-cutaneous epithelial cancer in the United States.  
Metastasis contributes to the majority of cancer-related deaths in this disease.  Metastasis closely 
resembles the developmental process of EMT and reliable models to recapitulate this process can be 
useful to shed light onto the biology and prognosis of patients with colorectal cancer.  In Chapter 2, 
we describe an immunocompetent mouse model that led to the discovery of a gene signature of 
metastasis, which identified stage II and III colon cancer patients prone to recurrence and death from 
metastatic disease, in addition to a low-risk sub-group of stage III patients for whom adjuvant 
chemotherapy provided no additional survival benefit.  These findings form the basis for substantive 
pre-clinical biomarker testing and eventual translational application to a clinical trial.  This work was 
recently published (Smith et al.).   
    On the other hand, defects in tumor suppressor genes affect the majority of colorectal cancer 
patients.  Many pathways are defective in the pathogenesis of colorectal cancer; however, more than 
half of the patients have defects in the Wnt/-catenin and TGF signaling pathways which are critical 
for development and intestinal homeostasis.  In Chapter 3, we use in vitro and in vivo models to 
describe a new role for the tumor suppressor Smad4 in the repression of -catenin transcriptional 
activity in epithelial cells.  This repression was associated with down-regulation of Wnt signaling and 
reversal of EMT.  Clinical relevance of this effect was demonstrated by an epithelial cell-specific, 
Smad4-modulated gene expression profile associated with Wnt signaling suppression, which 
contributed prognostic information for colorectal cancer patients independently of pathological 
staging.  This work will be submitted for publication immediately post-dissertation.  These findings 
should facilitate hypothesis testing for biologically-targeted therapeutic interventions based on 
 24 
TGF/Smad and Wnt/-catenin pathway activity levels.  Overall, these results provide insight into the 
biology of metastasis and tumor suppression in colorectal cancer to promote seamless translation to 
care of the colorectal cancer patient at the bedside. 
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CHAPTER II 
 
AN EXPERIMENTALLY DERIVED METASTASIS GENE EXPRESSION PROFILE PREDICTS 
RECURRENCE AND DEATH IN COLON CANCER PATIENTS 
 
Abstract 
 
    Staging inadequately predicts metastatic risk in colon cancer patients. We used a gene expression 
profile derived from invasive, murine colon cancer cells that were highly metastatic in an 
immunocompetent mouse model to identify colon cancer patients at risk for recurrence.  This phase I, 
exploratory biomarker study used 55 colorectal cancer patients from Vanderbilt Medical Center 
(VMC) as the training dataset and 177 patients from the Moffitt Cancer Center as the independent 
dataset. The metastasis-associated gene expression profile developed from the mouse model was 
refined using comparative functional genomics in the VMC gene expression profiles to identify a 34-
gene classifier associated with high risk of metastasis and death from colon cancer. A metastasis 
score derived from the biologically based classifier was tested in the Moffitt dataset.  A high score 
was significantly associated with increased risk of metastasis and death from colon cancer across all 
pathological stages and specifically in stage II and stage III patients. The metastasis score was 
shown to independently predict risk of cancer recurrence and death in univariate and multivariate 
models. For example, among stage III patients, a high score translated to increased relative risk for 
cancer recurrence (hazard ratio = 4.7 [95% confidence interval=1.566-14.05]). Furthermore, the 
metastasis score identified stage III patients whose 5-year recurrence-free survival was >88% and for 
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whom adjuvant chemotherapy did not increase survival time.  A gene expression profile identified 
from in an experimental model of colon cancer metastasis predicted cancer recurrence and death, 
independently of conventional measures, in patients with colon cancer. 
 
Introduction 
 
 Colorectal carcinoma is the 3rd most commonly occurring non-cutaneous carcinoma and the 
2nd leading cause of cancer-related death in the United States (Jemal et al. 2009).  While it is well 
established that adjuvant chemotherapy for stage III colon cancer patients results in a survival benefit 
for the group, careful review of clinical trials data reveals that 40-44% of stage III patients enrolled in 
“surgery-only” groups did not recur in five years even without adjuvant treatment (Ragnhammar et al. 
2001).  Therefore, this subgroup of stage III patients, if prospectively identifiable, is unlikely to achieve 
benefit from and could be spared adjuvant chemotherapy. In addition, clinical trials have failed to 
demonstrate the benefit of adjuvant chemotherapy when applied to unselected patients with stage II 
colon cancer (Benson et al. 2004; Gill et al. 2004; Mamounas et al. 1999).  On the other hand, some 
studies suggest that a subset of high-risk stage II colon cancer patients may benefit from adjuvant 
therapy (Figueredo et al. 2004; Figueredo, Coombes, and Mukherjee 2008; Quasar Collaborative et 
al. 2007).  Much of these data for stage II patients come from meta-analyses and the question of 
whether adjuvant treatment really improves outcomes in stage II patients with “high-risk” features 
(e.g., T4 lesions, poorly differentiated histology or lymphovascular invasion) has not been answered 
in prospective clinical trials to date. Thus, an accurate and reliable method that identifies patients at 
greatest and least risk (e.g., “high-risk” stage II and “low-risk” stage III patients) could improve the 
selection of individualized therapy within these groups.   
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In this study, an experimental mouse model of metastasis was used to develop a gene 
expression profile that discriminated high versus low risk of cancer recurrence and death in colon 
cancer patients.  This biologically based model identified distinct subsets of stage II and III colon 
cancer patients at greater risk of cancer recurrence and death.  Using a metastasis score derived 
from the gene expression profile, we found that low metastasis score stage III patients did not gain 
significant benefit from adjuvant chemotherapy, suggesting that these patients could have been 
spared the potentially toxic and costly effects of these treatments.  Conversely, high metastasis score 
stage III patients treated with adjuvant chemotherapy had markedly improved outcomes compared 
with high metastasis score patients who did not receive adjuvant chemotherapy. Thus, our 
biologically based gene expression profile provides a potential platform to facilitate selection of colon 
cancer patients who may benefit from adjuvant systemic therapy. 
 
Materials and Methods 
 
Cell Culture and Mouse Model Overview 
 
     MC-38 mouse adenocarcinoma cells were obtained from the American Type Culture Collection 
(ATCC, Manassas, VA) (Lafreniere and Rosenberg 1986).  MC-38 cells were transfected with firefly 
luciferase gene (pGL3 basic, Promega, Madison, WI) and selected (G418, Invitrogen, Carlsbad, 
California).  To enrich for invasive cells, 7.5 x 105 cells were seeded onto 6-well, 8.0 μM pore 
transwell polycarbonate membrane inserts (Costar, Cambridge, MA) coated with 2.5 mg/mL matrigel 
and incubated with serum-free DMEM in the upper chamber and complete DMEM in the bottom well.  
After 12 hours, cells that invaded were aseptically harvested by brief, gentle trypsinization and 
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transferred to new dishes (Poste, Doll, and Fidler 1981) and six serial passages through matrigel-
coated Boyden chambers ensued.  The selected invasive cells and the parental luciferase-expressing 
MC-38 cells were injected into the tail vein and development of lung metastases was assessed (Fidler 
and Nicolson 1976). Development of metastases was determined by bioluminescence imaging 
(Jenkins et al. 2003; Wu et al. 2001). The MC-38met cells were derived by culture of tumor cells from 
a metastatic lung tumor (Whitehead 1976). The Vanderbilt Institutional Animal Care and Use 
Committee approved all animal work.  
Detailed Cell Culture and Mouse Methods 
MC-38 mouse adenocarcinoma cells were obtained from ATCC and cultured. MC-38 cells 
were transfected with firefly luciferase gene in pGL3 basic (Promega, Madison, WI) and selected in 
0.5 mg/mL G418 (Invitrogen, Carlsbad, California) and referred to as MC-38 parentals. To enrich for 
invasive MC-38 parental cells, 7.5 x 105 cells were seeded onto 6-well, 8.0 μM pore transwell 
polycarbonate membrane inserts (Costar, Cambridge, MA) coated with 2.5 mg/mL matrigel and 
incubated with serum-free DMEM in the upper chamber and complete DMEM in the bottom well.  
Cells collected after the 6th passage were designated “MC-38inv”.  To quantify the enrichment of 
invasive cells, cells were again incubated in matrigel-coated transwell filters for 24 hours at 37°C, 5% 
CO2.  Filters were washed and cells on the upper surface were removed with cotton swabs.  The cells 
that had invaded were fixed in 4% paraformaldehyde for 10 minutes and stained with 1% crystal 
violet.  Four random fields were counted to determine the numbers of invaded cells.  To determine 
metastatic potential in vivo, equivalent numbers of MC-38 parental or MC-38inv cells were injected 
into the tail veins of C57BL/6 mice and the mice were followed for development of pulmonary 
metastases.  Briefly, unanesthetized C57BL/6 mice were warmed with a heat lamp to allow for 
venous dilation.  Mice were then placed into a plastic restraining apparatus and 2.5 x 105 MC-38 
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parental, MC-38inv or MC-38met cells were injected via lateral tail vein (n = 10).  Successful injection 
and growth of metastatic lung nodules was confirmed by immediate and then weekly 
bioluminescence imaging (BLI).  MC-38 in vivo metastatic cells (“MC-38met”) were derived from 
metastatic lung nodules following washing and sterilization of fresh tumor tissue in 0.04% sodium 
hypochlorite.  The tissue was next rinsed in PBSA, minced into approximately 1mm3 pieces, collected 
and resuspended in collagenase / neutral protease solution for 90 minutes at 37°C with occasional 
shaking.  Remaining tissue pieces were allowed to settle, and were then re-suspended in fresh 
collagenase / neutral protease solution and incubated at 4°C overnight.  The single-cell suspension 
was transferred to a new tube, centrifuged at 100g for 5 minutes, washed once with growth medium 
and then re-suspended in growth medium and plated onto collagen-coated 25cm flasks and 24-well 
dishes.  Cells were grown at 37°C with 5% CO2 under G418 selection.  The invasive phenotype of the 
MC-38met cells was confirmed both in vitro and in vivo.  For the splenic assay, 2.5 x 105 cells were 
implanted under the splenic capsule 2-3 minutes prior to splenectomy and metastatic foci derived 
from resulting circulating tumor cells were followed as they formed in the liver by BLI.  This work was 
done by Fei Wu, M.D., Ph.D. in the Beauchamp laboratory.  The work that follows was performed by 
J. Joshua Smith, M.D. 
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Human Tissue and Microarray Platforms 
 
     The protocols and procedures for this study were approved by the Institutional Review Boards at 
the University of Alabama-Birmingham Medical Center, Vanderbilt Medical Center (VMC), the 
Veterans Administration Hospital (Nashville, TN) and the H. Lee Moffitt Cancer Center (MCC, Tampa, 
FL).  Representative sections of fresh tissue specimens were flash frozen in liquid nitrogen and 
stored at -80ºC until RNA isolation.  Quality assessment slides were obtained to verify the diagnosis.  
Stage was assessed by American Joint Commission on Cancer (AJCC) guidelines.  RNA was purified 
using the RNeasy kit (Qiagen, Valencia, CA).  Mouse and human samples were hybridized to 
Affymetrix arrays (Mouse Genome 430 2.0 GeneChip Expression and Human Genome U133 Plus 2.0 
GeneChip Expression Arrays, respectively). 
 
Statistical Methods and Identification of VMC High-Risk Patients 
  
    Microarray data for the metastatic MC-38met cells and the parental MC-38 cells and the human 
data were processed using the Robust MultiChip Analysis (Irizarry et al. 2003) algorithm as 
implemented by Bioconductor (pmid: 12582260).  Mouse probe set identifiers (IDs) were mapped to 
Ensembl Gene IDs based on the mapping provided by Ensembl V49 (http://www.ensembl.org). 
 Median expression levels from multiple probe sets corresponding to the same gene were calculated. 
Mouse genes with one-to-one human ortholog mapping as annotated by Ensembl V49 were carried 
forward for differential expression analysis using the limma package in Bioconductor (Smyth, 
Michaud, and Scott 2005)  The 300-gene metastasis-associated signature was determined with the 
limma package in Bioconductor (Smyth, Michaud, and Scott 2005) based upon 3 criteria: (1) Fold 
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change >2; (2) False discovery rate (FDR) based on the moderated t-test followed by Benjamini and 
Hochberg’s multiple-test adjustment <0.01; and (3) Log odds ratio of differential expression (B-
statistic) > 1. This analysis resulted in a subset of 300 differentially expressed genes that could be 
unambiguously mapped to human orthologs.  Gene expression datasets were separately 
standardized such that each gene had a mean expression value of 0 and a standard deviation of 1 
across samples in a dataset.  A direction of expression was assigned for each gene in each sample 
based on the sign of the standardized value.  Directional concordance between MC-38met cells and 
19 patients from VMC with poor outcome (17 stage IV patients and 2 stage III patients who developed 
metastatic recurrence (n=19)) was determined (exact binomial test, P.10) to refine the metastasis-
associated signature to the 34-gene recurrence classifier.  Specifically, each gene of the murine 
training-set was examined in the VMC patient-derived training set in patients with stage III or stage IV 
disease who had experienced metastasis or cancer-related death.  Nineteen patients fell into these 
categories and the median expression level of each of the 300 genes was examined for concordance 
with MC-38met median expression.  The genes with concordance (+1 or -1) in at least 13 of 19 
patients (Exact binomial test, P0.10) were selected for the putative recurrence profile.  The 
concordance analysis resulted in a 34-gene profile that was termed the ’34-gene metastasis score’ or 
more simply the ‘34-gene recurrence classifier’.  Integration of mouse and human microarray datasets 
was conducted (Lee and Thorgeirsson 2004).  Clustering (Pearson's correlation coefficient) was 
applied to the integrated data set as follows:  average linkage clustering based on Pearson's 
correlation coefficient was applied to the integrated data set. The ceiling was set to cover 95% of all 
data points (e.g., the top 5% z-scores were truncated).  The corresponding z-score is 2.00 for the 34-
gene classifier. 
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Clinical Outcomes and Testing of the 34-gene Based Metastasis Score 
 
    The association between individual gene expression level and clinical endpoint (overall survival 
(OS), disease-specific survival (DSS) and disease-free survival (DFS)) were first analyzed using a 
Cox Proportional Hazard (PH) model (Beer et al. 2002; Hedenfalk et al. 2001; Tukey 1993; 
Yanagisawa et al. 2003) and definitions for each are provided below (Vanderbilt Cox Model (Training 
Dataset)).  A compound score was calculated for each patient by summation of a Cox PH weighted 
sum (Wald score) of log-2 gene expression for each gene in the classifier (Yanagisawa et al. 2003). 
The compound score was used to measure the impact of the 34-gene classifier on survival (OS and 
DSS) and recurrence (DFS).  A Vanderbilt-derived Cox model and re-sampling Wald tests were 
utilized to rule out over-fitting of the model.  The estimated coefficients of the Cox PH model in the 
VMC data (n=55 patients) were applied to the MCC dataset (n=177 patients). In addition, a censored 
C-index (Harrell et al. 1982) was computed to validate the predictive value of the identified expression 
classifier.  The compound scores were used in a univariate analysis (e.g., log-rank test) to segregate 
patients into higher than median and lower than median compound score groups.  The compound 
score, age, gender and tumor grade were adjusted in the multivariate Cox model for both DSS and 
DFS.  Adjusted P-values as well as the adjusted 95% confidence intervals of the hazard ratios from 
the Cox model were reported.  Fisher’s exact test was used for the T4, histological, microsatellite 
instability status and the stage III metastasis score/chemotherapy analyses. 
Vanderbilt Cox Model (Training Dataset) 
    The association between individual gene expression level and clinical endpoint, (e.g., overall 
survival (OS) or disease-specific survival (DSS)), was first analyzed using a Cox Proportional Hazard 
(PH) model.  Overall-survival was defined as death from any cause.  Disease-specific survival was 
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defined as a documented cancer-related death. A disease-free survival event was defined as 
incidence of recurrence (~75% distant and ~25% local) after R0 resection.  Sixty Affymetrix probe 
sets can be found on the microarray HG U133 Plus 2.0 platform based on the thirty-four classifier 
genes (e.g., multiple probes for each gene were found that mapped to each of the 34 genes).  Their 
expression data were extracted from the VMC dataset (n=55).  Expression data for each Affymetrix 
probe set were treated as the independent variable, and the Cox proportional hazard model was used 
for survival analyses. A compound score was next calculated for each patient by obtaining a Cox PH 
weighted sum (Wald score) of log2 gene expression.  The compound score for patient i is defined as 
i Wi * Xii (where Wi=Wald statistic score for gene i and Xii = log2 gene i * expression level of patient 
i).  Finally, the compound score was used to measure the impact of the 34-gene profile on survival 
and a censored c-index was computed for the validation of the predictive value of the expression 
profile identified. The c-index is a probability of concordance between predicted and observed 
survival, with c = 0.5 for random predictions, and c = 1 for a perfectly discriminating model. The 
univariate analysis was completed using the compound scores to segregate patients into higher than 
median and lower than median compound score groups by Kaplan-Meier estimates to determine 
differences in survival by the log-rank statistic.  The compound score, age gender, and grade were 
adjusted in the multivariate Cox model for overall, disease-specific and disease-free survival.  The 
adjusted P-values as well as the adjusted 95% confidence intervals of the hazard ratios from the Cox 
model were reported.    
Moffitt Cox Model (Test Dataset) 
    Sixty Affymetrix probe sets can be found on the microarray HG U133 Plus 2.0 platform based on 
the thirty-four classifier genes. Their expression data were extracted from the MCC dataset (n=177).  
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Then we applied the estimated coefficients of the Cox PH model from the training set  (n=55) to the 
MCC dataset (n=177). 
Distribution of re-sampling Wald tests with the 34-gene recurrence classifier 
    Sixty Affymetrix probe sets can be found on the microarray HG U133 Plus 2.0 platform based on 
the thirty-four classifier genes.  Their expression data were extracted from the MCC dataset. 
Expression data for each Affymetrix probe set were treated as the independent variable, and the Cox 
proportional hazard model was used for survival analyses. Beta and Wald statistics for each 
Affymetrix probe set were used along with expression data to build up a compound score for each 
patient. The compound score was used as the independent variable to perform overall survival 
analysis based on the Cox model. The Wald test P value was saved as the observed P-value. For the 
re-sampling test, we randomly chose 60 Affymetrix probe sets from the 54675 sets on the whole 
array. We repeated the above procedure and generated one re-sampling Wald test P-value from the 
overall Cox model survival analysis. We repeated the re-sampling and survival analysis procedure 
10,000 times, generating 10,000 re-sampling Wald test P-values.  We transformed both the observed 
and re-sampling P-values into log10 format, plotted a histogram of the 10,000 re-sampling log10 (P- 
values), and added the observed log10 (P-value).  
Cox modeling of Disease-specific survival for relative risk according to percentile score 
    Percentiles across high-score patients were plotted related to relative risk.  Hazard ratios for 50th, 
75th and 90th percentiles were plotted as compared to the 10th percentile.  
Histologic Analysis and Microsatellite Instability in Association with Metastasis score 
    Fisher’s exact test for a 2 x 3 table was used to determine association between histology and 
metastasis score.  Fisher’s exact test was used for the metastasis score, T4 and histological analyses 
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in the stage II and III patients in the MCC dataset in addition to the analysis of the subgroup of 
microsatellite status patients for the combined VMC and MCC datasets. 
 
Pathway Analysis 
 
    Data were analyzed through the use of Ingenuity Pathways Analysis (IPA) and networks were 
generated with the use of IPA (Ingenuity Systems, www.ingenuity.com).  A dataset containing gene 
identifiers and corresponding expression values was uploaded into the application.  Each gene 
identifier was mapped to its corresponding gene object in the Ingenuity Pathways Knowledge Base.  
The cutoffs described in the statistical sections were used to identify genes whose expression was 
significantly differentially regulated.  These genes, called focus genes in IPA, were overlaid onto a 
global molecular network developed from information contained in the Ingenuity Pathways Knowledge 
Base.  Networks of these focus genes were then algorithmically generated based on their 
connectivity.  The Functional Analysis identified the biological functions and/or disease that were 
most significant in the data set.  Fisher’s exact test was used to calculate a P-value determining the 
probability that each biological function and/or disease assigned to the data set is due to chance 
alone. 
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Results 
 
Development of an Immunocompetent Mouse Model of Colon Cancer Metastasis 
 
    Tumors are a heterogeneous mixture of cells with varied invasive and metastatic potential. 
Therefore, we used a conventional invasion assay to enrich for a sub-population of highly invasive 
MC-38 mouse colon cancer cells (Fig. 5A, MC-38inv).  Following six serial passages through 
matrigel, MC-38inv cells were more invasive than MC-38 parental cells both in vitro and in vivo in a 
tail vein injection assay (Fig. 5B and Table 1, P<.001).  Lung tumors derived from MC-38inv cells 
were cultured to derive a highly metastatic cell line, MC-38met.  MC-38met cells were injected into 
the tail vein and spleen and produced extensive metastatic tumors in the lung and liver respectively 
(see Fig. 6 and Table 2).  Please note that the results from Chapter II are published (Smith et al.). 
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MC-38 parental and MC-38inv cells, derived as described in Figure 4 and Materials and Methods, were injected 
into the tail veins of C57BL/6 mice.  21 days post-injection, mice were humanely killed, and lung nodules were 
counted at necropsy. Summary statistics for the data and results are displayed (Mann-Whitney U test, median, 
standard deviation (s.d.)). 
 
 
 
 
 
 
 
 
 
Figure 5.  Cell Culture and Mouse Model:  murine model of metastasis, in vivo monitoring 
and ex vivo proof of metastases.  (A) MC-38 parental cells (heterogeneous: blue and red) 
were subjected to six sequential passages through matrigel-coated transwells (enrichment of 
invasive subpopulations of MC-38 cells (red)) called “MC-38inv”.  After in vivo passage, a 
stabilized cell line (pink cells) called “MC-38met” was established.  (B) MC-38inv cells were 
tested alongside MC-38 parental cells for the ability to form lung metastasis in a tail vein 
assay.  The figure shows representative tumor progression in live (C57BL/6) mice by 
bioluminescent imaging (days 1-21) and at the time of autopsy (day 21). 
38 
Figure 6.  MC-38 parental and MC-38met gross and histopathology in tail vein and splenic 
assays. Gross and representative histologic sections from lungs and livers of MC-38 parental 
(upper panel) and MC-38met (lower panel) injected mice are shown. For MC-38 parental-injected 
mice, minimal lung nodules (<10) and no liver metastases were noted. Prolific liver metastases 
(>200) were found in the MC-38met injected mice. 
Quantification of the incidence of liver metastasis in the splenic assay and mean 
liver weights taken at necropsy with summary statistics are shown (Mann-Whitney 
U test (SPSS, Version 16; SPSS Inc, Chicago, IL).  Median and standard 
deviation (s.d.) data are displayed.  Of note, in regard to MC-38met liver 
metastasis, 2 mice died prematurely of massive liver metastasis, and analysis 
was done on the 6 mice that survived to the end of the 3-week experiment. 
Quantification of lung weights from the tail vein assay is also shown in the lower 
panel of the table. 
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Discovery of a Gene Expression Profile Associated with Metastasis:  Mouse to Man 
 
    A flow diagram of the derivation of the metastatic gene expression signature and its refinement and 
testing is provided in Figure 7A.  MC-38 parental and MC-38met cell mRNA expression profiles were 
examined by microarray and directly compared to evaluate the gene expression changes associated 
with invasion and metastasis.  Gene elements from this microarray profile were mapped to 11,465 
corresponding human orthologs.  The initial cluster analysis and the 300 gene list are shown in Figure 
8 and Table 3 (Appendix).  In order to refine the signature with relevance to cancer recurrence, each 
of these 300 genes was scored for directional concordance (see Methods) with gene expression data 
from 19 “high-risk” VMC colon cancer patients that either had metastatic disease or had died from 
cancer progression (see Methods).  Thirty-four genes (Table 4) from the metastatic gene signature 
exhibited directional concordance in 13 of the 19 “high-risk” patients.  Since the 300 genes had been 
selected with stringent statistical criteria, we did not further attempt to determine the minimum number 
of genes that could discriminate outcomes. 
The resultant 34-gene expression pattern was designated the recurrence gene classifier and 
was next integrated with the entire VMC human microarray dataset and subjected to unsupervised 
cluster analysis. The recurrence gene classifier separated patients into two clusters (Fig. 7B).  The 
cluster associated with MC-38met cells (cluster 2) contained 17 of the 19 “high-risk” patients used in 
the signature refinement process. 
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Figure 7.  A) Recurrence classifier development.  VMC two-step schematic for enrichment and 
establishment of the 34-gene recurrence classifier for colon cancer.  Mouse genes were mapped to human 
orthologs and 300 differentially expressed genes (MC-38 parental vs. MC-38met) were identified. These 300 
genes were next refined with 19 “high-risk” patients from the VMC training dataset for concordance.  This 
analysis revealed 34 genes with concordant expression among the 19 high-risk patients and the MC-38met 
cells.  The 34-gene recurrence classifier was then applied to the independent MCC database to determine 
whether it could be used to discriminate patients on the basis of outcomes.  B) Functional genomic cluster 
analysis of the 34-gene recurrence classifier. Mean-centered gene expression data (rows) clustered with 
individual VMC patients (columns) results in two distinct patient groups (cluster 1, pink; cluster 2, green). 
The 19 VMC ”high-risk” patients used in the concordance analysis are marked with a red asterisk. 
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 Genes that were up-regulated or down-regulated in both MC-38met derived cells and in 19 VMC patients with 
poor-prognosis are shown. Gene symbols and associated fold-change in gene expression for MC-38 parental 
versus MC-38met as determined by microarray are given.  Known relationships (connectedness) between up-
regulated and down-regulated genes were determined independently and, where networks existed, functional 
enrichment within the networks was determined in Ingenuity Pathways Analysis (www.ingenuity.com), PubMed 
and on the Affymetrix website (see Materials and Methods).  Ensembl protein identifiers are also noted in Table 
3 (Appendix, p. 104). 
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The Recurrence Classifier Identifies Poor Outcome Colon Cancer Patients in an Independent Colon 
Cancer Dataset 
 
    An independent human colon cancer gene expression and clinical database from the H. Lee Moffitt 
Cancer Center (MCC) was used to test the ability of the recurrence classifier to discriminate patients 
at increased risk of cancer recurrence and death.  The demographics for the training (VMC) and test 
set (MCC) are shown in Table 5.  205 patients were available for analysis in the MCC group and 195 
of these patients had complete demographic, histological grade, stage and differentiation information.  
Of this 195 patient group, we focused on colon cancer patients (n=177) to avoid potential 
confounding effects of neoadjuvant and radiation therapy in rectal cancer patient tumor samples and 
outcomes.  A method for weighted scoring of the gene expression pattern for the recurrence classifier 
was applied (see Methods) and metastasis scores were created. Patients were segregated into 
higher and lower than median metastasis score groups and survival analysis was performed between 
the two groups.  To rule out over-fitting of the model, three separate statistical approaches were 
applied.  First, we developed the metastasis score based on the Cox Proportional Hazard (PH) model 
in the VMC data (n=55 patients) and then applied the estimated coefficients of the Cox PH model 
from VMC data to the MCC dataset (n=177 patients). Thus, the sign and magnitude of the coefficient 
was completely based on the training dataset (VMC) and then tested in the MCC dataset.  High 
metastasis score colon cancer patients across all stages in the MCC dataset had significantly worse 
overall and disease-specific survival compared with low metastasis score patients (Fig. 9A and B, 
P=.003 and P=.04 respectively).  Second, multiple permutation testing was performed using the 34-
gene recurrence classifier and the metastasis score was also robust in this model (see Fig. 10, 
Appendix).  Third, a c-index was calculated to validate the predictive value of the 34-gene metastasis 
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score. The c-index is a probability of concordance between predicted and observed survival, with c = 
0.5 for random predictions, and c = 1 for a perfectly discriminating model. 
In order to determine whether the metastasis score could be used to identify stage II and III 
patients at high risk for recurrence, we tested it on stage II and III patients in the MCC dataset.  Low 
metastasis score patients in each group (stage II alone, Fig. 11A-B and stage III alone, Fig. 11C-D) 
demonstrated significantly better outcomes than high metastasis score patients.  As can be seen in 
the figure, this finding held true in both analyses using the endpoints of disease-specific survival 
(cancer-related death, panels A, C) as well as disease-free survival (recurrence, panels B, D). 
Notably, there were no cancer-related deaths and only one recurrence event in low metastasis 
score stage II patients (see Fig. 11A, B).  At five years, 31% of the high metastasis score stage II 
patients had died of cancer versus none of the low score patients.  For the stage III patients, the five-
year mortality rate was 10.7% for low metastasis score patients as compared with 37.9% for the high 
metastasis score patients (see Fig. 11C).  The median survival time for stage III patients with a high 
metastasis score was 29.4 months.  In sharp contrast, the low metastasis score stage III patients as a 
group faired so well that this group had not reached the threshold to calculate their median survival 
time. We noted no association with either the high or the low metastasis score on available data 
regarding T4 lesions, lymph nodes retrieved, histological grade or microsatellite instability status in 
the MCC dataset (See details, pp. 44-45).  These data show that the 34-gene metastasis score can 
discriminate stage II and III colon cancer patients that have a low- or high-risk of cancer recurrence 
and death. 
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All patients were diagnosed with colorectal adenocarcinoma (stages I-IV) 
according to current American Joint Commission on Cancer (AJCC) 
guidelines.  On hundred seventy-seven of 205 MCC patients met the 
criteria of having AJCC stage I-IV colon cancer as well as complete 
demographic, histologic grade, stage and differentiation information. The 
Vanderbilt training set includes 14 patients from the University of Alabama-
Birmingham Medical Center (tumors provided by M.J.H).      Other in the 
VMC medical record implies not otherwise specified and it implies 
Hispanic or not otherwise specified in the MCC medical record. 
Figure 9. The 34-gene recurrence classifier as tested in the Moffitt Cancer Center (MCC) dataset 
across all stages. Kaplan-Meier estimates of overall and disease-specific survival in the MCC test set. 
Expression data for probes corresponding to the 34-gene recurrence classifier were used to build the 
Cox proportional hazard model from patient data in the Vanderbilt dataset. Plots represent survival 
analyses in the MCC patient data set, based upon Beta and Wald statistics (see Materials and 
Methods) from the Vanderbilt dataset.  (A) Overall and (B) disease-specific survival analyses were 
performed.  
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Figure 11.  Kaplan-Meier estimates from 114 colon cancer (stages II and III) patients under study at 
MCC analyzed with the 34-gene based metastasis score.  Lower than median metastasis score is 
denoted in black and higher than median metastasis score is noted in red.  A low score was associated 
with better disease-specific and disease-free survival in stage II patients (A) Cancer-related death: n = 
57 patients, high scores (9 of 9 total deaths) and (B) Disease-free survival: n = 55, high scores (10 of 11 
total events).  Similarly, a low score was associated with better disease-specific and disease-free 
survival in stage III patients (C) Cancer-related death: n = 57 patients, high scores (14 of 17 total deaths) 
and (D) Disease-free survival: n = 56, high scores (16 of 20 total events).  5-year mortality and 
recurrence rates are shown for stage II and III patients (A-D). 
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High Risk Characteristics and the Metastasis Score 
    In the stage II disease-free survival analysis, the four T4 lesions were evenly distributed between 
high (n=2) and low (n=2) metastasis score patients (P>.99).  The number of MCC T4 tumors is small 
and we will need to assess these characteristics as the metastasis score is tested in additional colon 
cancer patients to confirm this finding in association with the 34-gene metastasis score.  We found no 
significant differences in the distribution of well differentiated, moderately differentiated or poorly 
differentiated tumors in high or low score stage II patients (P=.47 and .22 respectively).  Furthermore, 
in regard to number of lymph nodes retrieved and metastasis score in the disease-specific survival 
analysis, we found equivalent numbers of patients with less than 12 lymph nodes retrieved in the low 
and high score groups (P>.99).  We also queried differentiation status and lymph nodes retrieved in 
the stage III patients and found no association with metastasis score and differentiation status or 
number of lymph nodes retrieved (data not shown).  These data indicate that the metastasis score 
performs independently of traditional pathological markers.  
    To determine if previously described, yet unproved, pathologic “high-risk” features in the stage II 
patients were associated with either the high or the low metastasis score we reviewed the available 
data regarding T4 lesions, lymph node retrieval and histology in the larger MCC dataset. In the 
disease-specific survival analysis, four of the 28 low metastasis score patients had T4 lesions, while 
only one of the 29 high metastasis score patients had a T4 lesion (P=0.19).  In the stage II disease-
free survival analysis, the four T4 lesions were evenly distributed between high (n=2) and low (n=2) 
metastasis score patients (P>0.99).  The numbers of T4 tumors are small in the MCC test set and we 
will need to assess these characteristics as the metastasis score is tested in a larger set of colon 
cancer patients before making any strong statements in association with the 34-gene metastasis 
score.  
 47 
    We found no significant differences in the distribution of well-differentiated, moderately 
differentiated or poorly differentiated tumors in high or low score stage II patients (P=.47 and .22 
respectively).  Furthermore, in regard to the number of lymph nodes retrieved and the metastasis 
score in the disease-specific survival analysis, we found that 12 of 28 low score patients had less 
than 12 lymph nodes retrieved while 12 of 29 high score patients had less than 12 lymph nodes 
retrieved (P>.99).  We also queried differentiation status and lymph nodes retrieved in the stage III 
patients and found no association with metastasis score and differentiation status or number of lymph 
nodes retrieved (data not shown).  These data indicate that the metastasis score performs 
independently of traditional pathological markers. 
Microsatellite Instability and the Recurrence Classifier 
    Other factors known to affect prognosis (e.g., microsatellite instability status [MSI] or CpG island 
methylator phenotype [CIMP]) could potentially impact our signature, however, only 73 (31%) of the 
patients analyzed in this study (VMC + MCC) had MSI status available which prevented a robust 
analysis adjusting for MSI status in a multivariate model. In a preliminary analysis of the 73 patients 
with known MSI status in the combined VMC and MCC datasets, 13 were MSI-high and 60 were 
microsatellite stable (MSS).  Of the MSI-high patients, 7 (54%) were in the low metastasis score 
group and 6 (46%) were in the high metastasis score group.  Additionally, 43% of the MSS patients 
were in the low metastasis score group while 57% were in the high score group.  No significant 
statistical association was noted comparing the recurrence classifier and microsatellite instability 
status in this study (P=.55).  We are prospectively collecting MSI-status on our patients and will factor 
this important prognostic factor into future work in light of the 34-gene classifier.  CIMP status was 
unavailable in the datasets used in our analysis. 
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A High Metastasis Score Predicts Recurrence and Survival in Univariate and Multivariate Models 
    The metastasis score was tested in the MCC patient dataset to determine the relative risk of 
recurrence and cancer-related death.  Patients with a high metastasis score had increased relative 
risk of recurrence, as measured by hazard ratios (HR) across all stages (Table 6, HR 4.9, P<.001).  
High score stage II patients were also at increased relative risk of recurrence (HR 13.1, P=.01). 
Finally, the relative risk of recurrence in stage III patients with a high score was increased in this 
analysis (HR 4.7, P=.006).  These data show that the metastasis score based on the 34-gene 
classifier is a strong predictor of recurrence and cancer-related death in colon cancer patients.   
    Multivariate analysis of the MCC patient data was performed to determine independent predictors 
of recurrence and survival.  After adjusting for metastasis score, gender, tumor stage, age and tumor 
grade, only the metastasis score (P<.001) and tumor stage (P=.002) were significant determinants of 
cancer recurrence (Table 7 (see Appendix)).  We observed similar results with disease-specific 
survival as the outcome measure in univariate and multivariate models (Tables 8 and 9 (see 
Appendix)).  Furthermore, the magnitude of the metastasis score was significantly associated with 
outcome.  Hazard ratios for cancer-related death demonstrated that across all stages, high 
metastasis score patients in the 50th, 75th and 90th percentiles are at increased relative risk of 
cancer-related death (HR=2.0, 3.1 and 4.6, respectively) compared with those patients with scores in 
the 10th percentile (Fig. 12). Therefore, the 34-gene metastasis score is an independent predictor of 
cancer recurrence and death in colon cancer patients even after adjustment for baseline 
characteristics available at resection (e.g., age, grade, stage and sex).  
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Univariate analysis was done with metastasis scores to 
segregate patients from the MCC data set into higher-than-
median and lower-than-median score groups. Hazard ratios 
(HRs) were calculated for each patient group related to 
disease-free survival. 
Figure 12.  Cox model hazard ratios. Percentiles across 
high-score MCC patients were plotted related to relative 
risk. Hazard ratios for the 50th, 75th, and 90th percentiles 
are plotted compared with the 10th percentile and show a 
2.0, 3.1, and 4.6 increased risk of cancer-related death 
from the 50th percentile upward. 
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The 34-gene Based Metastasis Score is Associated with Patient Benefit and Adjuvant Chemotherapy 
in Stage III Colon Cancer Patients 
 
    As described above, a significantly greater proportion of stage III patients with a high metastasis 
score died of cancer as compared with low metastasis score patients.  Thirty percent (17 of 57 
patients) of the stage III patients did not receive adjuvant chemotherapy (CTX).  Therefore, we sought 
to determine if there was a difference in survival between high and low metastasis score patients 
related to CTX administration. Stage III patients with a low metastasis score had equivalent survival 
outcomes regardless of whether or not they received adjuvant CTX (Table 10, 10% with CTX versus 
12.5% without CTX, P>.99).  Among stage III patients with a high metastasis score, a significantly 
greater proportion of patients who did not receive CTX died from their cancer as compared with those 
who did receive adjuvant CTX (86% vs. 36%, P=.04).  There was no statistically significant difference 
in follow-up interval or in the proportion of patients receiving CTX when comparing high and low 
metastasis score groups (P=.576 and P=.770). These data suggest that stage III patients with a low 
metastasis score did not gain significant benefit from adjuvant CTX, whereas stage III patients with a 
high metastasis score had a better outcome after adjuvant CTX. 
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Pathway Analysis of the 34-gene Recurrence Classifier 
 
    In order to relate our findings to basic tumor biology, we subjected the recurrence classifier to 
Ingenuity Pathways Analysis (IPA, Ingenuity Systems®, www.ingenuity.com).  Up-regulated genes 
formed a single network enriched for cancer and cell death while the down-regulated gene network 
was enriched for cell-to-cell signaling/interaction and immune response (see Table 4 and details 
below). 
Table of proportions shows associations between metastasis score, 
cancer-related death and exposure to adjuvant chemotherapy in 
stage III patients from the MCC data set.  As can be seen in the low 
score panel, no significant association was found between a low 
metastasis score and cancer-related death in those stage III patients 
receiving chemotherapy versus those who did not receive 
chemotherapy (Fisher’s exact test). 
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Figure 13. Functional enrichment of the up-regulated genes in the 
recurrence classifier. Genes or gene products are represented as 
nodes, and the biological relationship between 2 nodes is represented 
as an edge (line). All edges are supported by 1 reference from the 
literature, from a textbook, or from canonical information stored in the 
Ingenuity knowledge base. The 16 up-regulated genes in the classifier 
were considered for the analysis (shaded in gray). Predominant central 
regulatory nodes include p53 (TP53), tumor necrosis factor (TNF), and 
platelet-derived growth factor BB (PDGFBB). 
 Ingenuity Pathways Analysis and the Recurrence Classifier 
    In this analysis, up-regulated genes (n=16) formed a single interacting network that is functionally 
enriched for disease and process including cancer (CXCR7, EGR1, HES1, SPRY4, VDR, NQO1, 
ACTB, MGP), endocrine system disorders (HES1, VDR, EGR1), and cell death (EGR1, NQO1, 
HES1, VDR, MGP) (Table 4 and Fig. 13).  Down-regulated genes (n=18) similarly formed a single 
interacting network enriched for cell-to-cell signaling/interaction (MMP13, PRTN3, HPSE, DFBN31) 
and immune response/development/function (HPSE, PRTN3, MMP13) (Table 4 and Fig. 14). 
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Figure 14. Functional enrichment of the down-regulated genes in the 
recurrence classifier. Genes or gene products are represented as nodes, and 
the biological relationship between 2 nodes is represented as an edge (line). 
All edges are supported by 1 reference from the literature, from a textbook, or 
from canonical information stored in the Ingenuity knowledge base. The 18 
down-regulated genes from the high-risk signature were considered for the 
analysis (shaded in gray). Predominant central regulatory nodes in this 
network include tumor necrosis factor (TNF), cyclin-dependent kinase N1A 
(CDKN1A or p21), and interleukin-1 (IL-1). 
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As can be seen in Fig. 7B, the magnitude of the expression differences between up-regulated 
and down-regulated genes amongst patient samples from these two clusters is quite different, with 
differences in up-regulated genes being of higher magnitude than differences in down-regulated 
genes.  This distinction is suggestive of two uniquely regulated gene networks.  Indeed, when we 
performed network analysis, coordinate regulation of 11 of 16 up-regulated genes (69%) and 7 of 18 
down-regulated genes (39%) is apparent.  We found that the gene network represented by the up-
regulated genes is predominantly enriched in genes related to carcinogenesis, while the network 
represented by the down-regulated genes is predominantly enriched in genes related to inflammation. 
Specifically, a central node of the up-regulated genes was TP53, which has a significant role upon 
inactivation in the progression of colorectal cancer as discussed in Chapter I.  Additionally, a central 
node of the down-regulated genes was Tumor Necrosis Factor, which plays a major role in 
inflammation.  Chronic inflammation is a well-recognized risk factor for cancers of the alimentary tract 
(reviewed in (Wang and DuBois 2008)).  Experimental mouse models have been developed to 
demonstrate that inflammation is a potent tumor promoter in the gastrointestinal tract (Cooper et al. 
2000).  Indeed, the incidence of tumor formation in several genetic mouse models of intestinal 
neoplasia is dependent upon active immune responses induced by gut flora (Kado et al. 2001).  
Conversely, tumor progression is also associated with immune suppression.  In the current study, we 
used microarray analysis to identify perturbations in gene networks related to both carcinogenesis 
and inflammation.  Ongoing work in our laboratory aims to uncover the molecular mechanisms by 
which these two gene networks may interact to promote metastasis in our experimental model. 
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Discussion and Future Directions 
 
 In the present study, the biology of colon cancer metastasis was modeled in 
immunocompetent mice to develop a gene expression classifier that discriminates recurrence and 
survival outcomes in human colon cancer patients.  Stage II and stage III patients with primary colon 
cancers that reflected the recurrence-associated gene expression pattern were at greater relative risk 
of recurrence than those who did not (hazard ratios of 13.1 and 4.7, respectively). This gene 
expression profile, tested with a recurrence scoring method, performed independently of conventional 
pathological staging.   
Perhaps most importantly, this metastasis score identifies stage II patients at high risk of 
recurrence and death and stage III patients at low risk of recurrence and death.  Our biological model 
has identified a subset of high-risk stage II patients that may benefit from adjuvant therapy and a 
subset of low-risk stage II patients who may have an excellent outcome after surgical resection 
without adjuvant therapy.  We found that the 5-year survival rate was >95% in stage II patients with a 
low metastasis score, suggesting that adjuvant chemotherapy would provide minimal benefit in this 
group of patients. In contrast, 31% of stage II patients with a high metastasis score died of cancer.  
Our preliminary analyses of these data suggest that high metastasis score stage II patients should be 
further studied to determine whether they will benefit from adjuvant therapy.    
A unique aspect of our study is the inclusion of sufficient numbers of stage III patients who did 
not receive adjuvant chemotherapy in the MCC database.  This enabled an evaluation of whether the 
molecular metastasis score could predict response to adjuvant therapy.  Of the high metastasis score 
stage III patients who were treated with adjuvant chemotherapy only 36.4% died from cancer, 
whereas 85.7% of the high score patients who did not receive adjuvant chemotherapy died from 
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cancer.  Despite the small numbers in these sub-groups the differences were statistically significant.  
More importantly, equally low proportions of stage III patients with a low metastasis score died of 
cancer regardless of administration of chemotherapy.  Our data suggest that there is a low-risk group 
of stage III patients who could be surgically cured and spared the morbidity, expense and potential 
mortality associated with adjuvant chemotherapy.  This is consistent with prior observations from 
randomized clinical trials that established the benefits of adjuvant chemotherapy in stage III colon 
cancer where 40-44% of patients enrolled in the surgery-only groups did not recur in five years even 
without adjuvant treatment (Ragnhammar et al. 2001).  Determination of an objective scoring method 
whereby the 34-gene classifier can be tested in a prospective fashion is ongoing and will be required 
to determine if the 34-gene based metastasis score can be used clinically to guide decisions 
regarding adjuvant therapy for stage III colon cancer patients.   
Several investigative groups have reported gene expression classifiers with predictive power in 
breast, lung, liver and colorectal cancers (Barrier et al. 2006; Hoshida et al. 2008; Lin et al. 2007; Paik 
et al. 2004; Shedden et al. 2008; Wang et al. 2004). Like the previously described colon cancer 
classifiers, a weakness of our model is the retrospective analysis of prospectively collected clinical 
data.  A 43-gene poor-prognosis signature for colorectal cancer provides a classifier for stage II and 
III patients as a molecular staging device (Eschrich et al. 2005).  In a more recent study, a 
computational model was used to derive a 50-gene signature and a metastasis score for early stage 
colon cancer (Garman et al. 2008).  We found minimal overlap between our 34-gene classifier and 
the previously published, computationally derived colon cancer gene signatures.  We were not 
surprised at this finding since the prior models were computationally determined and ours is founded 
on the biology of metastasis.   
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We find it interesting that 13 of the 34 genes in our proposed classifier have previously 
described roles in cancer, and several others are involved in cell-cell signaling, immune response, 
cell proliferation, embryonic development and cell migration.  Inflammation plays a potent role in 
gastrointestinal tract tumor promotion and tumor progression is associated with immune suppression 
(Cooper et al. 2000; Kado et al. 2001; Wang and DuBois 2008).  In this study, microarray analysis 
identified perturbations in gene networks related to both carcinogenesis (e.g., TP53) and 
inflammation (e.g. TNF).  Ongoing work in our laboratory aims to unravel the molecular mechanisms 
by which these two gene networks may interact to promote metastasis in our experimental model. 
    A number of recent examples provide additional insight into the contributions of components in the 
34-gene classifier to the process of EMT.  For example, TNF- (a central node of the down-regulated 
genes in the classifier) has been connected to TGF-induced EMT via the Wnt target gene CD44 
(Takahashi et al.).  Additionally, hypoxia has been noted to promote EMT in breast cancer cells via 
up-regulation of HIF1- to promote transcriptional up-regulation of HES1 (Notch signaling target 
gene) and down-regulation of E-cadherin (Chen, Imanaka, and Griffin).  Also, Zeb1 (a known pro-
EMT gene inversely correlated with E-cadherin (Schmalhofer, Brabletz, and Brabletz 2009)) has been 
found to positively correlate with levels of vitamin D receptor in colorectal tumors (Pena et al. 2009).  
These data open up new possibilities that may inform the process of EMT that can be further 
explored in the MC-38 model in immunocompetent mice. 
The cross-species functional genomics approach yields insights into the molecular 
mechanisms of the metastatic process. Consistent with our approach, gene expression patterns 
identified in wound healing have been applied successfully to breast cancer outcomes (Chang et al. 
2004).  In addition, cell culture and mouse models have also demonstrated relevance to clinical 
outcomes in hepatocellular carcinoma using gene expression profiling (Kaposi-Novak et al. 2006; Lee 
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et al. 2004).  Similarly, our approach has uncovered a gene classifier with prognostic significance in 
colon cancer.   
Although a high score based on the 34-gene recurrence classifier worked well in this study, the 
number of significant genes reported was not based on the smallest number of genes that could 
discriminate the survival endpoint, but was based upon the combined statistical, biological and clinical 
evidence in the available data. There is also the possibility that some of the computationally derived 
genes discovered in human datasets would be missed in a mouse model; however, the biological 
basis of the 34-gene classifier derived from our mouse model seems to be a robust predictor.  The 
possibility of achieving similar or better survival discrimination with different subsets of the genes 
certainly exists; however, we feel that the biological basis of our study provides a solid foundation for 
further translational application and testing of our model. 
In conclusion, the 34-gene based metastasis score can identify stage II and III patients at 
greater risk of colon cancer recurrence and death.  Our biologically based expression classifier 
identifies a potential method for more appropriate selection of patients for systemic therapy after 
curative-intent surgical resection of colon cancer.  Future prospective studies are needed to confirm 
whether chemotherapy may be safely avoided in stage III patients with a low metastasis score and 
whether stage II patients with a high metastasis score can achieve a better outcome if they receive 
adjuvant chemotherapy.  Furthermore, we have begun work to determine the strongest drivers of the 
34-gene classifier with additional statistical modeling as we move forward with the determination of an 
objective score that can be taken into a prospective trial in stage II colon cancer patients.  Finally, 
since the model is based on the biology of metastasis we are currently looking into the ability of the 
34-gene classifier to predict outcome in other epithelial cancers such as breast or lung cancer. 
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CHAPTER III 
 
SMAD4 INHIBITS WNT SIGNALING IN EPITHELIAL CELLS BY TRANSCRIPTIONAL 
REPRESSION OF -CATENIN 
 
Abstract 
 
    Transforming Growth Factor- and Wnt signaling pathways are essential during embryonic 
development, and later regulate intestinal epithelial cell differentiation and proliferation. Central 
mediators of these pathways, Smad4 and -catenin, have important roles in cellular signaling and 
colorectal cancer pathogenesis.  Smad4 is a tumor suppressor frequently mutated in colon cancer; 
whereas -catenin accumulation and nuclear localization contribute to both the initiation and 
progression of colorectal cancers.  Smad4 expression in Smad4-mutant colon cancer cells results in 
decreased -catenin protein levels and inhibition of -catenin/TCF-driven transcription. Here, we 
determine the mechanism and significance of Smad4 inhibition of Wnt signaling in colorectal cancer.  
We found that Smad4 mediates a direct transcriptional repression of -catenin with resultant inhibition 
of -catenin-mediated gene expression in epithelial cells.  Consistent with these findings, we 
observed that the biological consequence of Smad4 expression in colon cancer cells is reversal of 
epithelial-to-mesenchymal transition (EMT) and cell invasiveness.  From analysis of clinical tumor 
samples, we found that patients whose tumors exhibited high Smad4 expression and reduced 
expression of Wnt target genes have significantly better prognosis than those who exhibit low Smad4 
expression with elevated gene expression of Wnt targets and EMT markers.  
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Introduction 
 
    Mutational inactivation of Adenomatous polyposis coli (APC) occurs in >80% of sporadic colorectal 
cancers associated with the loss of a master cell regulatory mechanism for epithelial cell growth, 
renewal and homeostasis (Ashton-Rickardt et al. 1989; Morin et al. 1997; Rowan et al. 2000; Sansom 
et al. 2004).  APC is part of a cellular protein complex that regulates the availability of the Wnt 
signaling mediator, -catenin, which is critical for maintenance of the intestinal epithelial stem cell 
compartment at steady-state (Aberle et al. 1997; Ikeda et al. 1998; Kishida et al. 1998; Korinek et al. 
1997; Munemitsu et al. 1995; van de Wetering et al. 2002).  In the absence of functional APC, -
catenin accumulates and translocates to the nucleus along with TCF/LEF co-transcriptional mediators 
where it may inappropiately propagate canonical Wnt signaling outside of its normal stem cell niche 
(Radtke and Clevers 2005).  Pathological activation of Wnt signaling participates in the initiation and 
progression phases of colorectal cancer and accumulating evidence suggests that it drives epithelial-
mesenchymal transition (EMT), particularly where signaling is further amplified at the invasive front in 
colorectal cancer specimens (Brabletz et al. 2005; Hlubek et al. 2007).  The EMT process has been 
linked to invasive phenotype and metastatic potential in cancer (Thiery 2002, 2003). 
    The Transforming Growth Factor- (TGF) family of ligands (TGFs, Inhibin, Activin, Nodal, Bone 
Morphogenetic Proteins (BMPs)) and cell signaling responses underlie fundamental epithelial cell 
processes of proliferation, apoptosis and differentiation (Massague 2008; Shi and Massague 2003).   
TGF inhibits epithelial cell growth and proliferation in normal cells, a property which is lost in many 
transformed cells (Ko et al. 1995; Manning et al. 1991) and in cancer (Hanahan and Weinberg 2000; 
Moses, Yang, and Pietenpol 1990; Pietenpol et al. 1990).  Over 50% of colorectal cancers harbor 
inactivating mutations in the TGF/BMP signaling pathway (e.g., receptor or Smad signaling protein 
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(Grady et al. 1999)).  TGF and BMP signaling occurs through interaction with heterotypic (Type 
I/Type II) serine/threonine kinase receptors which phosphorylate receptor-associated Smads 
(Smad2/3 or Smad1/5/8), and then complex with Smad4 and translocate to the nucleus to promote 
transcription (Shi and Massague 2003).  Smad4, the common mediator of TGF/BMP signaling, is the 
most frequently disrupted Smad mediator in pancreatic (Hahn et al. Homozygous deletion map at 
18q21.1 in pancreatic cancer 1996) and colorectal cancers (Thiagalingam et al. 1996).  Smad4 
mutations have been identified in 50% of pancreatic cancers (Hahn et al. Homozygous deletion map 
at 18q21.1 in pancreatic cancer 1996; Hahn et al. Dpc4, a candidate tumor suppressor gene at 
human chromosome 18q21.1 1996) and 10-35% of colorectal cancers (Markowitz and Bertagnolli 
2009; Riggins et al. 1997; Riggins et al. 1996).  
    TGF/BMP and Wnt signaling pathway crosstalk has an important impact on embryonic 
development and homeostasis (Cadigan and Nusse 1997; Whitman 1998).  For example, expression 
of BMP antagonists is associated with dedifferentiation, increased proliferation and enhanced -
catenin nuclear localization in normal human intestinal epithelium and in cancer (Kosinski et al. 2007).  
Transgenic Noggin expression in the mouse intestine results in intestinal polyps similar to humans 
with Juvenile Polyposis Syndrome (JPS) and these lesions were noted to have increased nuclear -
catenin immunostaining (Haramis et al. 2004).  Smad4 loss plays a significant role in JPS as patients 
with reduced intestinal Smad4 expression are predisposed to the development of intestinal 
carcinomas (Howe et al. 1998).  In Xenopus, Smads interact with TCF/LEF1 and activate 
transcription from the Xenopus Wnt signaling target, Xtwn (Labbe, Letamendia, and Attisano 2000; 
Nishita et al. 2000).  Interestingly, compound Smad4/APC-heterozygous mutant mice develop more 
invasive intestinal carcinomas than APC heterozygous mutant mice in which benign intestinal 
adenomas are the predominant lesion, suggesting that Smad4 expression tempers APC-driven tumor 
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formation (Takaku et al. 1998).  Therefore, dual-regulation of TGF and Wnt pathways can modulate 
differential responses of growth inhibition, tumor promotion or de-differentiation in epithelial cells; 
however, specific mechanisms by which Smad4 interacts with components of the Wnt signaling 
pathway in colorectal cancer remain largely undefined. 
    In this study, we examined the mechanism by which Smad4 represses -catenin expression and 
Wnt signaling in colorectal cancer.  We found that Smad4 expression results in transcriptional 
repression of -catenin expression and thereby inhibits Wnt signaling, with an associated inhibition of 
the downstream program of Wnt target gene expression.  Finally, the clinical relevance of this effect 
was demonstrated by an epithelial cell-specific, Smad4-modulated gene expression profile associated 
with suppression of Wnt signaling in human colorectal cancer specimens.  This Smad4-modulated, 
Wnt-associated gene expression program yields prognostic information, independent of conventional 
pathological staging in a large cohort of colorectal cancer patients. 
   
Materials and Methods 
 
Primers 
    Primers for all PCR reactions were obtained from either realtimeprimers.com (Elkins Park, PA) or 
from Integrated DNA Technologies, Inc. (Coralville, Iowa) and are listed in (Table 17, see Appendix p. 
187).  
Reverse Transcriptase Polymerase Chain Reaction (RT-PCR) 
    RNA (see collection method below) was reverse transcribed with MMLV reverse transcriptase 
(Promega, City, State, M170A) in each reaction as described below (Sequences obtained and then 
ordered as above).  RNA (0.5 μg), random hexamers (2.5μL) and RNase/DNase free water (5μL) 
 63 
were incubated at 70ºC for 5 minutes (11μl reaction).  MMLV-RT 5X buffer (5μL), dinucleoside 
triphosphates (dNTPs, 10mM, 5μL), RNAse inhibitor (1μL), MMLV-RT enzyme (1μL) and water (5μL) 
were placed into the 11μL reaction and incubated at 37ºC for 5 minutes, 25ºC for 10 minutes, 37ºC 
for 60 minutes and stopped at 70ºC for 10 minutes.  Red Taq buffer (2μL), Red Taq polymerase 
(Sigma-Aldrich, St. Louis, MO) enzyme (1μL), dNTPs (0.4μL), cDNA (2μL), Primer set (2μL, Forward 
+ Reverse) and RNase/DNase free water (12.6μL) were used for each 20μL reaction.  Each cDNA 
reaction was prepared on the same day and then run on a Gene Amp PCR System 9700, Applied 
Biosystems (Foster City, CA) under the following protocol (94°C--5min; 32 cycles of 94°C--20sec; 
55°C-20sec; 72°C-20sec; 72°C--1min).  Twenty μL of the PCR product and 4μL of 6X DNA loading 
dye was then loaded into 2% agarose gel and run at 100V for 1-1.5 hour and visualized on a BioRad 
Molecular Imager (Hercules, CA). 
 
Quantitative real-time PCR (qPCR) 
RNA Collection 
     SW480vector and SW480Smad4 colon cancer cells were seeded equally into 6-well plates.  At 80% 
confluence, cells were harvested in parallel using the Qiagen RNeasy® kit (Valencia, CA), according 
to the manufacturer’s instructions. Samples were DNAse treated during purification and eluted with 
50 μL RNAse/DNAse free water. RNA integrity was checked by visual inspection following agarose 
gel electrophoresis.  Quantitation was conducted in triplicate by UV Spectrophotometry.  RNA 
(300ng) was reverse transcribed using Superscript III (Invitrogen) in each reaction using gene specific 
primers (see Appendix, p. 187).  Reactions were performed for 20 min at 50oC followed by 10min at 
95oC to inactivate enzymes. For PCR reactions, each well contained SYBR Green Master Mix 
(12.5μL) from SuperArray, RNase/DNase free water (10.5μL) combined with 10μM Primer sets (1μL) 
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and 1μL of freshly prepared cDNA.  Each cDNA reaction (25μL) was loaded in quadruplicate in 96 
well plates and run on a Bio-Rad iCycler (Hercules, CA) under the following protocol (1:  95°C, 30sec; 
2:  95°C, 30sec (x2); 3:  95°C, 13min-30sec; 4:  95°C, 15sec; 55°C, 30sec; 72°C, 30sec (x45); 5:  
72°C--7min; 6: 55°C, 10 sec (x100)).  
mRNA Stability 
    SW480vector cells and SW480Smad4 cells were grown in regular medium and treated at 4-hour 
intervals with 5,6-Dichlorobenzimidazole, 1--D-ribofuranoside (DRB, Sigma, St. Louis, MO).  After 
RNA isolation, qPCR was utilized to determine the difference in -catenin steady-state mRNA levels 
after DRB treatment.  Cells were harvested at 4-hour intervals for 24 hours.  RNA was isolated from 
cells as above at each time point.  Two doses of DRB were used.  qPCR was used to analyze the 
amounts of -catenin mRNA at each time point and analysis of covariance was used to determine if 
the slope if the two lines was significantly different.  Cyber-green qPCR was performed using human 
-catenin primer (see Appendix, p. 187 and main methods). 
Data Analysis 
    For each individual well, fluorescence curves were log transformed and the slope of the logarithmic 
portion of the reaction was extracted to determine efficiency. Ct values and efficiency were utilized to 
calculate the relative expression levels and plotted as 1/Ct (Cronin et al. 2007; Schefe et al. 2006). 
 
Flow Cytometry 
    Transient expression of Smad4 was carried out in SW480 cells and HEK-293T cells along with 
GFP.  GFP-positive cells were separated from GFP-negative cells with a cell sorter and the 
populations were compared.  RNA and protein were isolated from the two populations as described 
and the difference in -catenin mRNA was determined by qPCR after Smad4 expression was 
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confirmed by Western analysis (Flag and Smad4 antibody, see Immunodetection section).  Flow 
Cytometry experiments were performed in the VMC Flow Cytometry Shared Resource.  Specifically, 
SW480 and HEK-293T cells were transiently co-transfected with pRK5 DPC4 Flag (Zhang et al. 
1996) (Addgene, Cambridge, MA), pRK5 and GFP plasmid (pEGFP-C3, BD Biosciences Clontech, 
Mountain View, CA).  After validation that the GFP+ cells represented cells transfected with pRK5 
DPC4 (e.g., +Flag band and Smad4 band on western compared to control SW480 cells; data not 
shown) then qPCR was completed.  pRK5 was used as a negative control and was found to be 
equivalent to GFP- cells by Western and qPCR (e.g., no Flag on Western for SW480s, no change in 
baseline Smad4 levels for HEK-293T cells and no difference in -catenin by qPCR).  Qiagen 
Effectene reagents (Qiagen, Valencia, CA) were used for the transfections and equal amounts of 
DNA (1.0μg) were transfected per well for each experiment.      
 
Chromatin Immunoprecipitation (ChIP) Assay 
    ChIP assays were performed using the EZ-Magna ChIPTM kit (Millipore Cat. # 17-408, Billerica, 
MA) according to the manufacturer’s instructions.  Briefly, SW480vector and SW480Smad4 colon cancer 
cells were fixed in fresh 18.5 % PFA for ten minutes at room temperature prior to cross-linking. After 
cell and nuclear fractionation, DNA from the nuclear fractions was sheared by sonication.  For the 
immuno-precipitation, Protein A beads (Millipore CS200637) were blocked by coating with bovine 
serum albumin (BSA) (1μg/mL) overnight (50-100μL of BSA for each 20μL of Protein A beads).  Cell 
nuclear lysates were pre-cleared by addition of 10μL of coated beads and 2μL of mouse IgG (Santa 
Cruz Biotechnology, Santa Cruz, CA)).  Five microliters of precleared lysates were saved as input.  
500μg of the precleared lysate was used in overnight incubation at 4°C with each of 5 μg Smad4 
antibody (Santa Cruz Biotechnology, Santa Cruz, CA), Anti-Acetyl Histone 3 antibody (Millipore, 
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Billerica, MA ), RNA polymerase II antibody  (Millipore, Billerica, MA),  or mouse IgG (Santa Cruz 
Biotechnology, Santa Cruz, CA).  Following washes and reverse crosslinking, DNA was isolated and 
preparations were made for PCR reactions.  
ChIP PCR 
    For the 20μL PCR reactions, each well contained:  ChIP DNA (2μL), RNase/DNase free water 
(12.4μL), 10X PCR Buffer (2μL), 25 mM magnesium chloride  (1.2μL), 10mM dNTPs (1.6μL), 10μM 
primer set (0.8μL) and Qiagen HotStart Taq (5U/μL, 0.4μL, Valencia, CA).  The following protocol was 
used:  1:  94°C, 3 min; 2:  94°C, 45 sec; 3:  55°C, 45 sec; 4:  72°C, 45 sec (x35); 5:  72°C--2min; 6: 
4°C.  The PCR product and 4μL of 6X DNA loading dye were loaded into a 12% acrylamide gel and 
run at 100 volts for 1.5 hours and visualized on a BioRad Molecular Imager (Hercules, CA, USA). 
 
Transcription Assays 
    SW480vector and SW480Smad4 colon cancer cells were used as described (Shiou et al. 2007). 
SW480 cells from American Type Culture Collection and HEK-293T were cultured in DMEM and 
RPMI media (Invitrogen, Carlsbad, CA) supplemented with 10% fetal bovine serum, L-glutamine, 
penicillin and streptomycin. See below for collection and use of Wnt3a conditioned medium for HEK-
293T cells (added post-transfection).  Cells were transiently transfected with pRK5 or pRK5 DPC4 
Flag (Zhang et al. 1996) (Addgene, Cambridge, MA) in addition to TOPflash or FOPflash reporter 
plasmids (Millipore, Billerica, MA) to determine TCF-mediated transcriptional activity 
(Topflash/FOPflash ratio, representative of independent experiments).  Qiagen Effectene reagents 
(Qiagen, Valencia, CA) were used for the transfections and equal amounts of DNA were transfected 
per well for each experiment.  SW480 and SW480Smad4 cells were transiently transfected with wild-
type -catenin (Xenopus and human (simian CMV promoter in pCS2+), gifts from E. Lee laboratory, 
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Vanderbilt) and TCF-mediated transcription was determined 48 hours post-transfection via 
luminometer (BioTek II, Winooski, VT) and data shown is representative of at least three independent 
experiments.  Luciferase reagents (Dual-Glo Luciferase Assay System Cat# E 2940, Promega, 
Madison, WI) were used per manufacturer instructions.  
 
Microarray Experiments:  Human tissues, Cell Lines and Microarray Platform 
    The protocols and procedures for the Vanderbilt Medical Center (VMC) cohort were approved by 
the Institutional Review Boards at the University of Alabama-Birmingham Medical Center, Vanderbilt 
Medical Center and the Veterans Administration Hospital (Nashville, TN).  The Moffitt samples were 
also approved by their local IRB.  Representative sections of fresh tissue specimens were flash 
frozen in liquid nitrogen and stored at -80ºC until RNA isolation.  Quality assessment slides were 
obtained to verify the diagnosis of cancer or normal adjacent mucosa.  Stage was assessed by 
American Joint Commission on Cancer (AJCC) guidelines for both cohorts of tumor samples.  RNA 
for human tissue and cells was purified using the RNeasy kit (Qiagen, Valencia, CA).  Cells were 
harvested at 70-80% in regular medium for RNA isolation.  Samples were hybridized to the Human 
Genome U133 Plus 2.0 GeneChip Expression Affymetrix array.  Six, independent biologic replicates 
were harvested for SW480vector cells and each of the three independent SW480Smad4 clones.  RNA 
was isolated as above and hybridized to the same platform. 
 
Wnt target list 
    A Wnt target list was verified, updated and gene identifiers were collected.  Published support for 
these targets was verified and the gene identifiers were converted to Affymetrix probe identifiers.  
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This list was then used to determine Wnt enrichment for the Smad4-modulated cell line and human 
data as described in the statistical methods (see Appendix, pp. 177).  
 
Wnt3a Conditioned Medium 
     L Wnt-3A cells (ATCC #CRL-2647) were brought up in high glucose DMEM supplemented with 
10% FBS, l-glutamine, pen-strep, and G418 at 400μg/mL.  They were allowed to grow to ~60% 
confluence, and were then split at 1:10 into five T75 flasks in 10mL complete DMEM / flask without 
G418. The cells were allowed to grow for 4 days, then the conditioned medium was removed from the 
flasks, sterile filtered, and placed into a 50mL conical tube.  The five flasks were re-fed with 10mL 
complete DMEM, and were cultured for an additional 4 days.  The medium was removed and sterile 
filtered as before.  The first and second harvest of conditioned medium were labeled as such and 
stored at 4°C.   The 1st and 2nd batch of conditioned medium was mixed 1:1 and per ATCC protocol 
and we applied the conditioned medium at 1:1. 
 
Immunodetection 
Immunoblots 
    Cells were lysed in radioimmunoprecipitation assay buffer and lysates were sonicated and 
centrifuged and protein concentration was determined with bovine serum albumin standards. Western 
blotting was carried out as described (Dhawan et al. 2005) with antibodies to E-cadherin (BD 
Biosciences, San Jose, CA), -catenin (BD Biosciences, San Jose, CA), Vimentin (Santa Cruz 
Biotechnology, sc-6260, Santa Cruz, CA), Smad4 (Santa Cruz Biotechnology, Santa Cruz, CA), anti-
Flag M2 (Sigma, St. Louis, MO), PARP (nuclear control, Santa Cruz Biotechnology, Santa Cruz, CA) 
and -actin (Santa Cruz Biotechnology, Santa Cruz, CA).  SW480, SW480vector and SW480Smad4 
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clones were harvested and cell lysates were subjected to western blot with use of E-cadherin and 
vimentin specific antibodies (-actin was used as a loading control).  Active Motif Nuclear Extract 
Reagents (Carlsbad, CA) were used to obtain nuclear fractions per manufacturer’s instructions 
Immunofluorescence 
    SW480vector and SW480Smad4 cells were each stained for -catenin, E-cadherin or p120 catenin and 
4’6’-diamidino-2-phenylindole (DAPI) after methanol fixation.  Antibodies for immunofluorescence: -
catenin (Sigma, 1:2000, anti-rabbit, Alexa-fluor 579); E-cadherin (BD Biosciences, 1:100, anti-mouse, 
alexa-fluor 488) and p120 catenin (courtesy of Albert B. Reynolds, Ph.D. laboratory, p120 rabbit: 
1:250, p120 mouse: 1:1000 (p120-rabbit: red-594; p120-mouse: Green-488). DAPI was used as 
indicated in the figure legends (Vector Laboratories, Inc., Burlingame, CA).  Photomicrographs of 
confocal images were acquired with an Olympus Fluoview microscope (Olympus FV-1000) fitted with 
a 40X objective.  Images were merged using Olympus Fluoview software.  Experiments, data 
analysis and presentation of figures were performed in part through the use of the VUMC Cell 
Imaging Shared Resource. 
Immunohistochemistry 
     Colorectal and normal adjacent tissue samples from Vanderbilt Medical Center were stained for 
Smad4 and -catenin.  Slides were stained using a 1:50 dilution of mouse monoclonal anti-Smad4 
antibody (100μg/mL stock, Santa Cruz Biotechnology, Santa Cruz, CA) or a 1:800 dilution of mouse 
monoclonal anti--catenin antibody (250μg/mL stock, BD Biosciences, San Jose, CA).  In both cases, 
antigen retrieval was carried out in citrate buffer (pH = 6.0) under pressure for 15 minutes, followed by 
quenching with H202.  Antigen retrieval was carried out in EDTA at 98
oC in a decloaking chamber and 
quenched with H202.  Photomicrographs were taken with the Ariol® SL-50 system at 20X. All images 
were acquired with a 20X objective on a CoolSNAP-ES CCD camera.  Images were captured as a 
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montage and selected areas in original resolution are displayed as enlarged images.  Native 
resolution (0.322 microns/pixel) is shown. 
 
Functional Assays 
Matrigel invasion assay 
    Transwells (8 μm pore size, 6.5 mm in diameter) from Costar (Cambridge, MA) were coated with 
40μL of 2.5 mg/mL Matrigel and incubated for 2h.  Cells were trypsinized, washed with PBS, 
resuspended in serum-free medium with 0.2% BSA, and then seeded in Transwells (75,000 
cells/well).  Cells were grown on Transwells with 10% FBS containing medium in the lower chamber 
for 72h.  Transwells were fixed in 70% ethanol for 1 hour at 4oC. Cells remaining in the top chamber 
were removed with cotton swabs, and the cells that traversed to the reverse side of the inserts were 
rinsed with PBS and stained with propidium iodide for 1h to overnight at room temperature.  Cells 
were counted under a light microscope (at 200X) and invasive cell numbers were the averages of five 
areas on each insert.  Each invasion assay was done in triplicate and repeated thrice. 
Athymic (nude) mouse tumorigenicity assay 
    SW480vector and SW480Smad4 cells were grown in regular medium and 1 x 106 cells were injected 
into sixteen, 6-week old, athymic nude (female, nu/nu ((Harlan Sprague Dawley, Indianapolis, IN)) on 
opposite flanks (e.g., SW480vector on the left and SW480Smad4 colon cancer cells on the right).  The 
mice were followed every other day and the tumors were measured at weekly intervals and the mice 
were sacrificed uniformly at week 4.  Tumors were assumed to be spheroid and volume was 
calculated by the appropriate formula (volume = 4/3 (r2)).  The Vanderbilt Institutional Animal Care 
and Use Committee approved all animal work. 
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Gene set analysis 
     WebGestalt (Zhang, Kirov, and Snoddy 2005) (http://bioinfo.vanderbilt.edu/webgestalt) was used 
to analyze the top signaling pathways in the refined, Smad4-modulated, epithelial-specific target list 
(n=787 probesets).  This tool can be used to suggest biological areas that are important to a gene set 
and warrant further investigation.  Kyoto Encyclopedia of Genes and Genomes (KEGG, Kanehisa 
Laboratories, Kyoto University, Japan) pathway function was utilized and the cut-offs of P<.05 
(Fisher’s exact test) and minimum of 5 genes per pathway were selected. 
 
Statistical analysis 
    Microarray data were normalized with the Robust MultiChip Averaging (RMA) algorithm (Irizarry et 
al. 2003) as implemented in the Bioconductor package Affy.  For pairwise group comparisons, t-test 
in the Limma package (Smyth 2004) in Bioconductor was used to identify differentially expressed 
probe sets between the two groups under comparison (e.g., SW480vector versus SW480Smad4 or 
normal adjacent specimens versus stage I cancers).  The implementation of t-test in Limma uses an 
empirical Bayes method to moderate the standard errors of the estimated log-fold changes, this 
results in a more stable inference, especially for experiments with a small number of arrays.  The 
Wilcoxon rank sum test was used to assess the inverse relationship between Smad4 and -catenin. 
To test if the direction of change between Smad4 and -catenin was significant, we tested the 
interaction effect between genes (Smad4, -catenin) and groups (normal, cancer).  An FDR  of 
0.0005 was used as a cut-off to evaluate the potential enrichment of Wnt targets in the SW480vector 
and SW480Smad4 comparison.  Fisher’s exact test was then utilized to determine if there was a 
significant enrichment upon comparison of the genes significantly differentially regulated by Smad4 
and an annotated and updated Wnt target list.  Smad4-modulated human tumor signatures were 
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generated by determination of genes differentially expressed for each of the three Smad4 probes on 
the Affymetrix array.  We focused on available ‘grade A’ Affymetrix probes for Smad4 mapped to 
exonic transcript regions.  The genes for the probe with the most significant number of differentially 
expressed targets (FDR<0.05) were then overlapped with the Smad4 gene expression profile from 
the cells to determine epithelial-specific Smad4 target genes.  We then determined if there was a 
significant enrichment of Wnt target genes in this epithelial-specific list.  We then used the Smad4-
modulated, Wnt enriched gene list to execute unsupervised hierarchical cluster analysis and clinical 
outcome determination.  Hierarchical clustering with complete linkage and Euclidean distance was 
applied to generate heatmaps. The three clusters were discovered by unsupervised, hierarchical 
clustering and Kaplan-Meier estimates were performed. The log-rank test was used to determine if 
there were significant differences across three clusters for survival outcomes.   To assess the 
independence of cluster membership and cancer stages of the patients, we used the chi-square test.  
Student’s t-test or ANOVA was used for qPCR and TOPflash assays and P-values were designated 
as indicated (*P<.05, **P<.01 or ***P<.001 and non-significant (P>.05, ns)). Difference in slope 
between groups in Fig. 17B was found by analysis of variance (no significant interaction between 
groups by dose or time was noted (P=.88)).  GraphPad Prism software was used for analysis of 
data in Figures 15; 17; 18; 20; 22, 26 and 27  (*P<.05, **P<.01, ***P<.001 and P>.05=ns by ANOVA 
and Student’s t-test respectively). 
 
 
 
 
 
 73 
Results 
 
Smad4 Expression Reduces Transcription of -catenin mRNA 
    SW480 cells are microsatellite stable, 18q21del and harbor a splice site disruption in the remaining 
Smad4 allele (Woodford-Richens et al. 2001).  In addition, these cells have additional inactivating 
mutations of the tumor suppressor genes, APC and p53, plus an activating mutation of k-Ras (Capon 
et al. 1983; Rodrigues et al. 1990; Rowan et al. 2000).  We previously reported that Smad4 
restoration in SW480 colon cancer cells is associated with suppression of -catenin/TCF-dependent 
expression of TOPflash reporter gene activity and reduction in steady-state levels of cellular -catenin 
protein (Shiou et al. 2007); however, the mechanism by which this occurs is unknown.  In the present 
studies, we found that expression of -catenin mRNA is significantly reduced in SW480 cells in which 
Smad4 is either stably or transiently expressed (Figure 15A-C).  These findings were reproduced by 
overexpression of Smad4 in HEK-293T cells demonstrating that the observed effect is independent of 
mutations in APC and KRAS (Fig. 15D).  Thus, Smad4 expression reduces steady-state levels of -
catenin mRNA in both colon cancer cells and in epithelial, human embryonic kidney cells.  
    To determine whether the decrease in -catenin mRNA levels is due to decreased transcription of 
the -catenin gene (ctnnb1), RNA polymerase II bound to the 2nd exon (+460 to +579) was assessed 
by chromatin immunoprecipitation (ChIP).  A clear decrease in RNA polymerase II (POL2RA) binding 
at the ctnnb1 gene was observed in SW480Smad4 cells as compared with control SW480vector cells 
(Fig. 16A).  These data indicate transcriptional suppression of ctnnb1 upon Smad4 expression in 
SW480 cells. 
    The ctnnb1 promoter/enhancer region (-4500 to +1) contains ~15 putative Smad binding elements 
(Fig. 17A, Appendix).  The area around which we designed the ctnnb1 promoter/enhancer region 
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primers is shown in Fig. 18A (see Appendix; ~ -3400 to -3000).  Four minimal Smad binding elements 
are noted at this location (see bold gray text and bars).  To determine whether the decrease in -
catenin mRNA transcription is associated with Smad4 interaction with the ctnnb1 5’ upstream region, 
we performed a Smad4 ChIP experiment specific for the -3393 to -3136 5’ region and observed a 
marked increase in Smad4 binding to this region in SW480Smad4 compared to SW480vector cells (Fig. 
16B, lanes 5 and 6).  These data indicate that direct Smad4 interaction with the ctnnb1 5’ upstream 
regulatory region may contribute to suppression of -catenin mRNA transcription.  
    It should be noted that these effects on -catenin mRNA were reflected at the protein level.  Smad4 
restoration in SW480 cells is associated with significant down-regulation of -catenin in both whole 
cell and nuclear lysates (Figure 17A and B).  Because others have reported that -catenin mRNA 
stability may play a role in its activity  (Gherzi et al. 2006), we assessed whether Smad4 restoration 
alters -catenin mRNA stability in SW480 cells.  SW480vector and SW480Smad4 cells were treated with 
the RNA polymerase II inhibitor, 5,6-Dichlorobenzimidazole, 1--D-ribofuranoside (DRB) and -
catenin mRNA levels were assessed at 4 hour intervals.   No significant differences were observed in 
-catenin mRNA stability in the SW480vector cells compared with SW480Smad4 cells in independent 
experiments using two different concentrations of DRB carried out to 24 hours (P=.88, Fig. 18B, 
Appendix).  Thus, we concluded that Smad4 restoration in SW480 colon cancer cells does not reduce 
-catenin mRNA by decreasing -catenin mRNA stability. 
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Figure 15.  Smad4 expression represses transcription of -catenin mRNA.  (A) RT-PCR and (B) quantitative 
RT-PCR (qPCR) analysis of steady-state -catenin mRNA levels in SW480Smad4 clones vs. SW480vector.  
Each of two independent SW480
Smad4
  clones were compared to SW480 colon cancer cells (independent 
replicates are displayed; ***P<.001, ANOVA, mean +/- SEM).  (C-D) Transient expression of Smad4 was 
carried out in SW480 cells and HEK-293T cells along with GFP.  GFP positive cells were compared to GFP-
negative cells and the difference in -catenin mRNA was determined by qPCR (plotted as 1/Ct, independent 
replicates are shown; *P<.05, student’s t-test, mean +/- SEM displayed). 
Figure 16.  Smad4 restoration in SW480 cells is associated with transcriptional down-regulation and binding to the ctnnb1 
promoter/enhancer.  (A) Representative, gel resolved, 119bp PCR amplified bands from exon 2 of ctnnb1 in a POL2RA 
Chromatin immunoprecipitation (ChIP) assay are displayed.  Histone and IgG antibodies are used as positive and negative 
controls, respectively, and amplification of input DNA is shown on the right. Amplified bands for the control gapdh promoter 
(166bp) are also displayed.  (B) Representative ctnnb1 promoter-specific PCR amplified bands (225bp) from a Smad4 
ChIP assay are shown on an agarose gel.  IgG serves as a negative control and Histone H3 as a positive control for 
binding to the ctnnb1 promoter.  Amplification of input DNA using -catenin primers is shown on the right hand side of the 
gel.  Amplified bands for the control gapdh promoter (166bp) are also displayed.  Lanes 1, 3, 5 and 7 represent SW480
vector
 
cells while lanes 2, 4, 6 and 8 represent SW480
Smad4.3
 as indicated (+ or -) for (A) and (B). 
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Figure 17.  Smad4 restoration in SW480 cells is associated with down-regulation 
of -catenin mRNA which is reflected at the protein level.  Steady-state protein 
levels for -catenin and Smad4 in cellular fractions by Western blot are displayed. 
(A) -actin was the loading control for whole cell lysates.  (B) PARP served as the 
nuclear marker.  Antibodies were used as described in Methods.  
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Smad4 Repression of Wnt Activated Transcription is Independent of APC Mutation and Occurs in a 
Dose-Dependent Manner 
    SW480 cells lack functional APC and therefore exhibit relatively high Wnt transcriptional activity.  
We previously reported that restoration of Smad4 expression in SW480 cells causes a marked 
reduction in activity of the Wnt signaling reporter, TOPflash (Shiou et al. 2007).  To further evaluate 
the inhibition of TOPflash by Smad4, we first confirmed that transient co-expression of Smad4 inhibits 
TOPflash activity in SW480 cells (Fig. 19A).  We also determined that transient overexpression of 
Smad4 suppressed TOPflash activity in HEK-293T cells (wild type APC) in the presence or absence 
of Wnt3a ligand (Fig. 19B).  Finally, we found that increasing doses of Smad4 in SW480 and HEK-
293T cells results in increasing suppression of TOPflash activity (Fig. 19C and D).  Thus, Smad4 
expression suppresses TOPflash in a dose-dependent manner and it does so independently of Wnt 
pathway activation and in the presence of wild-type APC. 
 
Smad4 Inhibition of TOPflash Activity is -catenin Dependent 
    TOPflash activity is controlled by a transcriptional complex composed of several proteins, any of 
which might be altered by Smad4 expression to inhibit reporter activity.  We next determined whether 
inhibition of TOPflash by Smad4 is -catenin dependent.  First, we co-expressed TOPflash along with 
wild-type -catenin under the control of a constitutively active CMV promoter.  We found that co-
expression of wild-type -catenin restored robust TOPflash activity in SW480Smad4 cells to comparable 
levels observed in parental SW480 cells demonstrating that suppression of TOPflash activity by 
Smad4 is restored by expression of -catenin with a heterologous promoter (Fig. 20A, p. 77).  Next,  
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Figure 19.  Smad4 expression represses TOPflash activity in an APC independent manner.  (A) 
SW480 and (B) HEK-293T cells were transiently transfected with TOPflash and FOPflash reporter 
plasmids.  The ratio of measured light units from TOP and FOPflash luciferase is graphed with either 
empty vector or Smad4 transfection as indicated (0.4μg used).  Each graph is representative of at 
least 2 independent experiments (***P<.001, student’s t-test, mean +/- SEM displayed).  Wnt3a 
conditioned medium (1:1) was added to HEK-293T cells as indicated after transfection.  (C) 
SW480
parental
 and (D) HEK-293T cells were transiently transfected with TOPflash and FOPflash 
reporter plasmids.  The ratio of measured light units (relative luciferase activity) from TOPflash 
luciferase and FOPflash luciferase is graphed with doses of Smad4 transfection as indicated. 
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we conducted a Smad4 concentration-response transfection experiment in SW480 cells with and 
without co-expression of wild-type -catenin.  As seen in Fig. 20B, transient Smad4 expression in 
SW480 cells suppressed Wnt-specific transactivation in a concentration-dependent fashion when no 
exogenous -catenin was present.  Consistent with the proposition that Smad4 directly suppresses 
transcriptional activity of the ctnnb1 gene, Smad4 expression does not suppress TOPflash upon co-
expression of exogenous -catenin under the control of a heterologous promoter (Fig. 20C).  These 
data further support a model in which Smad4 acts to inhibit Wnt-signaling through transcriptional 
repression at the -catenin promoter.  
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Figure 20.  Smad4 inhibition of TOPflash activity is -catenin dependent.  (A) SW480vector and SW480Smad4.3 
were transiently transfected with wild-type -catenin (Xenopus data shown and representative of independent 
replicates with human -catenin).  Luciferase activity, expressed in light units, from the TOPflash reporter is 
graphed for each condition (**P<.01 and ***P<.001, student’s t-test,  ***P<.001, ANOVA, mean +/- SEM 
displayed).  (B) TOPflash activity was assessed in SW480 cells transiently transfected with control vector (0.4g, 
0.6g and 0.8g, lanes 2-4), Smad4 (0.4g, 0.6g and 0.8g, lanes 5-7) and reporter plasmids (all lanes).  Relative 
light units from TOP/FOPflash luciferase is displayed for one representative biological replicate (ns=P>.05, 
ANOVA for SW480 vs. control vector; *P<.05, ANOVA for SW480 vs. Smad4, mean +/- SEM displayed for all). 
(C) TOPflash activity was likewise assessed in SW480 cells transiently transfected with control vector (0.4 μg, 
0.6 μg and 0.8 μg, lanes 2-4), Smad4 (0.4μg, 0.6μg, and 0.8μg, lanes 5-7) and also co-transfected with 0.2 μg 
wild-type human -catenin (lanes 2-8).  (two biologic replicates displayed, ns=P>.05, ANOVA, mean +/- SEM 
displayed). 
 81 
Figure 21.  Smad4 cannot suppress TOPflash independently of -catenin.  TOPflash 
activity was determined as described in Materials and Methods in SW480vector cells (lane 1: 
TOP and FOP only; lane 5:  TOP, FOP and the N-Lef1-VP16 fusion construct) and 
SW480Smad4 cells (lanes 2-4:  TOP and FOP only;  lanes 6-8:  TOP, FOP and the N-Lef1-
VP16 construct); ***P<.001 and ns=P>.05, ANOVA for both, mean +/- SEM displayed. 
We tested whether or not Smad4 represses TOPflash activity independently of -catenin with use of 
the N-Lef1-VP16 construct.  This construct directs the expression of an N-terminal truncated form of 
Lef1 fused to a VP16 activator protein removing the -catenin binding site on Lef1 and eliminating the 
requirement for -catenin interaction with Lef1 to activate TOPflash. Thus, if Smad4 suppresses TOP-
flash in the presence of N-Lef1-VP16, we would conclude that Smad4-mediated inhibition of Wnt 
signaling is -catenin independent, implicating other members of the Wnt-sigaling transcriptional 
complex.  In these experiments, we found that Smad4 expression does not suppress TOPflash 
activity when N-Lef1-VP16 is expressed (Fig. 21).  These data confirm that attenuation of Wnt-
specific transactivation by Smad4 restoration is -catenin-dependent and cannot be attributed to 
altered activity in other members of the TCF/LEF transcriptional complex. 
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Smad4 Inhibits Wnt Target Gene Expression While Reversing EMT 
    Since we observed inhibition of -catenin/TCF-dependent reporter activity in SW480 cells, we 
assessed whether Wnt target gene expression is also altered by Smad4 expression.  Global gene 
expression analysis of SW480vector and SW480Smad4 colon cancer cells by microarray was performed 
to assess changes in gene expression caused by restored Smad4 expression.  We used the following 
stringent criteria to determine differential expression of SW480vector compared with SW480Smad4 colon 
cancer cells:  FDR<0.005 and fold-change >4 (see Materials and Methods) to obtain an epithelial- 
specific, Smad4 expression profile (see Table 11, Appendix).   
Smad4 Inhibition of Wnt Target Gene Expression 
    We then queried this list of significantly altered genes for enrichment of published and annotated 
Wnt target genes (see Table 12 and Fig. 22 (schematic) in the Appendix).  This Wnt target gene 
identifier list was mapped to Affymetrix probesets and overlapped with the Smad4 expression profile 
(n=1668 probesets) to determine enrichment.  We observed significant changes and enrichment in 
expression of Wnt target genes (P<.001) and EMT markers in the differentially expressed profile (see 
hierarchical cluster analysis in Fig. 23A) indicative of negative regulation of Wnt pathway targets.  The 
Smad4-modulated, Wnt-enriched targets are noted in Table 13 (see Appendix).  For example, 
expression of Wnt target genes known to be associated with negative regulation of the Wnt pathway, 
namely E-cadherin (Jamora et al. 2003) (also associated with reversal of EMT), -transducin repeat 
containing (BTRC) and dickkopf 1 (DKK1) was significantly up-regulated by Smad4 restoration 
whereas expression of Wnt targets associated with pathway activation such as Axin2, Lef1, Apcdd1 
(Takahashi et al. 2002), CyclinD1 and Claudin1 were significantly down-regulated when Smad4 was 
expressed.  We verified the microarray-predicted expression changes in Axin2, Lef1, Apcdd1, 
CyclinD1 and E-cadherin by RT-PCR and qPCR (Fig. 23B-C and data not shown).   
83 
 84 
Figure 23.  A Smad4-specific gene expression profile reflects down-regulation of Wnt signaling.  
(A) Unsupervised clustering (p.80) of SW480vector (indicated by red bar, n = 6) and SW480Smad4.1-3 (indicated 
by blue bar, n = 6 each of 3 clones) in columns and Wnt target genes in rows are shown in the heatmap. 
Up-regulated genes are indicated by dark blue and down-regulated genes are indicated by dark red.  (B) 
RT-PCR and (C) qPCR assessment of representative steady state Wnt target mRNAs (Axin2, Lef1 and 
Apcdd1) in SW480Smad4 clones versus SW480vector cells (three biological replicates (loading control, 
Gapdh)).  For qPCR, SW480vector and each of two independent SW480Smad4 clones were compared to the 
SW480 colon cancer cells.  At least three biologic replicates were completed and representative biologic 
replicate data is shown (***P<.001, ANOVA). 
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Smad4 Expression is Associated with Reversal of EMT in Colon Cancer Cells 
      It is well established that Wnt signaling is deregulated secondary to an adenomatous polyposis 
coli (APC) mutation in >80% of colorectal cancers and recently, nuclear localization of -catenin has 
been associated with EMT in this setting (Hlubek et al. 2007).  As previously noted, the most 
commonly disrupted Smad mediator in cancer, including colorectal cancer, is Smad4, located on 
chromosome 18q21 (Hahn et al. Dpc4, a candidate tumor suppressor gene at human chromosome 
18q21.1 1996; Thiagalingam et al. 1996).  SW480 colon cancer cells are a useful model to investigate 
potential cross-talk between canonical Wnt signaling and TGF signaling in colorectal cancer for the 
following reasons:  1) They exhibit high baseline canonical Wnt activity due to a mutation in APC.  
This mutation constitutes a deletion at the carboxyl terminus at residue 1338.  This missing area 
contains Ser-Ala-Met-Pro (SAMP) motifs otherwise known as SAMP repeats, which are important for 
Axin binding (Behrens et al. 1998) (the truncated protein still contains -catenin binding sites (Yang et 
al. 2006)); and 2) Smad4 is mutated via loss of one allele of chromosome 18 with the second allele 
not expressed due to a splice site mutation (Woodford-Richens et al. 2001). 
    Smad4 restoration has been associated with induction of E-cadherin and P-cadherin in colon 
cancer cells and loss of Smad4 has been associated with loss of E-cadherin in colon cancer patients 
(Muller et al. 2002; Reinacher-Schick et al. 2004).  These studies were some of the first to 
demonstrate the potential role of Smad4 in the reversal of EMT.  Since -catenin is part of the 
basolateral junctional complex along with E-cadherin and p120 catenin we sought to determine if 
Smad4 restoration in SW480 colon cancer cells is associated with a reversal of EMT and 
establishment of a functional cell membrane complex.  We noted E-cadherin induction upon Smad4 
restoration along with marked reduction in the intermediate-filament protein vimentin (Fig. 24A).  
Vimentin has been characterized as an EMT marker and a putative Wnt target gene (Gilles et al. 
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Figure 24.  Smad4 expression restores an epithelial cell phenotype in colon cancer cells. (A) An immunoblot for 
SW480, SW480vector and SW480Smad4 cells (SW480
Smad4.1-4.3
) for E-cadherin and vimentin antibodies is shown (-actin, 
loading control).  (B and C) Confocal immunofluorescence of -catenin (red) is shown to demonstrate junctional 
membrane localization in SW480
Smad4
 cells (left panel) compared with SW480
vector
 cells (right panel).  The cell nuclei 
were stained with DAPI (blue).  Images were acquired with the Olympus FV-1000 as described in Methods and scale 
bars are 20μM (white). 
2003; Kalluri 2009).  We analyzed SW480, SW480vector and SW480Smad4 cells for localization and 
distribution of -catenin, E-cadherin and p120 catenin with confocal microscopy.  A marked increase 
in membrane-localized -catenin in addition to a marked cuboidal phenotype was noted in 
SW480Smad4 cells compared with SW480vector cells (Fig. 24B and C).   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 87 
Figure 25.  Smad4 expression is associated with membrane localization of -catenin and E-
cadherin in colon cancer cells.  Confocal immunofluorescence for -catenin (red) and E-cadherin 
(green) is shown for SW480Smad4 (A) and SW480vector (B) cells. Images were acquired with the 
Olympus FV-1000 as described in Methods.  The merged images along with DAPI (blue) are 
shown along with the z-stack (z height of 32.5μM is shown for both).  Scale bars are 20μM (white). 
    As can be seen in the vertical plane of the image (Fig. 25A, z-stack), -catenin and E-cadherin 
demonstrate membranous co-localization upon Smad4 expression compared with lack of 
membranous co-localization of these components in the SW480vector cells (Fig. 25B).  These data 
strongly support functional reversal of EMT with re-introduction of Smad4 in SW480 colon cancer 
cells.  Additionally, we noted markedly enhanced nuclear and cytoplasmic -catenin in the 
SW480vector cells along with poorly localized E-cadherin (Fig. 24C).  These data support observations 
made by Hublek, et. al. where high nuclear -catenin activity was noted at the invasive front of 
colorectal cancers (Hlubek et al. 2007).  These data are supportive of the idea that a reduction in total 
levels of -catenin mediated by the transcriptional repression via Smad4 is part of the Smad4-
mediated tumor suppressor program in colon cancer cells. 
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    Lastly, we noted that -catenin co-localized with p120 catenin and that p120 catenin in turn co-
localized with E-cadherin at the cell membrane (data not shown) in an independent SW480Smad4 clone 
compared with the dense cytoplasmic and sparse membrane decoration of p120 catenin and -
catenin that we had observed in the SW480vector and SW480 cells (Fig. 26A and B, z-stack not 
shown).  These data indicate that Smad4 restoration in SW480 colon cancer cells is associated with 
reversal of EMT.  
     Recent work by an independent group (Tian et al. 2009) recapitulates our previously published 
findings of suppression of TOPflash and down-regulation of the Wnt target gene Claudin-1 upon 
Smad4 re-expression (Shiou et al. 2007).  This group did not demonstrate basolateral membrane 
component co-localization, nor do they explore further mechanistic insights into our initial 
observations.  Our current data extend previous observations by multiple independent laboratories to 
demonstrate that Smad4 restoration in colon cancer cells reverses EMT and leads to an epithelial 
phenotype as supported by co-localization of basolateral membrane components in association with a 
significant down-regulation of -catenin levels.  In summary, as previously reported (Shiou et al. 
2007), we observed marked up-regulation of E-cadherin in addition to the new observations of -
catenin and p120 cell membrane co-localization, reduction in nuclear -catenin and down-regulation 
of the putative Wnt target and EMT marker, vimentin (Gilles et al. 2003), in response to restoration of 
Smad4 expression (Fig. 24-26). 
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Figure 26.  Smad4 expression is associated with membrane localization of p120 catenin and -
catenin in colon cancer cells.  (A) Junctional localization of -catenin (red) co-localized with p120 
catenin (green) is show by confocal immunofluorescence in SW480
Smad4
 cells compared with (B) 
cytoplasmic and nuclear localization in the SW480
vector
 cells.  (C) Merged images along with DAPI 
are shown as above.  Images were acquired with the Olympus FV-1000 as described in Methods. 
Scale bars are 20μM for each image (white). 
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  We further sought to determine the functional consequences of Smad4 restoration in SW480 colon 
cancer cells in vitro and in vivo with invasion and xenograft flank tumorigenicity assays.  SW480vector 
cells are significantly more invasive in an invasion assay compared with SW480Smad4 cells (Fig. 27, 
P<.01).  Smad4 has been noted to decrease tumorigenicity in a unilateral flank model in nude mice 
(Schwarte-Waldhoff et al. 1999); however, this phenomenon has not been tested in a model that 
more closely mimics that of human tumor development and progression.  We placed SW480vector cells 
on the left flank of 6-week old nude mice and SW480Smad4 cells on the right flank.  We did this so that 
each mouse would serve as it’s on control and more closely resemble tumor cells in a human 
colorectal tumor where Smad4 loss and retention occur in the same organism.  Tumors were 
monitored weekly over the course of 4 weeks and the mice were sacrificed and final ex vivo tumor 
volume was determined.  SW480vector cells were significantly more tumorigenic than SW480Smad4 cells 
in this bilateral flank xenograft model (Fig. 28, P<.05).  These data further substantiate the tumor 
suppressive role for Smad4 in colon cancer and its potential role in the reversal of EMT in the context 
of deregulated canonical Wnt signaling in epithelial biology.  These data substantiate our 
observations that Smad4 restoration and marked reduction in -catenin mRNA levels and 
transcriptional activity mediate downstream inhibition of Wnt signaling and reverse EMT in colon 
cancer cells and corroborate the role of Smad4 as a tumor suppressor (Schwarte-Waldhoff et al. 
1999). 
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Figure 27.  Smad4 expression significantly decreases colon cancer cell invasion.  Matrigel 
invasion assays (representative biological replicates shown) demonstrate significant reduction 
of invasion ((proliferation control not shown) **P<.01, Student’s t-test, mean +/- SEM 
displayed).   
Figure 28.  Smad4 expression significantly decreases tumorigenicity in a nude mouse model. 
Suppression of tumorigenicity upon Smad4 restoration in SW480 cells in a nude mouse model 
is displayed (tumor volumes calculated from post-sacrifice ex vivo measurements taken at 4 
weeks post-injection of cells are shown (*P<.05, Student’s t-test, mean +/- SEM displayed)). 
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Smad4 and -catenin Levels Demonstrate Significant Inverse Expression Patterns in Human 
Colorectal Cancer Patient Specimens 
    In order to assess the clinical relevance of our cell culture studies, we examined the relationship 
between Smad4 and -catenin expression in surgically resected colorectal cancer specimens.  
Smad4 and -catenin expression were analyzed in tumor samples from 250 colorectal cancer 
patients as compared with ten normal adjacent colorectal tissue specimens, by microarray analysis in 
a combined dataset of patient samples from Vanderbilt Medical Center and the Moffitt Cancer Center 
(Table 14).  As seen in Fig. 29A-B, we noted significant down-regulation of Smad4 and up-regulation 
of -catenin in colorectal tumors, and this trend was noted for each stage of colorectal cancer as 
compared with normal adjacent mucosa.  Furthermore, we noted highly significant inverse expression 
of Smad4 and -catenin (Fig. 30, P<.0001).  Further supportive evidence for this inverse expression 
pattern was noted when we stained normal adjacent colon and colon adenocarcinoma specimens for 
Smad4 and -catenin.  We noted positive Smad4 nuclear and cytoplasmic staining in the stroma and 
epithelium of normal adjacent mucosa while -catenin demonstrated membranous staining along the 
crypt with nuclear and cytoplasmic staining at the base of the crypt (Fig. 31 A-B and native resolution 
in E-H).  Interestingly, we observed negative staining for Smad4 in a colon cancer specimen except 
for sparse positive stromal cells.  In contrast, we noted strong nuclear and cytoplasmic -catenin 
staining in the serial section of the same tumor (Fig. 31 C-D and native resolution in I-J).  These data 
support the clinical significance of the association between Smad4 down-regulation and a parallel up-
regulation of -catenin in the progression from normal colonic epithelium to colon adenocarcinoma.  
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Human colorectal and normal adjacent specimen microarray dataset 
demographics.  Colorectal cancer patients from Vanderbilt Medical Center 
(VMC, n=55)), Moffitt Cancer Center (MCC, n=195) and 10 MCC normal 
adjacent colon specimen patients used for microarray analyses are 
displayed.  All patients were diagnosed with colorectal adenocarcinoma and 
staged according to American Joint Commission on Cancer (AJCC) 
guidelines (stages I-IV) and the 10 normal adjacent specimens were 
evaluated by a pathologist and determined to contain no adenocarcinoma 
contribution (only normal colonic mucosa).  The normal specimens were 
normal adjacent colon mucosa specimens from patients whose colons were 
resected for colon cancer.  VMC 55 includes 14 patients from the University 
of Alabama-Birmingham Medical Center.  Other in the VMC medical record 
implies ‘not otherwise specified’ and implies ‘Hispanic, not otherwise 
specified’ in the MCC medical record. 
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Figure 29.  (A) Smad4 expression is significantly down-regulated in colorectal cancer patient 
tumors compared with normal adjacent mucosal specimens.  Comparison of expression for exonic 
Smad4 probes on the Affymetrix® microarray platform for normal adjacent colon tissue versus 
colorectal cancers (stages I-IV) is shown for the combined VMC/MCC data (202526_at (**P<.001 
for all comparisons); 235725_at (***P.01 for all comparisons);  202527_s_at (*P.02 for all 
comparisons except normal versus stage II)).  (B) -catenin expression is significantly up-regulated 
in colorectal cancer patient tumors compared with normal adjacent mucosal specimens. 
Comparison of expression for exonic -catenin probes on the Affymetrix® microarray platform for 
normal adjacent colon tissue versus colorectal cancers (stages I-IV) is shown for the combined 
VMC/MCC data (223679_at (**P<.01 for all comparisons); 1554411_at (*P<.05 for all comparisons 
except for stage 4, P=.06); 201533_at (*P<.05 for all comparisons)). 
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Figure 30.  Smad4 and -catenin demonstrate significant inverse expression patterns 
in colorectal cancer patients.  250 patients with colorectal cancer evaluated by 
microarray analysis are compared with normal adjacent colonic mucosa for Smad4 
and -catenin expression levels.  Normalized expression values for normal tissue and 
colorectal adenocarcinomas (all stages) are displayed. The P-values of normal vs all 
colorectal cancers for Smad4 and for -catenin are not shown on the graph  (P=.01 
for Smad4 and P<.001 for -catenin, Wilcoxon rank sum test).  The P-value for the 
interaction effect between Smad4 and -catenin is displayed (P<.0001) to 
demonstrate the significant inverse expression patterns. 
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Figure 31.  Smad4 and -catenin levels show inverse expression in colorectal cancer tumors. 
Representative photomicrographs of normal adjacent colon (A-B) and a colon 
adenocarcinoma (C-D) stained for Smad4 and -catenin are shown.  Scale bars represent 100 
microns (p. 93).  Scaled images are shown in A-D (p. 93) and native resolution is shown in E-J 
(p. 94). Images were captured as a montage and selected areas in original resolution are 
displayed in E-J.  All images were acquired with a 20X objective on a CoolSNAP-ES CCD 
camera (see Methods). Scale bars in E-H are 20 microns (normal) and in I-J serial sections 
are 50 microns (cancer). 
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A Smad4-Modulated, Wnt Target Gene Expression Pattern is Correlated with Outcome in Colorectal 
Cancer Patients 
    Given that Smad4 expression suppresses -catenin mRNA and TOPflash activation and these 
changes are associated with EMT, we wanted to test whether a Smad4-dependent, Wnt 
transcriptional program contains predictive information for clinical outcomes in colorectal cancer 
patients.  We reasoned that the human colorectal cancer microarray dataset would reflect a 
repressed Wnt transcriptional program since we observed a highly significant inverse pattern of 
expression between Smad4 and -catenin.  Thus, we conducted a stringent differential expression 
analysis between Smad4 high vs. Smad4 low patients in the primary tumor dataset (FDR<0.05).  To 
generate this list, we focused on the Smad4 probe with the most significant number of differentially 
expressed genes.  Next, in order to refine the list of differentially expressed genes for epithelial-
specific targets, the differential expression profile from the colon cancer cell lines (SW480 and 
SW480Smad4) was intersected with the list of differentially expressed genes in the patient tumor 
samples (Fig. 32A, Appendix).  We queried this group of targets (451 mapped genes corresponding 
to 787 probes) in WebGestalt and discovered enrichment in the following signaling pathways:  
Mitogen-activated protein kinase (MAPK), TGF, Wnt, and T and B Cell Receptor signaling (Table 15, 
P<.05).   
 
 
 
 
 
 Signaling Pathways implicated in the human colorectal cancer Smad4-modulated, epithelial-specific co-expression 
module.  The top 5 signaling pathways implicated by the Smad4-modulated, epithelial-specific global expression 
analysis (n=787 probesets) as found in WebGestalt with Kyoto Encyclopedia of Genes and Genomes (KEGG) 
pathways are indicated.  Cut-offs of P<.05 and 5 molecules per pathway were used.  Fisher’s exact P-value and 
number of implicated molecules is displayed. 
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    We then asked if there was significant enrichment of Wnt target genes in this intersected list (see 
Fig. 32B, Appendix) and found that Wnt target gene representation was significant  (P<.001) in this 
Smad4 co-regulated, epithelial-specific expression profile (32 probes, 18 distinct Wnt target genes 
are shown in Table 16).  High Smad4 expression was associated with significant down-regulation of 
Axin2 and Claudin1 (both Wnt-induced) whereas low Smad4 expression was associated with 
significant up-regulation of Lef1, Versican, Fibronectin and Twist (all activated by Wnt in the absence 
of Smad4).  Claudin1 is associated with metastatic behavior in colorectal cancers (Dhawan et al. 
2005), while Fibronectin and Twist are well-known markers of EMT (Yang and Weinberg 2008).  
These data compliment the cell culture array findings and provide a solid clinical parallel to our colon 
cancer cell line observations.  
 
 
 
 
 
 
 
 
 
 
 
 
Smad4-modulated, epithelial-specific Wnt target genes in human colorectal cancer.  32 
Wnt target probesets (18 individual gene IDs displayed) in common amongst the SW480 
Smad4-modulated, Wnt-enriched gene expression profile and the 202527_s_at (Smad4 
probe) gene expression profile are displayed.  Blue indicates down-regulation with high 
Smad4 levels and red indicates up-regulation upon low Smad4 levels for this display (the 
reverse scenario is not displayed).  These Smad4 co-regulated Wnt enriched probes were 
then used to determine if they could separate patient groups based upon unsupervised 
hierarchical cluster analysis and subsequently to determine if they could predict outcome in 
colorectal cancer patients (see Fig. 31).   
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    Since Smad4 is a tumor suppressor and has shown promise as a potential biomarker in colorectal 
cancer patients (Alazzouzi et al. 2005), we assessed whether the Wnt target gene probes co-
regulated by Smad4 expression could identify distinct colorectal cancer patient groups in 
unsupervised cluster analysis.  The Smad4-modulated Wnt target genes clustered patients into three 
distinct groups (Fig. 33A).  Importantly, Wnt target gene expression exhibited a marked change in 
these groupings; for example, Cysteine-rich angiogenic inducer, 61 (CYR61), Versican, and 
Fibronectin are markedly down-regulated in cluster 1 while Lef1, Axin2 and Twist 1 are up-regulated 
in clusters 2 and 3.  These data are consistent with the notion that Wnt target genes previously 
implicated in processes of Wnt activation and EMT are down-regulated (e.g., Fibronectin in (ten 
Berge et al. 2008)) in the context of high Smad4 expression and up-regulated when Smad4 
expression is reduced (e.g., Twist1 in (Howe et al. 2003)).   
    In order to determine whether this Smad4 co-regulated gene list discriminates patient groups on 
the basis of clinical outcome, overall and disease-free survival analyses were conducted in the 250 
patient colorectal cancer combined databases (VMC and MCC).  We observed significant differences 
in outcomes for patients in each of these three clusters for overall survival (P<.001) and disease-free 
survival, (P=.01, Fig. 33B). These data suggest that although there are significant differences by 
overall survival for clusters 2 and 3 that these differences are diminished when recurrence is the 
primary outcome measure.  One interpretation may be that loss of the Smad4-modulated 
transcriptional program is important for both overall survival (death from all causes including cancer-
related deaths) and disease-free survival (evidence of recurrent disease) whereas the transcriptional 
program found in clusters 2 and 3 may become similar when the outcome measured is recurrence 
only.  These differences in outcome could not be attributed to cancer stage as determined by analysis 
of stage distribution among each cluster of patients (P=.48).  These data indicate that the epithelial 
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Figure 33.  Smad4-modulated Wnt target genes are significantly associated with better survival in colorectal cancer 
patients. (A) Unsupervised cluster analysis of Smad4-modulated Wnt targets in 250 colorectal cancer patients. 
Individual clusters are denoted by red, purple and navy lines.  Individual patients are represented by columns and Wnt 
specific Affymetrix probes are represented in rows. Up-regulated genes are indicated by dark blue and down-regulated 
genes are indicated by dark red.  (B) Kaplan-Meier survival estimates for each cluster of patients are shown for overall 
and disease-free survival (OS, DFS).  P-values shown compare all three clusters.  
cell-specific transcriptional program regulated by Smad4 specifically related to suppression of Wnt 
signaling correlates with stage-independent prognostic information in colorectal cancer patients. 
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Discussion and Future Directions 
 
    In this chapter, we provide evidence that Smad4 is an important modulator of -catenin gene 
expression and downstream Wnt signaling.  Smad4 expression inhibits Wnt activity and associated 
Wnt target gene expresson patterns in colon cancer cells and in tumors resected from colon cancer 
patients.  The clinical relevance of these findings was demonstrated by application of the Smad4-
associated Wnt transcriptional program to colorectal cancer patient datasets.  
    Dynamic signaling interplay between Wnt and TGF superfamily members is evident in embryonic 
development and in homeostasis of the adult organism (Nishita et al. 2000; Radtke and Clevers 
2005).  For example, BMPs can suppress TCF/LEF transcription in hair follicles (Jamora et al. 2003) 
and can influence TCF4 transcription in muscle (Bonafede et al. 2006).  Smads interact with TCF/LEF 
transcription factors in a cooperative fashion to activate target genes both developmentally (Nishita et 
al. 2000) and during carcinogenesis (Labbe et al. 2007).  In other contexts, expression of a BMP 
antagonist, such as Noggin, is associated with increased nuclear and cytoplasmic -catenin and with 
up-regulation of Wnt target genes (Kosinski et al. 2007).  Independent studies also show that 
transgenic expression of Noggin in vivo is associated with increased expression of -catenin 
(Haramis et al. 2004).  Similarly, expression of other TGF superfamily antagonists is associated with 
EMT (Zeisberg et al. 2003).  Notably, direct regulatory interaction between the central mediators of 
Wnt and TGF signaling, -catenin and Smad4, has not been described, even though defects in both 
pathways contribute to more than half of all colorectal cancers. 
    Negative regulation of Wnt signaling can occur at multiple levels; however, the dominant paradigm  
for pathway regulation is through post-translational modification of -catenin leading to proteasomal 
mediated degradation of intracellular levels to meter the Wnt signal (Clevers 2006).  However, recent 
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work also suggests transcriptional activation of -catenin as potentially important at the invasive front 
of colorectal cancers (Bandapalli et al. 2009; Nollet et al. 1996).  Here, we provide additional 
evidence, in support of a new model for regulation of Wnt signaling in which Smad4 directly represses 
-catenin transcription in epithelial cells.  
    Our data show that Smad4 associates with the 5’ region upstream of ctnnb1 suggesting that the 
suppression of ctnnb1 transcription may be a direct effect of Smad4.   Future work will determine 
precisely which cis-elements of the implicated area of the ctnnb1 promoter/enhancer are necessary 
and sufficient for transcriptional repression induced by Smad4, and will determine which 
transcriptional co-regulators participate with Smad4 in this regulation (e.g., p300, Smads 1/5/8 or 
Smads 2/3).   Additionally, determination of the ligand dependence of this effect remains to be 
addressed.   For example, Smad4 restoration in colon cancer cells may enable autocrine TGF or 
BMP signaling ((Beck et al. 2006) and our unpublished observations) as a potential mechanism to 
further propagate resultant downstream tumor suppressor effects of Smad4.  Our gene expression 
microarray observations of the significant inverse correlation of Smad4 and -catenin expression in 
250 colorectal cancer patients corroborated the observations we made in cultured colon cancer cells.  
In addition, analysis of the epithelial-specific, Smad4 co-regulated genes confirm that expression of 
Smad4 in colorectal cancers is associated with suppression of specific Wnt target genes.  For 
example, we found that Wnt stimulated targets, Axin2, Claudin1, Inhibitor of DNA binding 2, dominant 
negative helix-loop-helix protein (ID2) and Jun oncogene are all significantly down-regulated when 
Smad4 expression levels are high in the primary colorectal tumors.  Finally, we observed that the 
Smad4 co-regulated gene list contains stage-independent prognostic information that can be tested in 
future clinical datasets for potential use in prospective identification of high-risk colorectal cancer 
patients.  These data indicate that the transcriptional profile associated with Smad4 loss may be more 
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informative than analysis of Smad4 loss alone in prediction of clinical outcomes in colorectal cancer 
patients.  
    In summary, our data uncover a previously unrecognized function of Smad4 in transcriptional 
repression of the ctnnb1 gene.  Our data also provide new insights into the modulation of the Wnt 
transcriptional program by Smad4 that has important implications for their cooperative roles in 
homeostasis in intestinal epithelium and tumorigenesis.  This Smad4-modulated, epithelial-specific, 
Wnt-enriched gene signature has potential prognostic value beyond conventional pathological staging 
of colorectal cancer patients. These findings should also facilitate hypothesis testing for biologically 
targeted therapeutic interventions based on the level of activity of the TGF/Smad or Wnt signaling 
pathways.    
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CHAPTER IV 
 
SUMMARY OF FINDINGS AND FUTURE DIRECTIONS 
 
Brief Review 
 
    Colorectal cancer is the second leading cause of cancer-related deaths in the United States, and 
most of these deaths are a consequence of metastatic disease.  Understanding the biology of 
metastasis and loss of tumor suppression is critical to identify patients at highest risk of cancer-
related death.  We used biological models to gain mechanistic insights into these areas to translate 
into optimal care of colorectal cancer patients.  Chapter II:  Staging inadequately predicts metastatic 
risk in colon cancer patients.  We addressed this problem by developing a biological mouse model of 
metastasis where gene expression analysis led to the discovery of a metastasis-associated profile.  
Profile refinement in a colorectal cancer patient test set uncovered a 34-gene classifier that when 
translated to a metastasis score identified colon cancer patients in an independent test set at highest 
risk of death from recurrence.  It also identified high-risk stage II and III patients, and importantly 
revealed low-risk stage III patients for whom adjuvant chemotherapy did not improve survival.  This 
34-gene classifier predicted poor outcome, independently of conventional measures, thereby 
providing insight into the biology of colon cancer metastasis.  Chapter III:  Loss of tumor suppressor 
genes is evident in the majority of colorectal cancer patients. TGF and Wnt signaling pathways are 
implicated in this process and are essential during development, epithelial cell differentiation and 
proliferation.  Since we previously noted reduction in -catenin levels and suppression of Wnt activity 
upon Smad4 restoration in colon cancer cells, we examined the mechanism by which Smad4 
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represses -catenin expression and Wnt signaling.  Smad4 expression results in transcriptional 
repression of -catenin and thereby inhibits Wnt signaling, with associated inhibition of downstream 
Wnt target gene expression and reversal of epithelial-mesenchymal transition.  The clinical relevance 
of this effect was demonstrated by an epithelial cell specific, Smad4-modulated gene expression 
profile associated with suppression of Wnt signaling, which contributed prognostic information 
independent of conventional pathological staging, in a large cohort of colorectal cancer patients.  
These findings should facilitate hypothesis testing for biologically targeted therapeutic interventions 
based on TGF/Smad or Wnt signaling pathway activity levels. 
 
Future Directions for the 34-gene Classifier 
 
Validation and Optimization of the 34-gene Classifier in Clinical Samples 
    We are currently working on three separate fronts to move the 34-gene classifier toward clinical 
application.  First, we are developing an objective metastasis score for colorectal cancer.  The validity 
of the proposed molecular predictor must be tested as an objective score that can be applied to 
individual patients prospectively.  However, before this can be done we are using primary tumors 
resected from stage II and III patients with colorectal cancer with mature follow-up data (>3 years) to 
build a statistically robust model represented by data from four independent academic centers (VMC, 
UAB, MCC and The Ludwig Cancer Institute in Melbourne Australia).  We will build the model in a 
combined dataset from the VMC/MCC groups (n=250 patients, see Chapter III) and test it in 
retrospectively collected, mature samples from UAB and Melbourne.  We will combine the 34-gene 
classifier and several other credible colon cancer signatures (Barrier et al. 2006; Eschrich et al. 2005; 
Garman et al. 2008; Jorissen et al. 2009; Lin et al. 2007) proposed to predict a recurrence-prone 
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phenotype to systematically evaluate combinations of gene expression patterns for their association 
with colon cancer metastasis and recurrence according to the method proposed by Paik (Paik et al. 
2004).  The results of these analyses will be competed head-to-head with the biologically based 34-
gene metastasis score.  We will re-build the Cox Model (see Chapter II) in the combined 250 patient 
dataset and then test the results in an independent dataset made up of Melbourne and UAB patients 
for whom microarray data is readily available (n=180 patients).  Our proposed sample size will allow 
at least 80% power to detect a hazard ratio of 1.70 between high and low score groups with an FDR = 
0.003.  These efforts will allow us to determine an objective metastasis score in a foundation of 
patients samples linked to mature clinical outcome in four independent academic settings to be 
carried forward in prospective analysis of the resultant metastasis score. 
    Secondly, we will determine the optimal platform for detection of the 34-gene metastasis score.  
Many technical issues stand in the way of the development of a robust clinical assay and include 
preservation of resected surgical specimens, amount and quality of purified RNA and reproducibility 
and robustness of the assay.  We and our collaborators have overcome many of the collection issues 
and are now focusing on continual high quality RNA isolation from pathologically verified tissues that 
can be analyzed by the proposed assays (see below).  We will compete head-to-head comparisons of 
expression values of the 34-genes from matched fresh frozen samples versus formalin fixed paraffin 
embedded (FFPE) tissues.  Since routine tissue collection (e.g., community and regional hospitals) 
does not employ rigorous standardization methods as have been used to develop the original 
metastasis score (see Chapter II), a clinical test will be designed to detect the metastasis signature in 
FFPE tissues in order to be widely applicable.  The details of this process are beyond the scope of 
this dissertation, but briefly we will use the following three competing platforms to determine the best 
method of detection:  a) Applied Biosystems qPCR; b) High Throughput Genomics’ qNPA 
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technology; c) GeneTitan based microarray with Affymetrix technology.  The major goals of this 
work will be to determine whether differential expression analysis is comparable in fresh frozen 
versus FFPE tumor tissue and to determine which platform for a clinical test is most reliable.   
    Lastly, we will test the optimized metastasis signature (determined as described above) in a 
blinded fashion on archival FFPE tissue collected in our multi-institutional collaboration, in order to 
determine the sensitivity, specificity, accuracy and clinical validity of the resultant score.  This 
optimized signature will provide us with preliminary data that will be required to advance the work 
toward a prospective clinical trial to predict outcomes in stage II and III patients.  The ultimate goal is 
to develop a deliverable assay on a robust platform that is ready to be applied to a prospective clinical 
trial.  Future clinical trials would be based on collaboration with National Cancer Institute cooperative 
groups who have access to large numbers of patients across many academic centers and institutions. 
   
Determination of the Primary Drivers of the 34-gene Classifier 
    We are concurrently in the process of determining which of the 34 genes in the metastasis score 
truly drive the predictive ability of the score.  We are collaborating with our colleagues in biostatistics 
to model the ‘driver’ genes in the signature using the compound scoring method as applied to the 
combined VMC/MCC data and then will validate this in additional test sets.  So far, our work has 
shown that 11 genes of the signature show equivalent predictive power compared to the 34 genes 
(preliminary data, not shown).  We are also comparing the specificity and sensitivity of these 11 
genes to the 34 genes in this dataset.  Additionally, preliminary work has shown that the biologically-
based metastasis score may be informative in other epithelial cancers such as breast and lung 
cancer (data not shown).  We are in the process of finishing a manuscript to describe these findings. 
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Identification of Central Transcriptional Regulators in the 34-gene Classifier 
    In collaboration with colleagues in the biostatistics and bioinformatics departments at VMC we 
have begun to identify metastasis-related co-expression modules in a biologically meaningful way to 
reflect potential underlying regulatory mechanisms central to the transcriptional program driving the 
molecularly encoded, metastasis-prone phenotype.  For example, the 300-gene metastatic gene 
signature (see Chapter II) has been used to identify 18 metastasis-related transcriptional modules 
that appear to be robust in prediction of colorectal cancer survival.  These data are based on the idea 
that it is possible to identify regulatory mechanisms responsible for gene de-regulation in cancer 
signatures by searching for the unifying, coordinate transcription factor binding sites amongst genes 
in a gene expression classifier (Rhodes et al. 2005).   Work to identify novel transcriptional regulators 
of the metastatic phenotype has begun and this work has subsequently been funded to further 
identify metastasis-related networks and screen for metastasis-related transcriptional modules using 
mouse and human colorectal cancer cell lines.  These networks and transcriptional modules will then 
be tested and validated in our growing set of test and training datasets for clinical outcomes.  For 
example, transcriptional factors discovered in this manner will be tested functionally via small 
interfering RNA and short hairpin RNA-mediated approaches to verify biological relevance in both 
mouse and human cell line models.  Specifically, cell migration and invasion assays (see Chapters II 
and III) will be used to evaluate loss or gain of invasive capacity for each identified transcriptional 
factor that has been validated in a survival-prediction model.  We will subsequently validate effects on 
apoptosis, proliferation and anoikis in addition to proceeding with in vivo experiments to confirm 
regulation of an invasive phenotype.  Repressors of metastasis can be identified in a like manner and 
will be validated as above.  Both metastasis effectors and metastasis repressors can then be 
validated in colorectal cancer samples by qPCR (and potentially immunohistochemistry) via our 
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continued collaboration with Dr. Kay Washington in Pathology.  These approaches bring together the 
unique strengths of bioinformaticists, systems biologists, cancer cell biologists, biostatisticians, 
physician-scientists and clinical teams to address a complex clinical problem.  The use of 
complimentary network-based models and biological models to determine functions of genes 
identified in metastasis-prone signatures will provide a means whereby valuable regulators of 
metastasis can discovered, validated and moved toward robust clinical application. 
 
Differences and Overlap Between the 34-gene Classifier and Recently Published High-risk 
Gene Signatures for Colorectal Cancer Patients 
 
    As discussed in Chapter II, numerous gene expression signatures that identify high-risk colorectal 
cancer patients have been put forth as potentially useful in various prediction models.  Unfortunately, 
prior prediction classifiers were determined on inconsistent microarray platforms to prevent a 
balanced comparison.  In this section, I will focus on two of the most recent signatures, which have 
been developed on the same modern Affymetrix platform as described in Chapters II and III of this 
work, and their relevance and potential relationship with our 34-gene classifier.    It should be noted 
that all other published gene expression signatures for colorectal cancer used computational methods 
to determine their classifiers, whereas we used a biological model refined with a comparative 
functional genomics approach to determine the 34-gene classifier.   
    The most recent unit of published work is from the Ludwig Colon Cancer (LCC) Initiative 
Laboratory in Australia (Jorissen et al. 2009).  We note some interesting similarities between our 
proposed 34-gene recurrence classifier and their work.  This group used a comparison between early 
stage (stage I) and late stage (stage IV) patients to determine a 128-gene signature that was 
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validated in an independent set of stage II and III colorectal cancer patients.  Of note, some of the 
MCC patients used in this analysis were also used in both Chapters II and III of our work.  Even 
though there is no specific gene overlap between our 34-gene classifier and this 128-gene classifier 
there is similarity in the biological processes implicated.  For example, amongst the up-regulated 
genes in the LCC classifier, processes of extracellular matrix biology and embryonic development 
were implicated by Gene Ontology analysis (e.g., COL5A1 (collagen, type V, alpha 1), Integrins 
(ITGB1)), and similarly, in our use of Ingenuity Pathways Analysis we found that up-regulated genes 
were enriched for processes of cellular and embryonic development and connective tissue 
development / function (e.g., EGR1 (early growth response 1), HES1 (hairy and enhancer of split 1 
(Drosophila), SPRY4 (sprouty homolog 4 (Drosophila)), ACTB (-actin), PDLIM5 (PDZ and LIM 
domain 5)).  The LCC down-regulated genes implicated processes of immune function as well as 
proteasomal genes (e.g. Immunoglobulins (IGHA1), chemokines (CCL28) and PSMB genes like 
PSMB9 (proteasome-related)).  Our biologically-based signature derived from an immunocompetent 
mouse model showed that the down-regulated genes formed a network around Tumor Necrosis 
Factor (e.g., MMP13 (matrix metallopeptidase 13 (collagenase 3)) and HPSE (heparanase)) to 
suggest a prominent role for the immune system in the modulation of the metastasis-prone 
phenotype.  We also found that the 300-gene metastatic gene signature had twelve genes in common 
with the 128-gene signature.  These genes (e.g., PDGFC (platelet derived growth factor C), POSTN 
(periostin, osteoblast specific factor) and ITGBL1 (integrin, beta-like 1 (with EGF-like repeat 
domains)) are involved in processes of connective tissue development and cellular adhesion 
indicating that our approaches while different have implicated similar biological processes and 
networks that are important for the pathogenesis of a high-risk colorectal cancer phenotype.  The 
discrepancy in overlap could be attributed to our use of a mouse model that may have missed human 
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genes important for the process of metastasis that were uncovered in the LCC signature.  Likewise, it 
is possible that our approach uncovered novel regulators of metastasis with a purely biological basis 
that extend even beyond colorectal cancer epithelial pathobiology.   
 Another recent genomic approach to stratify colon cancer risk was put forth by a group from 
Duke University (Garman et al. 2008), wherein they developed a classifier that identified high-risk 
patients with computational models in early stage patients who had recurred and applied it to two 
independent datasets.  They went on to show that this 50-gene classifier was able to identify 
compounds (e.g. COX-2 inhibitors, PI3K inhibitors) with biological activity against colorectal cancer 
cell lines in culture.  Unlike our 34-gene classifier, they did not note any association with their 
signature and chemotherapeutic intervention in colorectal cancer patients.  We found no intersection 
between the 50-gene classifier and our 34-gene classifier; however, upon further review it was 
interesting to note that the 50-gene signature implicated COX-2 (using a Connectivity Map approach 
(Lamb et al. 2006)), an important inflammatory mediator in colorectal cancer pathogenesis, and our 
signature uncovered a transcriptional module of down-regulated genes that suggest modulation of 
inflammation to be important for the metastatic phenotype.  Prior to the publication of their 50-gene 
signature, I performed an independent analysis where the 34-gene signature was input into the 
Connectivity Map (Lamb et al. 2006), and I noted that the top compound implicated was 
acetylsalicylic acid (also known as aspirin, 18 Sept 2008 analysis, unpublished results, data not 
shown).  These data compliment the Duke University group’s findings.  Even though we found some 
broad similarities, there was still minimal overlap amongst the 50-gene classifier and the 300-gene 
metastatic signature with only two genes overlapping, POSTN (periostin, osteoblast specific factor) 
and NDRG family member 2.  POSTN has now been identified in three recent models and will surely 
be used in our development of an objective score as we more forward.  Again, the minimal overlap 
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could be due to loss of important human genes with use of the mouse model, but it is encouraging to 
note that central processes amongst the analyses (e.g., inflammation and extracellular matrix / 
connective tissue biology) seem to remain relevant to inform factors critical for the identification of the 
high-risk colorectal patient.  It is important to note that all three of these signatures are highly 
enriched for processes related to carcinogenesis such as cell-cell signaling, cellular development, 
cellular proliferation, cytoskeletal remodeling and modulation of inflammatory mediators.  These data 
support our development of an objective score (as above) since it is likely that a combination of gene 
co-expression modules may uncover a superior gene expression classifier.   
    Lastly, since we used a comparative functional genomics approach originally modeled in the 
prediction of high-risk hepatocellular carcinoma (HCC) patients, we asked if there was any overlap 
amongst these pioneering studies (Lee et al. 2004; Lee et al. 2006) and our work.  We found overlap 
amongst the genes downstream of FOS and JUN as they related to the hepatoblast subtype of HCC 
who had associated poor outcome (Lee et al. 2006).  For example, ATF3 (activating transcription 
factor 3), TNC (tenascin C) and NR4A1 (nuclear receptor subfamily 4, group A, member 1) were 
found in both our 300-gene signature and the cluster associated with the hepatoblast sub-type of 
HCC.  These genes are implicated in processes of apoptosis (e.g., NR4A1), extracellular matrices 
(e.g., TNC) and transcriptional modulation of apoptotic events and response to TGF signaling 
partners (e.g., ATF3).   Indirect connections include PTGS2 (prostaglandin-endoperoxide synthase 2 
(prostaglandin G/H synthase and cyclooxygenase), also known as COX-2) and MMP1 (matrix 
metallopeptidase 1 (interstitial collagenase)).  This is interesting as an inflammatory central node that 
seems to become a common theme across this survey of prognostic classifiers.  Also, MMP10, 
MMP12 and MMP13 were implicated in the 300-gene metastatic signature in our MC-38parental to 
MC-38met comparison as well as in the functional genomic enrichment of the rat hepatoblast 
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phenotype in poor prognosis patients with HCC.  We noted very little overlap from the initial 2004 
paper from this group other than enrichment of proteinases (MMPs) in the selection of optimal mouse 
models of human HCC (e.g., Myc, E2f1 and Myc E2f1 transgenic mice).  In conclusion, gene overlap 
in the comparison of high-risk colorectal cancer and HCC patients reflect common processes on the 
pathway of carcinogenesis that were revealed in independent comparative genomic model systems 
(e.g., modulation of immune responses).  These data support the use of these models, but suggest 
that specific carcinoma sub-types will result in distinctive gene expression profiles with common 
themes important for the metastatic process. 
 
Interactions Amongst the 34-gene Classifier and the Smad4-expression Profile 
 
    As described in Chapter III, we discovered a Smad4-modulated, epithelial-specific, Wnt-enriched 
gene expression classifier that identified colorectal cancer patient sub-groups with regard to clinical 
outcome independently of conventional measures.  One interesting notion is that this tumor 
suppressor-modulated gene expression profile could validate putative tumor suppressors and 
oncogenes in the 34-gene classifier.  In regard to putative tumor suppressors, we noted that SYT17 
(synaptotagmin XVII), MUM1L1 (melanoma associated antigen (mutated) 1-like 1) and HPSE 
(heparanse) were all up-regulated in the presence of Smad4.  Very little is known about the ‘syt-like’ 
proteins.  Synaptotagmins are thought to play a role in calcium sensing and neurotransmitter release 
and may be involved in calcium-dependent exocytosis (Koh and Bellen 2003).  This might suggest 
that Smad4 has a role in processes of neural development and homeostasis which is supported in 
other neural environments as Smad4 has a transcriptional and synergistic effect with BMP2 on -
aminobutyric acid (GABA)-modulated neuronal differentiation via Gat1 (GABA transporter sub-type I) 
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(Yao et al.).  GABA is the chief inhibitory neurotransmitter in mammalian neurobiology.  This is quite 
interesting as investigators from Baylor College of Medicine recently noted an association between 
neuronal ingrowth (e.g., perineural invasion) and tumor invasiveness / poor prognosis in colorectal 
cancer patients (Liebig et al. Perineural invasion in cancer: A review of the literature 2009; Liebig et 
al. Perineural invasion is an independent predictor of outcome in colorectal cancer 2009).  This brings 
up the possibility of an undiscovered association with Smad4 loss and perineural invasion.  One could 
speculate that Smad4 tempers neuronal outgrowth into epithelial structures via inhibitory action 
through GABAergic control of differentiated neurons.  There is no published literature on MUM1L1; 
however, it is interesting to note that several melanoma-associated genes with generally unknown 
biological functions (e.g., MAGEB2 (melanoma antigen family B, 2), MAGEA3 (melanoma antigen 
family A, 3) are up-regulated in the presence of Smad4 in SW480 cells.  These melanoma-associated 
genes, typically only expressed in the testes, have been implicated in a p53-dependent manner to 
apoptosis in colon cancer cells (Yang et al. 2007).   HPSE is thought to play a role in invasiveness of 
renal cell carcinoma and has been found to be associated with increased tumor stage and disease-
free survival (Mikami et al. 2008).  These data provide some additional evidence to support the idea 
that down-regulation of these genes in the 34-gene classifier as putative tumor suppressors are 
important in the progression of the metastatic phenotype.   
    Regarding putative oncogenes, VDR (vitamin D (1,25- dihydroxyvitamin D3) receptor) was found in 
the genes down-regulated by Smad4 in SW480 colon cancer cells (see Chapter III, FDR<0.005, fold-
change > 4).  Interestingly, as noted in Chapter II there is now some data to support the role of VDR 
in EMT as related to ZEB1 expression (see page 57).  As shown in Chapter III, Smad4 restoration in 
SW480 colon cancer cells is associated with down-regulation of -catenin, inhibition of Wnt signaling 
and reversal of EMT in vitro and in vivo.  The finding of VDR up-regulation in the highly invasive MC-
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38met cells and as part of the 34-gene classifier indicate that the gene encoding the Vitamin D 
receptor may be an important target of Wnt/-catenin signaling that plays an potential role in the 
acquisition of a more mesenchymal and invasive phenotype.  Recent evidence suggests that VDR 
does interact with Wnt signaling components (e.g., TCF4, E-cadherin and Snail) in association with a 
less invasive phenotype (Beildeck et al. 2009; Pena et al. 2009), although it should be noted that the 
biological validation of the interaction in these studies was unimpressive.  The potential connection 
between Smad4 and VDR is made more intriguing by the mounting level of evidence that implicates 
Vitamin D deficiency as a potential factor in colorectal cancer progression (Egan et al. ; Kure et al. 
2009).  Chronically low vitamin D levels could potentiate compensatory up-regulation of the vitamin D 
receptor in the setting of APC and Smad4 loss, which then promotes progression from dysplastic 
adenoma to carcinoma.  Smad3-4 heteromeric complexes may bind the VDR promoter in COS cells 
in a synergistic manner requiring both TGF-responsive and Vitamin D-responsive promoter 
elements (Subramaniam et al. 2001).  The biological effects of this transcriptional interaction are 
unknown, but open the door to interesting hypotheses in regard to the relationship with the central 
mediator of TGF signaling and the complex biology of VDR homeostasis. 
 
Further Dissection of the Mechanism of Smad4 Inhibition of Wnt/-catenin Signaling 
 
    Use of a nude mouse model as described in Chapter III could be used to provide in vivo evidence 
of the biological mechanism of Smad4 repression of -catenin transcriptional activity.  We could 
repeat the experiment as described in Chapter III, but this time use laser capture microdissection to 
isolate the invading front of the resultant tumors to prove whether Smad4 expression and the 
observed reduction in tumorigenicity is indeed due to repression of -catenin mRNA at the invasive 
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edge of the tumors.  We could also determine if there is indeed a down-regulation of -catenin mRNA 
and protein in the Smad4 expressing tumors as indicated by qPCR, Western, and 
Immunohistochemistry/Immunofluorescence analyses.  Another way to use this model would be to 
incorporate the use of a novel Wnt inhibitor developed by our collaborator Ethan Lee.  We would be 
able to determine if Smad4 expression could potentiate suppression of tumorigenicity in the presence 
of the inhibitor or if suppression of tumorigencity occurs independently of administration of the Wnt 
inhibitor.  Since the Wnt inhibitor prevents -catenin-mediated Wnt transcriptional activity upstream of 
-catenin transcription, we would be able to determine if Smad4 has an additional effect on -catenin 
transcriptional activity downstream of this inhibitor to affect tumorigenicity and measures of invasion 
in vitro.  Either way, we could determine whether Smad4 is required for suppression of Wnt activity in 
association with -catenin repression in vivo and complimentary in vitro approaches. 
    Another in vivo model that we are currently developing is an inducible, epithelial-specific Smad4 
knockout mouse.  As we gain more numbers for each timepoint of inducible Smad4 depletion in the 
colony, we can determine if Smad4 loss alone is sufficient to promote up-regulation of -catenin 
levels (mRNA and protein) in the areas of Smad4 loss.  Another mouse model in development is the 
epithelial-specific Smad4 knockout mouse crossed with the APCMin1638 mouse.  This mouse could 
inform our hypothesis that Smad4 tempers progression toward a more invasive phenotype even in 
the absence of APC.  It would also tell us if APC loss must occur in order to see the biological effects 
of -catenin repression in vivo.  Another interesting mouse model to directly inform whether this 
transcriptional repression occurs in vivo is to cross the epithelial-specific Smad4 knockout mouse with 
a TOPflash mouse.  The development of this mouse is also underway in the laboratory and will 
provide an additional model whereby we can directly test our hypothesis that Smad4 does indeed 
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repress -catenin transcriptional activity in vivo to promote a more epithelial phenotype and prevent 
progression to invasive adenocarcinoma via inhibition of Wnt transcriptional activation.   
    We are also collaborating with Kay Washington in Pathology to further examine a number of 
colorectal cancer specimens where the invasive front or leading edge of the tumor can be examined.  
We hypothesize that in the invasive, EMT-prone areas where Brabletz’s group (Schmalhofer, 
Brabletz, and Brabletz 2009) has noted loss of E-cadherin and gain of -catenin that we would 
observe loss of Smad4.  Furthermore, we hypothesize that areas of colorectal cancer tumors that 
remain differentiated (membranous E-cadherin and -catenin staining) also have retained Smad4 
expression.  We are also accumulating more colorectal cancer tumor specimens to determine if the 
loss of Smad4, gain of -catenin and loss of E-cadherin can further inform colorectal cancer 
outcomes.  It is certainly possible that the transcriptional program of Smad4 loss is more informative 
than simply looking at Smad4 gain or loss by immunohistochemical analysis alone. 
    Lastly, we have begun collaboration with local experts in transcriptional and protein regulation (Dr. 
Bill Tansey and Dr. Dan Liebler) to further investigate the mechanisms by which Smad4 represses 
Wnt/-catenin signaling.  For example, we will determine the transcriptional program regulated by 
Smad4 modulation of Wnt signaling in colorectal cancer cells by extending our ChIP findings with 
massively parallel short-read sequencing of DNA fragments obtained through ChIP-sequencing 
(ChIP-seq).  We can conduct Smad4 and TCF4 ChIP-seq experiments where we anticipate that we 
will observe reduced TCF4-binding to Wnt target genes in the presence of intact BMP/Smad4 
signaling.  These data will provide more sensitive and quantitative support to our proposed 
mechanism and will allow sequence-specific detail that can inform critical co-regulators with Smad4 in 
this process of Wnt/-catein suppression.  Additionally, we will identify co-regulatory proteins involved 
in Smad4-driven repression of Wnt/-catenin transcriptional activity in colon cancer cells.  We will use 
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a shotgun proteomic approach (liquid chromotagraphy and tandem mass-spectrometry) to gain 
insight into the transcriptional regulatory protein complexes with high sensitivity.  We can then use a 
small-interfering RNA approach to prove the necessity and sufficiency for identified co-regulatory 
proteins that may work in concert with Smad4 in repression of Wnt/-catenin signaling.  The multiple 
approaches at our disposal will provide important insights into the homeostatic, intersecting regulatory 
roles of the TGF and Wnt/-catenin signaling pathways to illuminate our understanding of their 
contribution to the progression of colorectal cancer.  These findings can then facilitate identification of 
new molecular targets to translate into therapeutic interventions that benefit colorectal cancer 
patients. 
 
Summary 
 
    Colorectal cancer is the second most lethal, non-cutaneous epithelial cancer in the United States.  
Metastasis contributes to the majority of cancer-related deaths in this disease.  Metastasis closely 
resembles the developmental process of epithelial-mesenchymal transition and reliable models to 
recapitulate this process can be useful to shed light onto the biology and prognosis of patients with 
colorectal cancer.  Herein we describe a mouse model that led to the discovery of a gene signature of 
metastasis using comparative functional genomics, which identified stage II and III colon cancer 
patients prone to recurrence and death from metastatic disease, in addition to a low-risk sub-group of 
stage III patients for whom adjuvant chemotherapy provided no additional survival benefit.  These 
findings form the basis for substantive pre-clinical biomarker testing and eventual translational 
application to a clinical trial.  On the other hand, loss of tumor suppressor genes affects the majority 
of colorectal cancer patients to permit progression of disease.  Many pathways are defective in the 
 120 
pathogenesis of colorectal cancer; however, more than half of the patients have defects in the Wnt/-
catenin and Transforming Growth Factor- signaling pathways, which are critical for development and 
intestinal homeostasis.  This body of work also uses in vitro and in vivo models to describe a new role 
for the tumor suppressor Smad4 in the repression of -catenin transcriptional activity in epithelial 
cells.  This repression was associated with down-regulation of Wnt signaling and reversal of EMT.  
Clinical relevance of this effect was demonstrated by an epithelial cell-specific, Smad4-modulated 
gene expression profile associated with Wnt signaling suppression, which contributed prognostic 
information for colorectal cancer patients independently of pathological staging.  These findings 
should facilitate hypothesis testing for biologically-targeted therapeutic interventions based on 
TGF/Smad and Wnt/-catenin pathway activity levels.  Overall, these results provide insight into the 
biology of metastasis and tumor suppression in colorectal cancer to promote seamless translation to 
care of the colorectal cancer patient at the bedside. 
 
 
 
 
 
 
 
 
 
 
 
121 
 
Figure 8. Functional genomic clustering of the 300-gene metastatic 
signature.  Cluster analysis of mean-centered gene expression data (rows) 
with individual VMC patients (columns). Individual gene symbols in the 
metastasis-associated signature are listed at the right side of the 
dendrogram, and the 34 genes that make up the recurrence classifier are 
highlighted in yellow. Patient IDs are listed along the bottom. The patients 
who clustered with MC-38 parental cells are highlighted in red and those 
who clustered with MC-38met cells are highlighted in green. The heatmap 
key is 4-fold on the original signal intensity scale, which corresponds to 2-
fold on a log2 scale. Key (1) Sample source: red, MC-38 parental; green, 
MC-38 invasive derivative (MC-38met); blue, patient samples; (2) Ensembl 
Human Gene identifiers: right side of heatmap.  
Appendix 
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TABLE 3 
 
300 GENE METASTATIC SIGNATURE 
 
Display ID Gene Stable 
ID 
Fold 
Change 
Description (Protein name) 
AQP1 ENSG000001
06125 
17.613 Aquaporin-1 (AQP-1) 
OGN ENSG000001
06809 
13.176 Mimecan precursor (Osteoglycin) (Osteoinductive factor) (OIF). 
IL2RG ENSG000001
47168 
13.041 Cytokine receptor common gamma chain precursor (Gamma-C) (Interleukin- 2 receptor gamma chain) (IL-
2R gamma chain) (p64) 
GRAMD1C ENSG000001
78075 
11.665 GRAM domain-containing protein 1C. 
AQP5 ENSG000001
61798 
10.694 Aquaporin-5 (AQP-5) 
C2orf40 ENSG000001
19147 
8.53 Esophageal cancer related gene 4 protein precursor. 
C15orf26 ENSG000001
56206 
6.934 Uncharacterized protein C15orf26. 
EREG ENSG000001
24882 
6.87 Epiregulin precursor (EPR). 
OLR1 ENSG000001
73391 
6.555 Oxidized low-density lipoprotein receptor 1 (Ox-LDL receptor 1) (Lectin-type oxidized LDL receptor 1) 
(Lectin-like oxidized LDL receptor 1) 
PTGS1 ENSG000000
95303 
6.348 Prostaglandin G/H synthase 1 precursor (EC 1.14.99.1) (Cyclooxygenase- 1) (COX-1) (Prostaglandin-
endoperoxide synthase 1) 
TMEM98 ENSG000000
06042 
6.279 Transmembrane protein 98 (Protein TADA1). 
PDZRN3 ENSG000001
21440 
6.012 PDZ domain-containing RING finger protein 3 (Ligand of Numb-protein X 3) (Semaphorin cytoplasmic 
domain-associated protein 3) 
C13orf33 ENSG000001
02802 
5.998 Uncharacterized protein C13orf33 (Activated in W/Wv mouse stomach 3 homolog) (hAWMS3). 
IGFBP4 ENSG000001
41753 
5.842 Insulin-like growth factor-binding protein 4 precursor (IGFBP-4) (IBP- 4) (IGF-binding protein 4). 
APOD ENSG000001
89058 
5.723 Apolipoprotein D precursor (Apo-D) (ApoD). 
DIO2 ENSG000002
11448 
5.179 Type II iodothyronine deiodinase (EC 1.97.1.10) (Type-II 5' deiodinase) (DIOII) (Type 2 DI) (5DII). 
MYH10 ENSG000001
33026 
5.127 Myosin-10 (Myosin heavy chain 10) (Myosin heavy chain, nonmuscle IIb) (Nonmuscle myosin heavy chain 
IIb) (NMMHC II-b) (NMMHC-IIB) 
MME ENSG000001
96549 
5.066 Neprilysin (EC 3.4.24.11) (Neutral endopeptidase) (NEP) (Enkephalinase) (Neutral endopeptidase 24.11) 
(Atriopeptidase) 
PRRX2 ENSG000001
67157 
5.022 Paired mesoderm homeobox protein 2 (PRX-2) (Paired-related homeobox protein 2). 
PLA2G7 ENSG000001
46070 
4.896 Platelet-activating factor acetylhydrolase precursor (EC 3.1.1.47) (PAF acetylhydrolase) (PAF 2-
acylhydrolase) 
PID1 ENSG000001
53823 
4.646 PTB-containing, cubilin and LRP1-interacting protein (P-CLI1) (Phosphotyrosine interaction domain-
containing protein 1) 
SCARA5 ENSG000001
68079 
4.597 Scavenger receptor class A member 5 (Scavenger receptor hlg). 
C14orf159 ENSG000001
33943 
4.261 UPF0317 protein C14orf159, mitochondrial precursor. 
PDLIM2 ENSG000001
20913 
4.222 PDZ and LIM domain protein 2 (PDZ-LIM protein mystique) (PDZ-LIM protein). 
NR4A2 ENSG000001
53234 
4.131 Orphan nuclear receptor NR4A2 (Orphan nuclear receptor NURR1) (Immediate-early response protein 
NOT) 
AGT ENSG000001
35744 
3.934 Angiotensinogen precursor (Serpin A8) [Contains: Angiotensin-1 (Angiotensin I) (Ang I); Angiotensin-2 
(Angiotensin II) 
SRPX2 ENSG000001
02359 
3.909 Sushi repeat-containing protein SRPX2 precursor. 
FAM84A ENSG000001
62981 
3.891 Protein FAM84A (Protein NSE1). 
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SYBU_HUM
AN 
ENSG000001
47642 
3.876 Syntabulin (Syntaxin-1-binding protein) (Golgi-localized syntaphilin- related protein). 
CXCR7 ENSG000001
44476 
3.854 C-X-C chemokine receptor type 7 (CXC-R7) (CXCR-7) (G-protein coupled receptor RDC1 homolog) 
(RDC-1) (Chemokine orphan receptor 1) 
ASPN ENSG000001
06819 
3.79 Asporin precursor (Periodontal ligament-associated protein 1) (PLAP- 1). 
C1QTNF3 ENSG000000
82196 
3.642 Complement C1q tumor necrosis factor-related protein 3 precursor (Secretory protein CORS26). 
PCDHB15 ENSG000001
13248 
3.564 Protocadherin beta 15 precursor (PCDH-beta15). 
SCAMP5 ENSG000001
98794 
3.553 Secretory carrier-associated membrane protein 5 (Secretory carrier membrane protein 5). 
ODZ4 ENSG000001
49256 
3.486 Teneurin-4 (Ten-4) (Tenascin-M4) (Ten-m4) (Protein Odd Oz/ten-m homolog 4). 
HS3ST1 ENSG000000
02587 
3.355 Heparan sulfate glucosamine 3-O-sulfotransferase 1 precursor (EC 2.8.2.23) (Heparan sulfate D-
glucosaminyl 3-O-sulfotransferase 1) 
HAS2 ENSG000001
70961 
3.347 Hyaluronan synthase 2 (EC 2.4.1.212) (Hyaluronate synthase 2) (Hyaluronic acid synthase 2) (HA 
synthase 2). 
GGTL3 ENSG000001
31067 
3.285 Gamma-glutamyltransferase 4 precursor (EC 2.3.2.2) (Gamma- glutamyltranspeptidase 4) 
ANKH ENSG000001
54122 
3.285 Progressive ankylosis protein homolog (ANK). 
SEMA3A ENSG000000
75213 
3.193 Semaphorin-3A precursor (Semaphorin III) (Sema III). 
ITGA8 ENSG000000
77943 
3.19 Integrin alpha-8 precursor [Contains: Integrin alpha-8 heavy chain; Integrin alpha-8 light chain]. 
MYBPHL ENSG000001
34222 
3.145 Proline/serine-rich coiled coil protein 1. 
TINAGL1 ENSG000001
42910 
2.994 Tubulointerstitial nephritis antigen-like precursor (Tubulointerstitial nephritis antigen-related protein) (TIN 
Ag-related protein) 
PDE4B ENSG000001
84588 
2.994 cAMP-specific 3',5'-cyclic phosphodiesterase 4B (EC 3.1.4.17) (DPDE4) (PDE32). 
RRBP1 ENSG000001
25844 
2.991 Ribosome-binding protein 1 (Ribosome receptor protein) (180 kDa ribosome receptor homolog) (ES/130-
related protein). 
RENBP ENSG000001
02032 
2.983 N-acylglucosamine 2-epimerase (EC 5.1.3.8) (GlcNAc 2-epimerase) (N- acetyl-D-glucosamine 2-
epimerase) (AGE) (Renin-binding protein) (RnBP). 
EDA2R ENSG000001
31080 
2.967 Tumor necrosis factor receptor superfamily member 27 (X-linked ectodysplasin-A2 receptor) (EDA-A2 
receptor). 
MRGPRF ENSG000001
72935 
2.908 Mas-related G-protein coupled receptor member F (Mas-related gene F protein) (G-protein coupled 
receptor 140) 
NR4A1 ENSG000001
23358 
2.886 Orphan nuclear receptor NR4A1 (Orphan nuclear receptor HMR) (Early response protein NAK1) (TR3 
orphan receptor) 
CHRNA1 ENSG000001
38435 
2.873 Acetylcholine receptor subunit alpha precursor. 
EVI2A ENSG000001
26860 
2.869 EVI2A protein precursor (Ecotropic viral integration site 2A protein homolog) (EVI-2A). 
AIG1 ENSG000001
46416 
2.843 Androgen-induced protein 1 (AIG-1). 
AK1 ENSG000001
06992 
2.817 Adenylate kinase isoenzyme 1 (EC 2.7.4.3) (ATP-AMP transphosphorylase) (AK1) (Myokinase). 
PTPLAD2 ENSG000001
88921 
2.807 protein tyrosine phosphatase-like A domain containing 2 
ACTB ENSG000000
75624 
2.805 Actin, cytoplasmic 1 (Beta-actin). 
MGP ENSG000001
11341 
2.794 Matrix Gla-protein precursor (MGP) (Cell growth-inhibiting gene 36 protein). 
FAM43A ENSG000001
85112 
2.794 Protein FAM43A. 
CRYAB ENSG000001
09846 
2.776 Alpha crystallin B chain (Alpha(B)-crystallin) (Rosenthal fiber component) (Heat-shock protein beta-5) 
(HspB5) 
HES1 ENSG000001
14315 
2.77 Transcription factor HES-1 (Hairy and enhancer of split 1) (Hairy- like) (HHL) (Hairy homolog). 
PCDHB16 ENSG000001
96963 
2.749 Protocadherin beta 16 precursor (PCDH-beta16) (Protocadherin 3X). 
NIPSNAP1 ENSG000001
84117 
2.74 Protein NipSnap1. 
EMB ENSG000001 2.712 Embigin precursor. 
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70571 
ALDH3A1 ENSG000001
08602 
2.684 Aldehyde dehydrogenase, dimeric NADP-preferring (EC 1.2.1.5) (ALDH class 3) (ALDHIII). 
ANGPT1 ENSG000001
54188 
2.659 Angiopoietin-1 precursor (ANG-1). 
SEMA3B ENSG000000
12171 
2.629 Semaphorin-3B precursor (Semaphorin V) (Sema V) (Sema A(V)). 
CAPN6 ENSG000000
77274 
2.611 Calpain-6 (Calpamodulin) (CalpM) (Calpain-like protease X-linked). 
ITGBL1 ENSG000001
98542 
2.592 integrin, beta-like 1 (with EGF-like repeat domains) 
TMEM14A ENSG000000
96092 
2.578 Transmembrane protein 14A. 
DUSP1 ENSG000001
20129 
2.571 Dual specificity protein phosphatase 1 (EC 3.1.3.48) (EC 3.1.3.16) (MAP kinase phosphatase 1) (MKP-1) 
MCTP2 ENSG000001
40563 
2.566 multiple C2 domains, transmembrane 2 
EGR1 ENSG000001
20738 
2.477 Early growth response protein 1 (EGR-1) (Krox-24 protein) (Transcription factor Zif268) (Nerve 
growth factor-induced protein A) (NGFI-A) 
CHST2 ENSG000001
75040 
2.477 Carbohydrate sulfotransferase 2 (EC 2.8.2.-) (N-acetylglucosamine 6-O- sulfotransferase 1) (GlcNAc6ST-
1) (Gn6ST) 
F2RL1 ENSG000001
64251 
2.473 Proteinase-activated receptor 2 precursor (PAR-2) (Thrombin receptor- like 1) (Coagulation factor II 
receptor-like 1) 
VDR ENSG000001
11424 
2.448 Vitamin D3 receptor (VDR) (1,25-dihydroxyvitamin D3 receptor). 
PDGFC ENSG000001
45431 
2.439 platelet-derived growth factor C precursor 
PCDHB18 ENSG000001
46001 
2.414 protocadherin beta 18 pseudogene (PCDHB18) on chromosome 5 
C6orf64 ENSG000001
12167 
2.394 Uncharacterized protein C6orf64. 
ELOVL6 ENSG000001
70522 
2.391 Elongation of very long chain fatty acids protein 6 (hELO2). 
NQO1 ENSG000001
81019 
2.385 NAD(P)H dehydrogenase [quinone] 1 (EC 1.6.5.2) (Quinone reductase 1) (NAD(P)H:quinone 
oxidoreductase 1) 
SEC16B ENSG000001
20341 
2.384 leucine zipper transcription regulator 2 
UBXD6 ENSG000001
04691 
2.351 UBX domain-containing protein 6 (Reproduction 8 protein) (Protein Rep- 8). 
PDGFRB ENSG000001
13721 
2.335 Beta platelet-derived growth factor receptor precursor (EC 2.7.10.1) (PDGF-R-beta) (CD140b antigen). 
TMEPAI ENSG000001
24225 
2.327 Transmembrane prostate androgen-induced protein (Solid tumor- associated 1 protein). 
TPBG ENSG000001
46242 
2.321 Trophoblast glycoprotein precursor (5T4 oncofetal trophoblast glycoprotein) (5T4 oncotrophoblast 
glycoprotein) (5T4 oncofetal antigen) (M6P1). 
C3orf33 ENSG000001
74928 
2.308 Uncharacterized protein C3orf33. 
CD300LB ENSG000001
78789 
2.308 CD300 molecule-like family member b 
PLP1 ENSG000001
23560 
2.299 Myelin proteolipid protein (PLP) (Lipophilin). 
COL12A1 ENSG000001
11799 
2.295 Collagen alpha-1(XII) chain precursor. 
RDH10 ENSG000001
21039 
2.293 retinol dehydrogenase 10 
PTPN22 ENSG000001
34242 
2.292 Tyrosine-protein phosphatase non-receptor type 22 (EC 3.1.3.48) (Hematopoietic cell protein-tyrosine 
phosphatase 70Z-PEP) 
SULF2 ENSG000001
96562 
2.284 Extracellular sulfatase Sulf-2 precursor (EC 3.1.6.-) (HSulf-2). 
TLR3 ENSG000001
64342 
2.277 Toll-like receptor 3 precursor (CD283 antigen). 
STOX2 ENSG000001
73320 
2.275 storkhead box 2 
ALOX5AP ENSG000001
32965 
2.255 Arachidonate 5-lipoxygenase-activating protein (FLAP) (MK-886-binding protein). 
TAPBPL ENSG000001
39192 
2.245 Tapasin-related protein precursor (TAPASIN-R) (Tapasin-like) (TAP- binding protein-related protein) 
(TAPBP-R) (TAP-binding protein-like). 
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ZMAT3 ENSG000001
72667 
2.242 p53 target zinc finger protein isoform 1 
SLAMF8 ENSG000001
58714 
2.241 SLAM family member 8 precursor (B-lymphocyte activator macrophage expressed) (BCM-like membrane 
protein). 
PSMB10 ENSG000002
05220 
2.237 Proteasome subunit beta type 10 precursor (EC 3.4.25.1) (Proteasome MECl-1) (Macropain subunit 
MECl-1) 
PSMB9 ENSG000002
04261 
2.225 Proteasome subunit beta type 9 precursor (EC 3.4.25.1) (Proteasome chain 7) (Macropain chain 7) 
ACYP2 ENSG000001
70634 
2.195 Acylphosphatase-2 (EC 3.6.1.7) (Acylphosphate phosphohydrolase 2) (Acylphosphatase, muscle 
type isozyme). 
XDH ENSG000001
58125 
2.186 Xanthine dehydrogenase/oxidase [Includes: Xanthine dehydrogenase (EC 1.17.1.4) (XD); Xanthine 
oxidase (EC 1.17.3.2) (XO) 
SOD3 ENSG000001
09610 
2.183 Extracellular superoxide dismutase [Cu-Zn] precursor (EC 1.15.1.1) (EC-SOD). 
NRP1 ENSG000000
99250 
2.174 Neuropilin-1 precursor (Vascular endothelial cell growth factor 165 receptor) (CD304 antigen). 
COL6A2 ENSG000001
42173 
2.171 Collagen alpha-2(VI) chain precursor. 
GLT8D4 ENSG000001
72986 
2.17 Glycosyltransferase 8 domain-containing protein 4 (EC 2.4.1.-). 
ADH7 ENSG000001
96344 
2.163 Alcohol dehydrogenase class 4 mu/sigma chain (EC 1.1.1.1) (Alcohol dehydrogenase class IV mu/sigma 
chain) (Retinol dehydrogenase) (Gastric alcohol dehydrogenase). 
TCN2 ENSG000001
85339 
2.158 Transcobalamin-2 precursor (Transcobalamin II) (TCII) (TC II). 
PARP9 ENSG000001
38496 
2.154 Poly [ADP-ribose] polymerase 9 (EC 2.4.2.30) (PARP-9) (B aggressive lymphoma protein). 
ATF5 ENSG000001
69136 
2.154 Cyclic AMP-dependent transcription factor ATF-5 (Activating transcription factor 5) (Transcription factor 
ATFx). 
STC2 ENSG000001
13739 
2.15 Stanniocalcin-2 precursor (STC-2) (Stanniocalcin-related protein) (STCRP) (STC-related protein). 
ADCY7 ENSG000001
21281 
2.133 Adenylate cyclase type 7 (EC 4.6.1.1) (Adenylate cyclase type VII) (ATP pyrophosphate-lyase 7) (Adenylyl 
cyclase 7). 
SERPINB8 ENSG000001
66401 
2.131 Serpin B8 (Cytoplasmic antiproteinase 2) (CAP-2) (CAP2) (Proteinase inhibitor 8). 
NAPRT1 ENSG000001
47813 
2.129 nicotinate phosphoribosyltransferase domain containing 1 
SCRN3 ENSG000001
44306 
2.115 Secernin-3. 
COL27A1 ENSG000001
96739 
2.109 collagen, type XXVII, alpha 1 
EGFR ENSG000001
46648 
2.1 Epidermal growth factor receptor precursor (EC 2.7.10.1) (Receptor tyrosine-protein kinase ErbB-1). 
SPRY4 ENSG000001
87678 
2.093 Sprouty homolog 4 (Spry-4). 
P2RX7 ENSG000000
89041 
2.084 P2X purinoceptor 7 (ATP receptor) (P2X7) (Purinergic receptor) (P2Z receptor). 
COLEC12 ENSG000001
58270 
2.084 collectin sub-family member 12 
GPC1 ENSG000000
63660 
2.075 Glypican-1 precursor. 
FLCN ENSG000001
54803 
2.074 Folliculin (Birt-Hogg-Dube syndrome protein) (BHD skin lesion fibrofolliculoma protein). 
ALG8 ENSG000001
59063 
2.072 Probable dolichyl pyrophosphate Glc1Man9GlcNAc2 alpha-1,3- glucosyltransferase (EC 2.4.1.-) 
RSAD2 ENSG000001
34321 
2.07 radical S-adenosyl methionine domain containing 2 
DCTD ENSG000001
29187 
2.059 Deoxycytidylate deaminase (EC 3.5.4.12) (dCMP deaminase). 
SORBS3 ENSG000001
20896 
2.054 Vinexin (Sorbin and SH3 domain-containing protein 3) (SH3-containing adapter molecule 1) (SCAM-1). 
TACC2 ENSG000001
38162 
2.052 Transforming acidic coiled-coil-containing protein 2 (Anti Zuai-1) (AZU-1). 
EMP3 ENSG000001
42227 
2.05 Epithelial membrane protein 3 (EMP-3) (YMP protein) (Hematopoietic neural membrane protein) (HNMP-
1). 
HOXB2 ENSG000001
73917 
2.049 Homeobox protein Hox-B2 (Hox-2H) (Hox-2.8) (K8). 
CYP51A1 ENSG000000 2.042 Cytochrome P450 51A1 (EC 1.14.13.70) (CYPLI) (P450LI) (Sterol 14-alpha demethylase) (Lanosterol 14-
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01630 alpha demethylase) 
CRABP2 ENSG000001
43320 
2.023 Cellular retinoic acid-binding protein 2 (Cellular retinoic acid- binding protein II) (CRABP-II) (Retinoic acid-
binding protein II, cellular). 
NP_001009
555.2 
ENSG000001
09686 
2.021 SH3 domain protein D19 
RAB3IL1 ENSG000001
67994 
2.021 RAB3A interacting protein (rabin3)-like 1 
PTPRE ENSG000001
32334 
2.016 Receptor-type tyrosine-protein phosphatase epsilon precursor (EC 3.1.3.48) (Protein-tyrosine 
phosphatase epsilon) (R-PTP-epsilon). ] 
SLC30A1 ENSG000001
70385 
2.016 Zinc transporter 1 (ZnT-1) (Solute carrier family 30 member 1). 
GHR ENSG000001
12964 
2.015 Growth hormone receptor precursor (GH receptor) (Somatotropin receptor) [Contains: Growth hormone-
binding protein (GH-binding protein) 
PDLIM5 ENSG000001
63110 
2.011 PDZ and LIM domain protein 5 (Enigma homolog) (Enigma-like PDZ and LIM domains protein). 
NP_079178.
2 
ENSG000001
78401 
2.006  
BBS4 ENSG000001
40463 
-2 Bardet-Biedl syndrome 4 protein. 
TMTC2 ENSG000001
79104 
-2.003 Transmembrane and TPR repeat-containing protein 2. 
STARD8 ENSG000001
30052 
-2.004 StAR-related lipid transfer protein 8 (StARD8) (START domain- containing protein 8). 
CORO2A ENSG000001
06789 
-2.007 Coronin-2A (WD repeat-containing protein 2) (IR10). 
SLC25A23 ENSG000001
25648 
-2.011 solute carrier family 25, member 23 
MATN2 ENSG000001
32561 
-2.011 Matrilin-2 precursor. 
HAO1 ENSG000001
01323 
-2.012 Hydroxyacid oxidase 1 (EC 1.1.3.15) (HAOX1) (Glycolate oxidase) (GOX). 
HTATSF1 ENSG000001
02241 
-2.017 HIV Tat-specific factor 1 (Tat-SF1). 
GPR155 ENSG000001
63328 
-2.018 Integral membrane protein GPR155 (G-protein coupled receptor PGR22). 
ALDH18A1 ENSG000000
59573 
-2.025 Delta 1-pyrroline-5-carboxylate synthetase (P5CS) (Aldehyde dehydrogenase 18 family member A1) 
MAOA ENSG000001
89221 
-2.03 Amine oxidase [flavin-containing] A (EC 1.4.3.4) (Monoamine oxidase type A) (MAO-A). 
NDRG2 ENSG000001
65795 
-2.035 Protein NDRG2 (Protein Syld709613). 
HS3ST5 ENSG000001
75818 
-2.039 Heparan sulfate glucosamine 3-O-sulfotransferase 5 (EC 2.8.2.23) (Heparan sulfate D-glucosaminyl 
3-O-sulfotransferase 5) 
ASAHL ENSG000001
38744 
-2.047 N-acylethanolamine-hydrolyzing acid amidase precursor (EC 3.5.1.-) (N- acylsphingosine amidohydrolase-
like) (ASAH-like protein) 
GAS2L3 ENSG000001
39354 
-2.047 GAS2-like protein 3 (Growth arrest-specific 2-like 3). 
LRRC20 ENSG000001
72731 
-2.048 Leucine-rich repeat-containing protein 20. 
PHEX ENSG000001
02174 
-2.05 Phosphate-regulating neutral endopeptidase (EC 3.4.24.-) (Metalloendopeptidase homolog PEX) (X-linked 
hypophosphatemia protein) 
FBXO32 ENSG000001
56804 
-2.05 F-box only protein 32 (Muscle atrophy F-box protein) (MAFbx) (Atrogin- 1). 
CXCL12 ENSG000001
07562 
-2.051 Stromal cell-derived factor 1 precursor (SDF-1) (CXCL12) (Pre-B cell growth-stimulating factor) (PBSF) 
(hIRH) 
MEX3D ENSG000001
81588 
-2.052 RNA-binding protein MEX3D (RING finger and KH domain-containing protein 1) (RING finger protein 193). 
8] 
LDLRAD3 ENSG000001
79241 
-2.059 low density lipoprotein receptor class A domain containing 3 
CA6 ENSG000001
31686 
-2.061 Carbonic anhydrase 6 precursor (EC 4.2.1.1) (Carbonic anhydrase VI) (Carbonate dehydratase VI) (CA-
VI) (Secreted carbonic anhydrase) . 
TMEM121 ENSG000001
84986 
-2.064 Transmembrane protein 121. 
NEFL ENSG000001
04725 
-2.065 Neurofilament light polypeptide (NF-L) (Neurofilament triplet L protein) (68 kDa neurofilament protein). 
C7orf46 ENSG000001
88732 
-2.067 Uncharacterized protein C7orf46. 
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PDLIM7 ENSG000001
96923 
-2.07 PDZ and LIM domain protein 7 (LIM mineralization protein) (LMP) (Protein enigma). 
NNMT ENSG000001
66741 
-2.078 Nicotinamide N-methyltransferase (EC 2.1.1.1). 
MMP12 ENSG000001
10347 
-2.081 Macrophage metalloelastase precursor (EC 3.4.24.65) (HME) (Matrix metalloproteinase-12) (MMP-12) 
(Macrophage elastase) (ME). 
EXOC6 ENSG000001
38190 
-2.09 Exocyst complex component 6 (Exocyst complex component Sec15A) (Sec15- like 1). 
ITPKB ENSG000001
43772 
-2.1 Inositol-trisphosphate 3-kinase B (EC 2.7.1.127) (Inositol 1,4,5- trisphosphate 3-kinase B) 
C6orf145 ENSG000001
68994 
-2.1 Uncharacterized protein C6orf145. 
NP_056994.
3 
ENSG000001
43951 
-2.104  
PTPRM ENSG000001
73482 
-2.104 Receptor-type tyrosine-protein phosphatase mu precursor (EC 3.1.3.48) (Protein-tyrosine phosphatase 
mu) (R-PTP-mu). 
FAM125B ENSG000001
96814 
-2.109 Protein FAM125B. [Source:Uniprot/SWISSPROT;Acc:Q9H7P6] 
C20orf74 ENSG000001
88559 
-2.118 250 kDa substrate of Akt (AS250). [Source:Uniprot/SWISSPROT;Acc:Q2PPJ7] 
KLHL8 ENSG000001
45332 
-2.123 Kelch-like protein 8. [Source:Uniprot/SWISSPROT;Acc:Q9P2G9] 
C8orf32 ENSG000001
56795 
-2.123 Uncharacterized protein C8orf32. [Source:Uniprot/SWISSPROT;Acc:Q96HA8] 
SNORA32 ENSG000001
66012 
-2.123 Protein JOSD3. [Source:Uniprot/SWISSPROT;Acc:Q9H5J8] 
MPPED2 ENSG000000
66382 
-2.125 Metallophosphoesterase domain-containing protein 2 (Fetal brain protein 239) (239FB). 
[Source:Uniprot/SWISSPROT;Acc:Q15777] 
LYPLA3 ENSG000001
03066 
-2.132 1-O-acylceramide synthase precursor (EC 2.3.1.-) (ACS) (Lysosomal phospholipase A2) 
(Lysophospholipase 3) (LPLA2) 
FAM62A ENSG000001
39641 
-2.138 Protein FAM62A (Membrane-bound C2 domain-containing protein). 
PRTN3 ENSG000001
96415 
-2.143 Myeloblastin precursor (EC 3.4.21.76) (Leukocyte proteinase 3) (PR-3) (PR3) (AGP7) (Wegener 
autoantigen) (P29) (C-ANCA antigen)  
NP_116012.
2 
ENSG000001
37463 
-2.15 ovary-specific acidic protein [Source:RefSeq_peptide;Acc:NP_116012] 
PTPRK ENSG000001
52894 
-2.152 Receptor-type tyrosine-protein phosphatase kappa precursor (EC 3.1.3.48) (Protein-tyrosine phosphatase 
kappa) (R-PTP-kappa). 
CCNG2 ENSG000001
38764 
-2.159 Cyclin-G2. [Source:Uniprot/SWISSPROT;Acc:Q16589] 
S100A3 ENSG000001
88015 
-2.163 Protein S100-A3 (S100 calcium-binding protein A3) (Protein S-100E). 
[Source:Uniprot/SWISSPROT;Acc:P33764] 
C3orf28 ENSG000001
14023 
-2.167 E2-induced gene 5 protein. [Source:Uniprot/SWISSPROT;Acc:Q96A26] 
HBEGF ENSG000001
13070 
-2.192 Heparin-binding EGF-like growth factor precursor (HB-EGF) (HBEGF) (Diphtheria toxin receptor) 
SLC44A2 ENSG000001
29353 
-2.206 Choline transporter-like protein 2 (Solute carrier family 44 member 2). 
[Source:Uniprot/SWISSPROT;Acc:Q8IWA5] 
GFRA2 ENSG000001
68546 
-2.215 GDNF family receptor alpha-2 precursor (GFR-alpha-2) (Neurturin receptor alpha) (NTNR-alpha) 
(NRTNR-alpha) 
HK1 ENSG000001
56515 
-2.216 Hexokinase-1 (EC 2.7.1.1) (Hexokinase type I) (HK I) (Brain form hexokinase). 
[Source:Uniprot/SWISSPROT;Acc:P19367] 
CXorf15 ENSG000000
86712 
-2.219 Gamma-taxilin (Lipopolysaccharide-specific response protein 5). 
[Source:Uniprot/SWISSPROT;Acc:Q9NUQ3] 
MARK1 ENSG000001
16141 
-2.221 Serine/threonine-protein kinase MARK1 (EC 2.7.11.1) (MAP/microtubule affinity-regulating kinase 1). 
ID1 ENSG000001
25968 
-2.228 DNA-binding protein inhibitor ID-1 (Inhibitor of DNA binding 1). 
B3GALNT1 ENSG000001
69255 
-2.231 UDP-GalNAc:beta-1,3-N-acetylgalactosaminyltransferase 1 (EC 2.4.1.79) (Beta-3-GalNAc-T1) (Beta-1,3-
galactosyltransferase 3) 
CLYBL ENSG000001
25246 
-2.235 Citrate lyase beta subunit-like protein, mitochondrial precursor (EC 4.1.-.-) (Citrate lyase beta-like). 
PRR6 ENSG000001
66582 
-2.249 Proline-rich protein 6 (Nuclear protein p30). [Source:Uniprot/SWISSPROT;Acc:Q7Z7K6] 
PVRL2 ENSG000001
30202 
-2.261 Poliovirus receptor-related protein 2 precursor (Herpes virus entry mediator B) (HveB) (Nectin-2) (CD112 
antigen). 
STAMBPL1 ENSG000001 -2.262 AMSH-like protease (EC 3.1.2.15) (AMSH-LP) (STAM-binding protein-like 1). 
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38134 [Source:Uniprot/SWISSPROT;Acc:Q96FJ0] 
OSTF1 ENSG000001
34996 
-2.267 Osteoclast-stimulating factor 1. [Source:Uniprot/SWISSPROT;Acc:Q92882] 
CLCN3 ENSG000001
09572 
-2.288 Chloride channel protein 3 (ClC-3). [Source:Uniprot/SWISSPROT;Acc:P51790] 
C6orf141 ENSG000001
97261 
-2.303 Uncharacterized protein C6orf141. [Source:Uniprot/SWISSPROT;Acc:Q5SZD1] 
MXI1 ENSG000001
19950 
-2.308 MAX-interacting protein 1 (Protein MXI1). [Source:Uniprot/SWISSPROT;Acc:P50539] 
GADD45G ENSG000001
30222 
-2.308 Growth arrest and DNA-damage-inducible protein GADD45 gamma (Cytokine- responsive protein CR6). 
ARHGAP29 ENSG000001
37962 
-2.323 PTPL1-associated RhoGAP 1 [Source:RefSeq_peptide;Acc:NP_004806] 
VLDLR ENSG000001
47852 
-2.327 Very low-density lipoprotein receptor precursor (VLDL receptor) (VLDL- R). 
[Source:Uniprot/SWISSPROT;Acc:P98155] 
SPDYA ENSG000001
63806 
-2.327 Speedy protein A (Speedy-1) (Spy1) (Rapid inducer of G2/M progression in oocytes A) (RINGO A) 
(hSpy/Ringo A). 
CIRBP ENSG000000
99622 
-2.336 Cold-inducible RNA-binding protein (Glycine-rich RNA-binding protein CIRP) (A18 hnRNP). 
[Source:Uniprot/SWISSPROT;Acc:Q14011] 
BCKDHB ENSG000000
83123 
-2.339 2-oxoisovalerate dehydrogenase subunit beta, mitochondrial precursor (EC 1.2.4.4) 
ENAH ENSG000001
54380 
-2.339 Protein enabled homolog. [Source:Uniprot/SWISSPROT;Acc:Q8N8S7] 
NDRG1 ENSG000001
04419 
-2.349 Protein NDRG1 (N-myc downstream-regulated gene 1 protein) (Differentiation-related gene 1 protein) 
(DRG-1) 
DENND2A ENSG000001
46966 
-2.356 DENN domain-containing protein 2A. [Source:Uniprot/SWISSPROT;Acc:Q9ULE3] 
SLC2A1 ENSG000001
17394 
-2.36 Solute carrier family 2, facilitated glucose transporter member 1 (Glucose transporter type 1, 
erythrocyte/brain) (GLUT-1) 
NRN1 ENSG000001
24785 
-2.368 Neuritin precursor. [Source:Uniprot/SWISSPROT;Acc:Q9NPD7] 
EPHB2 ENSG000001
33216 
-2.369 Ephrin type-B receptor 2 precursor (EC 2.7.10.1) (Tyrosine-protein kinase receptor EPH-3) (DRT) 
(Receptor protein-tyrosine kinase HEK5) (ERK) (Tyrosine-protein kinase TYRO5) 
NMNAT3 ENSG000001
63864 
-2.369 Nicotinamide mononucleotide adenylyltransferase 3 (EC 2.7.7.1) (NMN adenylyltransferase 3) 
SH3BP4 ENSG000001
30147 
-2.396 SH3 domain-binding protein 4 (Transferrin receptor-trafficking protein) (EH-binding protein 10). 
[Source:Uniprot/SWISSPROT;Acc:Q9P0V3] 
INSIG2 ENSG000001
25629 
-2.4 Insulin-induced gene 2 protein (INSIG-2). [Source:Uniprot/SWISSPROT;Acc:Q9Y5U4] 
GLUL ENSG000001
35821 
-2.406 Glutamine synthetase (EC 6.3.1.2) (Glutamate--ammonia ligase) (GS). 
[Source:Uniprot/SWISSPROT;Acc:P15104] 
ETS2 ENSG000001
57557 
-2.407 Protein C-ets-2. [Source:Uniprot/SWISSPROT;Acc:P15036] 
ENO2 ENSG000001
11674 
-2.424 Gamma-enolase (EC 4.2.1.11) (2-phospho-D-glycerate hydro-lyase) (Neural enolase) (Neuron-specific 
enolase) (NSE) 
NAALAD2 ENSG000000
77616 
-2.427 N-acetylated-alpha-linked acidic dipeptidase 2 (EC 3.4.17.21) (N- acetylated-alpha-linked acidic 
dipeptidase II) (NAALADase II). 
TFRC ENSG000000
72274 
-2.437 Transferrin receptor protein 1 (TfR1) (TR) (TfR) (Trfr) (CD71 antigen) (T9) (p90) [Contains: Transferrin 
receptor protein 1, serum form (sTfR)]. 
CTH ENSG000001
16761 
-2.458 Cystathionine gamma-lyase (EC 4.4.1.1) (Gamma-cystathionase). 
[Source:Uniprot/SWISSPROT;Acc:P32929] 
REEP1 ENSG000000
68615 
-2.462 Receptor expression-enhancing protein 1. [Source:Uniprot/SWISSPROT;Acc:Q9H902] 
TRIB3 ENSG000001
01255 
-2.474 Tribbles homolog 3 (TRB-3) (Neuronal cell death-inducible putative kinase) (p65-interacting inhibitor of 
NF-kappaB) (SINK). 
CSN3 ENSG000001
71209 
-2.475 Kappa-casein precursor. [Source:Uniprot/SWISSPROT;Acc:P07498] 
C9orf72 ENSG000001
47894 
-2.479 Uncharacterized protein C9orf72. [Source:Uniprot/SWISSPROT;Acc:Q96LT7] 
NP_001070884.
1 
ENSG000002
05084 
-2.501 CDNA: FLJ22167 fis, clone HRC00584 (Hypothetical protein FLJ22167). 
[Source:Uniprot/SPTREMBL;Acc:Q9H6L2] 
ZFPM2 ENSG000001
69946 
-2.521 Zinc finger protein ZFPM2 (Zinc finger protein multitype 2) (Friend of GATA protein 2) (FOG-2) (hFOG-2). 
ARRDC4 ENSG000001
40450 
-2.523 Arrestin domain-containing protein 4. [Source:Uniprot/SWISSPROT;Acc:Q8NCT1] 
C20orf112 ENSG000001
97183 
-2.53 Uncharacterized protein C20orf112. [Source:Uniprot/SWISSPROT;Acc:Q96MY1] 
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C9orf30 ENSG000000
66697 
-2.54 UPF0439 protein C9orf30 (Protein L8). [Source:Uniprot/SWISSPROT;Acc:Q96H12] 
GALNT12 ENSG000001
19514 
-2.541 Polypeptide N-acetylgalactosaminyltransferase 12 (EC 2.4.1.41) (Protein-UDP 
acetylgalactosaminyltransferase 12) 
GADD45A ENSG000001
16717 
-2.549 Growth arrest and DNA-damage-inducible protein GADD45 alpha (DNA- damage-inducible transcript 1) 
(DDIT1). 
RAB7L1 ENSG000001
17280 
-2.566 Ras-related protein Rab-7L1 (Rab-7-like protein 1). [Source:Uniprot/SWISSPROT;Acc:O14966] 
NP_001071087.
1 
ENSG000002
15114 
-2.574  
LAMA4 ENSG000001
12769 
-2.576 Laminin subunit alpha-4 precursor. [Source:Uniprot/SWISSPROT;Acc:Q16363] 
TCEAL1 ENSG000001
72465 
-2.576 Transcription elongation factor A protein-like 1 (TCEA-like protein 1) (Transcription elongation factor S-II 
protein-like 1) 
SLC25A30 ENSG000001
74032 
-2.586 Kidney mitochondrial carrier protein 1 (Solute carrier family 25 member 30). 
[Source:Uniprot/SWISSPROT;Acc:Q5SVS4] 
CTGF ENSG000001
18523 
-2.599 Connective tissue growth factor precursor (Hypertrophic chondrocyte- specific protein 24). 
[Source:Uniprot/SWISSPROT;Acc:P29279] 
ERO1L ENSG000001
97930 
-2.622 ERO1-like protein alpha precursor (EC 1.8.4.-) (ERO1-Lalpha) (Oxidoreductin-1-Lalpha) (Endoplasmic 
oxidoreductin-1-like protein) (ERO1-L). 
ABTB2 ENSG000001
66016 
-2.624 Ankyrin repeat and BTB/POZ domain-containing protein 2. [Source:Uniprot/SWISSPROT;Acc:Q8N961] 
C9orf89 ENSG000001
65233 
-2.64 BINCA_HUMAN Isoform 2 of Q96LW7 - Homo sapiens (Human) [Source:Uniprot/Varsplic;Acc:Q96LW7-2] 
DNAJC12 ENSG000001
08176 
-2.671 DnaJ homolog subfamily C member 12 (J domain-containing protein 1). 
[Source:Uniprot/SWISSPROT;Acc:Q9UKB3] 
GNAZ ENSG000001
28266 
-2.687 Guanine nucleotide-binding protein G(z) subunit alpha (G(x) alpha chain) (Gz-alpha). 
[Source:Uniprot/SWISSPROT;Acc:P19086] 
THBS2 ENSG000001
86340 
-2.689 Thrombospondin-2 precursor. [Source:Uniprot/SWISSPROT;Acc:P35442] 
CITED1 ENSG000001
25931 
-2.726 Cbp/p300-interacting transactivator 1 (Melanocyte-specific protein 1). 
[Source:Uniprot/SWISSPROT;Acc:Q99966] 
PKIA ENSG000001
71033 
-2.729 cAMP-dependent protein kinase inhibitor alpha (PKI-alpha) (cAMP- dependent protein kinase inhibitor, 
muscle/brain isoform). 
TSC22D3 ENSG000001
57514 
-2.744 TSC22 domain family protein 3 (Glucocorticoid-induced leucine zipper protein) (Delta sleep-inducing 
peptide immunoreactor) 
CLU ENSG000001
20885 
-2.769 Clusterin precursor (Complement-associated protein SP-40,40) (Complement cytolysis inhibitor) (CLI) 
(NA1/NA2) (Apolipoprotein J) (Apo-J) 
SNCA ENSG000001
45335 
-2.792 Alpha-synuclein (Non-A beta component of AD amyloid) (Non-A4 component of amyloid precursor) 
(NACP). 
ADD3 ENSG000001
48700 
-2.8 Gamma-adducin (Adducin-like protein 70). [Source:Uniprot/SWISSPROT;Acc:Q9UEY8] 
PRELID2 ENSG000001
86314 
-2.802 PRELI domain containing 2 isoform c [Source:RefSeq_peptide;Acc:NP_612501] 
MBOAT2 ENSG000001
43797 
-2.825 Membrane-bound O-acyltransferase domain-containing protein 2 (EC 2.3.-.-) (O-acyltransferase domain-
containing protein 2). 
PDK1 ENSG000001
52256 
-2.825 [Pyruvate dehydrogenase [lipoamide]] kinase isozyme 1, mitochondrial precursor (EC 2.7.11.2) (Pyruvate 
dehydrogenase kinase isoform 1). 
MUM1L1 ENSG000001
57502 
-2.828 MUM1-like protein 1 (Mutated melanoma-associated antigen 1-like protein 1). 
[Source:Uniprot/SWISSPROT;Acc:Q5H9M0] 
HIST1H1C ENSG000001
87837 
-2.843 Histone H1.2 (Histone H1d). [Source:Uniprot/SWISSPROT;Acc:P16403] 
SASH1 ENSG000001
11961 
-2.911 SAM and SH3 domain-containing protein 1 (Proline-glutamate repeat- containing protein). 
[Source:Uniprot/SWISSPROT;Acc:O94885] 
IL33 ENSG000001
37033 
-2.916 Interleukin-33 precursor (IL-33) (Interleukin-1 family member 11) (IL- 1F11) (Nuclear factor from high 
endothelial venules) (NF-HEV). 
MDM1 ENSG000001
11554 
-2.963 Mdm4, transformed 3T3 cell double minute 1, p53 binding protein isoform 1 
C4orf31 ENSG000001
73376 
-2.968 Uncharacterized protein C4orf31. [Source:Uniprot/SPTREMBL;Acc:Q8TB73] 
CDKN1C ENSG000001
29757 
-2.977 Cyclin-dependent kinase inhibitor 1C (Cyclin-dependent kinase inhibitor p57) (p57KIP2). 
[Source:Uniprot/SWISSPROT;Acc:P49918] 
P4HA2 ENSG000000
72682 
-2.984 Prolyl 4-hydroxylase subunit alpha-2 precursor (EC 1.14.11.2) (4-PH alpha-2) (Procollagen-proline,2-
oxoglutarate-4-dioxygenase alpha-2 subunit). 
ITGA6 ENSG000000
91409 
-3.008 Integrin alpha-6 precursor (VLA-6) (CD49f antigen) [Contains: Integrin alpha-6 heavy chain; Integrin alpha-
6 light chain]. 
SH3YL1 ENSG000000 -3.01 SH3 domain containing, Ysc84-like 1 [Source:RefSeq_peptide;Acc:NP_056492] 
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SYT17 ENSG000001
03528 
-3.095 B/K protein [Source:RefSeq_peptide;Acc:NP_057608] 
KLF6 ENSG000000
67082 
-3.099 Krueppel-like factor 6 (Core promoter element-binding protein) (B- cell-derived protein 1) (Proto-oncogene 
BCD1) (Transcription factor Zf9) 
EVI1 ENSG000000
85276 
-3.265 Ecotropic virus integration site 1 protein homolog (EVI-1). [Source:Uniprot/SWISSPROT;Acc:Q03112] 
EDG3 ENSG000002
13694 
-3.28 Sphingosine 1-phosphate receptor Edg-3 (S1P receptor Edg-3) (Endothelial differentiation G-protein 
coupled receptor 3) 
TMCC3 ENSG000000
57704 
-3.305 Transmembrane and coiled-coil domains protein 3. [Source:Uniprot/SWISSPROT;Acc:Q9ULS5] 
DOCK10 ENSG000001
35905 
-3.311 Dedicator of cytokinesis protein 10 (Zizimin-3). [Source:Uniprot/SWISSPROT;Acc:Q96BY6] 
BBS2 ENSG000001
25124 
-3.339 Bardet-Biedl syndrome 2 protein. [Source:Uniprot/SWISSPROT;Acc:Q9BXC9] 
ENPP2 ENSG000001
36960 
-3.43 Ectonucleotide pyrophosphatase/phosphodiesterase family member 2 precursor (EC 3.1.4.39) (E-NPP 2) 
ATF3 ENSG000001
62772 
-3.488 Cyclic AMP-dependent transcription factor ATF-3 (Activating transcription factor 3). 
[Source:Uniprot/SWISSPROT;Acc:P18847] 
RUNDC3B ENSG000001
05784 
-3.539 RUN domain containing 3B [Source:RefSeq_peptide;Acc:NP_612147] 
RNF128 ENSG000001
33135 
-3.588 E3 ubiquitin-protein ligase RNF128 precursor (EC 6.3.2.-) (RING finger protein 128) (Gene related to 
anergy in lymphocytes protein). 
TEX11 ENSG000001
20498 
-3.655 testis expressed sequence 11 isoform 2 [Source:RefSeq_peptide;Acc:NP_112566] 
DEPDC7 ENSG000001
21690 
-3.777 novel 58.3 KDA protein isoform 1 [Source:RefSeq_peptide;Acc:NP_001070710] 
DFFB ENSG000001
69598 
-3.889 DNA fragmentation factor subunit beta (EC 3.-.-.-) (DNA fragmentation factor 40 kDa subunit) (DFF-40) 
(Caspase-activated deoxyribonuclease) 
ADAM8 ENSG000001
51651 
-4.022 ADAM 8 precursor (EC 3.4.24.-) (A disintegrin and metalloproteinase domain 8) (Cell surface antigen 
MS2) (CD156a antigen) (CD156). 
TMEM176B ENSG000001
06565 
-4.161 Transmembrane protein 176B (Protein LR8). [Source:Uniprot/SWISSPROT;Acc:Q3YBM2] 
MLF1 ENSG000001
78053 
-4.27 Myeloid leukemia factor 1 (Myelodysplasia-myeloid leukemia factor 1). 
[Source:Uniprot/SWISSPROT;Acc:P58340] 
TMEM176A ENSG000000
02933 
-4.5 Transmembrane protein 176A (Hepatocellular carcinoma-associated antigen 112). 
[Source:Uniprot/SWISSPROT;Acc:Q96HP8] 
HPSE ENSG000001
73083 
-4.673 Heparanase precursor (EC 3.2.-.-) (Heparanase-1) (Hpa1) (Endo- glucoronidase) [Contains: 
Heparanase 8 kDa subunit; Heparanase 50 kDa 
DFNB31 ENSG000000
95397 
-5.112 Whirlin (Autosomal recessive deafness type 31 protein). 
[Source:Uniprot/SWISSPROT;Acc:Q9P202] 
ALCAM ENSG000001
70017 
-5.185 CD166 antigen precursor (Activated leukocyte-cell adhesion molecule) (ALCAM). 
[Source:Uniprot/SWISSPROT;Acc:Q13740] 
ADM ENSG000001
48926 
-5.301 ADM precursor [Contains: Adrenomedullin (AM); Proadrenomedullin N-20 terminal peptide (ProAM-N20) 
(ProAM N-terminal 20 peptide) 
STBD1 ENSG000001
18804 
-5.85 Genethonin-1. [Source:Uniprot/SWISSPROT;Acc:O95210] 
C9orf19 ENSG000001
22694 
-6.111 Golgi-associated plant pathogenesis-related protein 1 (Golgi- associated PR-1 protein) (GAPR-1) (Glioma 
pathogenesis-related protein 2) 
POSTN ENSG000001
33110 
-6.552 Periostin precursor (PN) (Osteoblast-specific factor 2) (OSF-2). 
[Source:Uniprot/SWISSPROT;Acc:Q15063] 
TNC ENSG000000
41982 
-6.868 Tenascin precursor (TN) (Tenascin-C) (TN-C) (Hexabrachion) (Cytotactin) (Neuronectin) (GMEM) (JI) 
(Myotendinous antigen) 
MYOT ENSG000001
20729 
-7.135 Myotilin (Titin immunoglobulin domain protein) (Myofibrillar titin- like Ig domains protein) (57 kDa 
cytoskeletal protein). 
MMP10 ENSG000001
66670 
-7.886 Stromelysin-2 precursor (EC 3.4.24.22) (Matrix metalloproteinase-10) (MMP-10) (Transin-2) (SL-2). 
[Source:Uniprot/SWISSPROT;Acc:P09238] 
SYCE2 ENSG000001
61860 
-8.051 Synaptonemal complex central element protein 2 (Central element synaptonemal complex protein 1). 
[Source:Uniprot/SWISSPROT;Acc:Q6PIF2] 
ITM2A ENSG000000
78596 
-9.112 Integral membrane protein 2A (E25 protein). [Source:Uniprot/SWISSPROT;Acc:O43736] 
C10orf58 ENSG000001
22378 
-9.877 Uncharacterized protein C10orf58 precursor. [Source:Uniprot/SWISSPROT;Acc:Q9BRX8] 
BLNK ENSG000000
95585 
-10.908 B-cell linker protein (Cytoplasmic adapter protein) (B-cell adapter containing SH2 domain protein) (B-cell 
adapter containing Src homology 2 domain protein) 
GAP43 ENSG000001
72020 
-13.043 Neuromodulin (Axonal membrane protein GAP-43) (Growth-associated protein 43) (PP46) (Neural 
phosphoprotein B-50). 
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MC-38 parental versus MC-38met expression changes as determined in Materials and 
Methods are displayed for the 300 gene metastasis-associated signature.  Mouse 
probe set identifiers (IDs) were mapped to Ensembl Gene IDs based on the mapping 
provided by Ensembl V49 (http://www.ensembl.org) and are displayed in addition to 
fold-change and the gene name as noted in WebGestalt.  The genes in the 34-gene 
classifier are bolded. 
LCN2 ENSG000001
48346 
-16.838 Neutrophil gelatinase-associated lipocalin precursor (NGAL) (p25) (25 kDa alpha-2-microglobulin-related 
subunit of MMP-9) (Lipocalin-2) 
MMP13 ENSG000001
37745 
-17.341 Collagenase 3 precursor (EC 3.4.24.-) (Matrix metalloproteinase-13) (MMP-13). 
CRABP1 ENSG000001
66426 
-21.012 Cellular retinoic acid-binding protein 1 (Cellular retinoic acid- binding protein I) (CRABP-I) 
(Retinoic acid-binding protein I, cellular). 
FABP4 ENSG000001
70323 
-38.52 Fatty acid-binding protein, adipocyte (AFABP) (Adipocyte lipid-binding protein) (ALBP) (A-FABP). 
[Source:Uniprot/SWISSPROT;Acc:P15090] 
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Figure 10. Distribution of 10,000-permutation Wald tests for the 177 MCC 
patients with the 34-gene metastasis score. Beta and Wald statistics for each 
Affymetrix probe set were used along with expression data to build up a 
metastasis score for each patient. The score was used as the independent 
variable to perform overall survival analysis based on the Cox model. The Wald 
test P-value was saved as the observed P-value. For the re-sampling test, we 
randomly chose 60 Affymetrix probe sets from the 54,675 sets on the whole 
array. We repeated the above procedure and generated 1 re-sampling Wald 
test P-value from the overall Cox model survival analysis. We repeated the re-
sampling and survival analysis procedure 10,000 times, generating 10,000 re-
sampling Wald test P-values. We transformed both the observed and re-
sampling P-values into log10 format, plotted a histogram of the 10,000 re-
sampling log10 (P values), and added the observed log10 (P-value). 
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A summary of a multivariate analysis, using the MCC 
patient variables to calculate independent risk factors, 
is shown. Metastasis score (P<.001) and stage (P= 
.002) were each found to be significant predictors of 
DFS in the multivariate model. Metastasis score, age, 
sex, and grade were adjusted in the multivariate Cox 
model for DFS, and the results for each risk factor and 
DFS are shown.  Adjusted P-values as well as the 
adjusted 95% confidence intervals (CI) of the -
coefficient from the Cox model were reported. 
Univariate analysis with the use of the metastasis score to segregate 
patients from the MCC data set into higher-than-median and lower-
than-median score groups. Hazard ratios were calculated for each 
patient group related to DSS.  The 95% confidence intervals (CIs) 
and P-values for the test are given in the table. NA implies that no 
hazard ratio from the Cox model was calculated because no cancer-
related deaths occurred in the patients with stage II colon cancer with 
a low score. The P-value for stage II DSS in this model was 
calculated according to exact log-rank test for unequal follow-up 
(Heinze, Gnant, and Schemper 2003). 
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A summary of a multivariate analysis, using the MCC patient variables to calculate 
independent risk factors, is shown in the table. Metastasis score (P<.001), stage (P< .001) 
and age (P=.04) were each found to be significant predictors of DSS in the multivariate 
model. Metastasis score, age, sex, and grade were adjusted in the multivariate Cox model 
for both OS and DSS, and the results for each risk factor and DSS are shown. The 
adjusted P-values as well as the adjusted 95% confidence intervals (CIs) of the -
coefficient from the Cox model were reported. 
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Figure 18.  (A) Ctnnb1 promoter/enhancer minimal Smad binding elements and region of 
amplification schematic of an area of the ctnnb1 promoter (-3400 to -3000) is displayed.  Smad 
binding elements are in gray and the 5’ and 3’ primer regions are underlined and bold black.  (B) 
Smad4 restoration in SW480 cells does not affect -catenin mRNA stability. SW480vector and 
SW480Smad4 were treated with 5,6-Dichlorobenzimidazole 1--D-ribofuranoside (DRB, specific RNA 
polymerase II inhibitor) as indicated for 0, 4, 8, 12, 16, 20 and 24 hours.  Relative expression for 
steady-state -catenin mRNA was determined after DRB treatment and is displayed.  Analysis of 
variance was used to determine if any significant interactions occurred between groups (P = .88). 
SW480vector is denoted in black and SW480Smad4.1 is denoted in blue.  Two doses of DRB were used 
and data from the 100μM dose is shown. 
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TABLE 11 
 
 
GLOBAL GENE EXPRESSION ANALYSIS OF SW480VECTOR 
VERSUS SW480SMAD4 COLON CANCER CELLS 
UP-REGULATED BY SMAD4 
Affymetrix 
probe 
Coef FDR Gene 
Symbol 
228640_at -8.714577898 4.44E-25 PCDH7 
227711_at -7.958764655 1.21E-37 GTSF1 
206218_at -7.756652036 5.43E-36 MAGEB2 
209942_x_at -7.717070359 5.91E-36 MAGEA3 
214612_x_at -7.696179633 1.12E-37 MAGEA6 
211124_s_at -7.657882354 1.15E-32 KITLG 
201849_at -7.383997352 8.17E-32 BNIP3 
226534_at -7.173853692 1.02E-29 KITLG 
207029_at -7.000946956 2.42E-28 KITLG 
214603_at -6.883081796 5.43E-36 MAGEA2B 
1552767_a_at -6.784122115 2.48E-33 HS6ST2 
201445_at -6.727393674 4.08E-33 CNN3 
230030_at -6.615547924 9.59E-35 HS6ST2 
205919_at -6.535255899 4.65E-33 HBE1 
202983_at -6.531039709 2.61E-35 HLTF 
218186_at -6.442496555 2.94E-35 RAB25 
1553830_s_at -6.39486666 7.13E-35 MAGEA2 
243110_x_at -6.360154734 9.45E-34 NPW 
201117_s_at -6.217523105 3.19E-30 CPE 
209301_at -6.214799538 7.82E-29 CA2 
205767_at -6.06146787 1.31E-25 EREG 
218677_at -5.966475635 1.02E-22 S100A14 
227919_at -5.907829919 4.55E-24 UCA1 
201848_s_at -5.89585183 2.42E-28 BNIP3 
206295_at -5.885920052 5.68E-33 IL18 
204971_at -5.816499121 1.11E-28 CSTA 
205466_s_at -5.794299158 4.45E-22 HS3ST1 
223551_at -5.71991099 8.13E-25 PKIB 
225381_at -5.644466412 3.31E-34 LOC399959 
231192_at -5.553414689 3.85E-28 NA 
201116_s_at -5.534183303 6.95E-33 CPE 
208837_at -5.517704249 2.92E-29 TMED3 
223592_s_at -5.440415817 1.9E-32 RNF135 
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204688_at -5.439822765 8.91E-33 SGCE 
204035_at -5.396409789 6.4E-15 SCG2 
202388_at -5.386649931 3.1E-09 RGS2 
205347_s_at -5.384823628 4.25E-19 TMSB15A 
208937_s_at -5.356431362 4.42E-29 ID1 
234469_at -5.355394233 5.42E-34 OR51B4 
225945_at -5.344472359 2.98E-30 ZNF655 
226621_at -5.343865646 9.1E-26 FGG 
202527_s_at -5.294875093 1.38E-30 SMAD4 
235557_at -5.268789269 3.68E-28 LOC150763 
213816_s_at -5.208338904 5.32E-31 MET 
213258_at -5.203966325 2.58E-34 TFPI 
209199_s_at -5.181597286 7.11E-21 MEF2C 
202973_x_at -5.152029952 4.02E-32 FAM13A 
202620_s_at -5.104496061 2.41E-25 PLOD2 
229402_at -5.094923313 9.11E-29 SAMD13 
226302_at -5.059370209 6.24E-25 ATP8B1 
204083_s_at -5.023699267 2.73E-31 TPM2 
1554803_s_at -5.017672119 5.8E-33 TRIM72 
204304_s_at -5.016762846 3.94E-21 PROM1 
212094_at -4.965591224 9.12E-17 PEG10 
226909_at -4.961649578 9.54E-32 ZNF518B 
201272_at -4.939658251 3.03E-30 AKR1B1 
239913_at -4.907918746 5.75E-31 SLC10A4 
224022_x_at -4.794553413 1.67E-24 WNT16 
219412_at -4.748236738 6.75E-31 RAB38 
203708_at -4.734864329 5.71E-24 PDE4B 
201828_x_at -4.713025367 7.59E-32 FAM127A 
221690_s_at -4.711097692 9.47E-29 NLRP2 
203789_s_at -4.610964515 3.03E-30 SEMA3C 
1552766_at -4.608769757 4.27E-25 HS6ST2 
1555801_s_at -4.588397302 4.73E-33 ZNF385B 
211675_s_at -4.519218284 3.19E-31 MDFIC 
202072_at -4.505536699 2.98E-30 HNRNPL 
207826_s_at -4.489496389 3.88E-24 ID3 
201427_s_at -4.475176247 1.05E-23 SEPP1 
221731_x_at -4.455090423 5.36E-15 VCAN 
228297_at -4.440584307 3.31E-26 CNN3 
203510_at -4.437460842 1.19E-27 MET 
210664_s_at -4.425081818 4.4E-28 TFPI 
234994_at -4.406643543 4.9E-22 TMEM200A 
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213664_at -4.378061462 4.73E-26 SLC1A1 
212148_at -4.369511371 5.23E-15 PBX1 
213222_at -4.353416112 2.86E-24 PLCB1 
204620_s_at -4.349783568 2.54E-15 VCAN 
213156_at -4.3412992 3.65E-21 NA 
219355_at -4.328726428 2.12E-29 CXorf57 
205729_at -4.320124371 6.93E-28 OSMR 
1555800_at -4.317205827 4.76E-28 ZNF385B 
206155_at -4.297905664 1.8E-15 ABCC2 
219932_at -4.277046336 1.38E-27 SLC27A6 
208782_at -4.262519874 3.63E-32 FSTL1 
237159_x_at -4.255301528 1.43E-31 AP1S3 
203680_at -4.254882045 2.42E-28 PRKAR2B 
225540_at -4.209549986 2.8E-24 MAP2 
213158_at -4.203307735 1.73E-20 NA 
202619_s_at -4.190018133 3.67E-26 PLOD2 
1555733_s_at -4.188721418 6.51E-30 AP1S3 
228624_at -4.161792378 1.14E-29 TMEM144 
211302_s_at -4.146115095 4.78E-25 PDE4B 
217948_at -4.140555857 3.19E-30 FAM127B 
1555731_a_at -4.131869279 7.16E-30 AP1S3 
217047_s_at -4.1196971 8.47E-24 FAM13A 
1555148_a_at -4.111957437 1.36E-28 C2orf65 
232113_at -4.092979863 9.25E-24 NA 
209676_at -4.08367698 9.1E-26 TFPI 
228063_s_at -4.067851885 2.82E-24 NAP1L5 
218546_at -4.058686835 6.93E-28 C1orf115 
220615_s_at -4.056984743 5.66E-29 FAR2 
210273_at -4.054999962 3.74E-17 PCDH7 
226789_at -4.032101474 1.09E-27 LOC647121 
209200_at -4.023766598 7.29E-19 MEF2C 
205239_at -4.017174485 1.04E-12 AREG 
232202_at -3.994040074 3.94E-23 NA 
210868_s_at -3.993594161 6.24E-27 ELOVL6 
220445_s_at -3.968126454 4.52E-30 CSAG2 
242888_at -3.956452569 4.59E-24 NA 
203989_x_at -3.953777314 9.41E-26 F2R 
210145_at -3.936997211 9.51E-27 PLA2G4A 
238689_at -3.927653449 3.9E-10 GPR110 
233364_s_at -3.908621286 4.39E-25 NA 
204256_at -3.902968671 2.03E-31 ELOVL6 
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217564_s_at -3.890419141 6.14E-25 CPS1 
235148_at -3.884689862 3.44E-24 KRTCAP3 
203974_at -3.866536097 7.0E-28 HDHD1A 
227082_at -3.864585197 2.98E-19 NA 
232125_at -3.849416984 5.29E-18 NA 
225575_at -3.845970999 4.97E-26 LIFR 
201951_at -3.841131165 1.01E-28 ALCAM 
201952_at -3.808702785 4.03E-29 ALCAM 
223591_at -3.80165121 1.22E-28 RNF135 
226051_at -3.794081845 1.37E-24 SELM 
244111_at -3.792417998 1.67E-27 KRT222P 
230563_at -3.782348339 2.02E-25 RASGEF1A 
211668_s_at -3.750162363 2.27E-28 PLAU 
220513_at -3.746918551 2.23E-22 KHDC1 
204086_at -3.7337206 1.95E-28 PRAME 
205479_s_at -3.722298056 9.49E-28 PLAU 
231270_at -3.720636164 2.0E-27 CA13 
204172_at -3.702774939 1.2E-26 CPOX 
227522_at -3.690120227 2.12E-28 CMBL 
205226_at -3.686800911 1.07E-25 PDGFRL 
206125_s_at -3.682994854 2.14E-27 KLK8 
206504_at -3.657277738 3.47E-17 CYP24A1 
1554726_at -3.613681754 2.06E-24 ZNF655 
238717_at -3.605031631 4.52E-27 NA 
218976_at -3.590523155 6.32E-15 DNAJC12 
219263_at -3.577439277 2.26E-26 RNF128 
204036_at -3.574944814 5.03E-19 LPAR1 
204920_at -3.566868522 1.03E-22 CPS1 
212097_at -3.557795675 2.44E-25 CAV1 
219388_at -3.539240511 1.94E-27 GRHL2 
35201_at -3.528824527 8.4E-32 HNRNPL 
206204_at -3.522214479 4.28E-22 GRB14 
1565162_s_at -3.517355862 3.35E-25 MGST1 
218854_at -3.503859364 8.86E-25 DSE 
1555734_x_at -3.492347773 2.65E-27 AP1S3 
231766_s_at -3.490052336 7.74E-18 COL12A1 
205364_at -3.481846545 3.14E-22 ACOX2 
229019_at -3.466191232 1.3E-23 ZNF385B 
203695_s_at -3.462992194 2.08E-23 DFNA5 
225171_at -3.443087477 6.38E-26 ARHGAP18 
227121_at -3.4281626 1.36E-20 NA 
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203060_s_at -3.412554427 9.34E-27 PAPSS2 
229053_at -3.384903559 8.57E-25 SYT17 
209156_s_at -3.382179814 2.91E-26 COL6A2 
219298_at -3.37738782 5.34E-24 ECHDC3 
221113_s_at -3.374678227 3.5E-19 WNT16 
203355_s_at -3.370498665 1.16E-21 PSD3 
231736_x_at -3.368596188 7.85E-29 MGST1 
213094_at -3.367202397 1.45E-25 GPR126 
202489_s_at -3.359702254 1.62E-21 FXYD3 
212092_at -3.356624139 3.04E-13 PEG10 
202525_at -3.353412135 1.16E-26 PRSS8 
207057_at -3.349627303 8.45E-24 SLC16A7 
227070_at -3.346608462 2.39E-25 GLT8D2 
212096_s_at -3.344989331 4.44E-17 MTUS1 
202022_at -3.344215626 4.25E-23 ALDOC 
203153_at -3.33202304 4.56E-15 IFIT1 
210467_x_at -3.331867005 1.0E-24 MAGEA12 
206140_at -3.326595869 1.11E-21 LHX2 
225809_at -3.322894826 6.38E-26 DKFZP564O
0823 
204653_at -3.315954782 7.79E-26 TFAP2A 
228261_at -3.314303056 7.55E-28 MIB2 
230356_at -3.30586423 3.16E-18 NA 
1552849_at -3.30525836 1.38E-26 C2orf65 
204751_x_at -3.290821488 1.8E-24 DSC2 
210002_at -3.269376566 9.4E-25 GATA6 
204671_s_at -3.26738077 5.96E-25 ANKRD6 
224918_x_at -3.248369818 7.04E-29 MGST1 
243252_at -3.246229836 3.02E-23 NA 
203650_at -3.242541388 5.97E-29 PROCR 
205153_s_at -3.242324115 2.89E-25 CD40 
225173_at -3.234731199 8.89E-27 ARHGAP18 
203065_s_at -3.225436457 1.81E-23 CAV1 
226250_at -3.222065773 1.19E-18 NA 
212095_s_at -3.210585956 2.55E-16 MTUS1 
229160_at -3.209625482 9.41E-18 MUM1L1 
218692_at -3.208583974 3.33E-20 GOLSYN 
230720_at -3.207581907 2.41E-22 RNF182 
206197_at -3.193820402 4.26E-26 NME5 
205383_s_at -3.183059099 1.9E-17 ZBTB20 
219271_at -3.177097937 2.14E-24 GALNT14 
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202948_at -3.177013167 7.63E-25 IL1R1 
228062_at -3.172877406 1.61E-20 NAP1L5 
205581_s_at -3.15898932 4.48E-27 NOS3 
1569878_at -3.149466187 1.14E-24 CCNYL2 
213515_x_at -3.148007631 1.42E-27 HBG2 
206153_at -3.147855065 3.05E-18 CYP4F11 
236207_at -3.145806606 1.24E-29 SSFA2 
204472_at -3.145799656 6.29E-17 GEM 
207761_s_at -3.145321878 6.13E-24 METTL7A 
213807_x_at -3.143497429 5.0E-27 MET 
236016_at -3.143027237 7.49E-28 NA 
206429_at -3.142523286 2.42E-24 F2RL1 
204955_at -3.141921582 5.31E-25 SRPX 
238423_at -3.141814342 1.42E-09 SYTL3 
219750_at -3.132514368 2.23E-22 TMEM144 
226817_at -3.121466629 1.83E-26 DSC2 
230063_at -3.113323812 2.47E-21 ZNF264 
206653_at -3.111298887 3.8E-26 POLR3G 
1564220_a_at -3.090428336 1.61E-25 NA 
215646_s_at -3.086916374 6.75E-11 VCAN 
218613_at -3.083731234 3.94E-23 PSD3 
225664_at -3.080903286 5.73E-17 COL12A1 
204602_at -3.075203281 7.58E-13 DKK1 
205382_s_at -3.065475664 2.52E-27 CFD 
224657_at -3.063017504 1.5E-23 ERRFI1 
226771_at -3.054194491 7.15E-28 ATP8B2 
219313_at -3.049959847 2.48E-22 GRAMD1C 
1555742_at -3.035934535 6.89E-20 NA 
213913_s_at -3.035221065 2.23E-22 TBC1D30 
211599_x_at -3.014005885 5.87E-27 MET 
230033_at -3.007559616 2.74E-26 C19orf51 
206654_s_at -3.000015858 2.01E-23 POLR3G 
200884_at -2.999726868 4.81E-27 CKB 
229393_at -2.992552015 7.75E-25 L3MBTL3 
227176_at -2.985382221 3.39E-24 SLC2A13 
223302_s_at -2.976060076 5.81E-26 ZNF655 
238029_s_at -2.974147273 1.21E-25 SLC16A14 
226420_at -2.974099614 5.69E-19 EVI1 
225450_at -2.957741769 3.28E-24 AMOTL1 
206354_at -2.95763142 4.16E-21 SLCO1B3 
227481_at -2.95431255 6.92E-25 CNKSR3 
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218718_at -2.947594188 1.13E-24 PDGFC 
213506_at -2.945904401 5.52E-26 F2RL1 
243880_at -2.935303789 3.17E-23 GOSR2 
218858_at -2.931609016 2.64E-20 DEPDC6 
235515_at -2.927796442 3.67E-23 C19orf46 
219667_s_at -2.922669403 6.24E-17 BANK1 
213355_at -2.922156919 2.87E-17 ST3GAL6 
223674_s_at -2.915435592 7.24E-23 CDC42SE1 
230570_at -2.912693627 1.5E-24 NA 
223895_s_at -2.901323348 3.66E-21 EPN3 
231120_x_at -2.895096213 8.18E-17 PKIB 
229155_at -2.893568353 4.66E-25 NA 
212151_at -2.878455904 3.3E-12 PBX1 
221760_at -2.878257538 3.04E-20 MAN1A1 
209782_s_at -2.872259794 2.0E-17 DBP 
229842_at -2.864040635 1.22E-21 ELF3 
240304_s_at -2.853596666 3.58E-17 TMC5 
229522_at -2.852737795 9.45E-26 SDR42E1 
210508_s_at -2.85076924 1.27E-18 KCNQ2 
212503_s_at -2.849385138 2.04E-22 DIP2C 
221447_s_at -2.843512172 6.12E-23 GLT8D2 
235244_at -2.842713496 8.1E-25 CCDC58 
210445_at -2.842248415 2.44E-12 FABP6 
213309_at -2.836487168 7.62E-25 PLCL2 
222881_at -2.833888932 4.51E-23 HPSE 
219518_s_at -2.832936119 7.63E-21 ELL3 
228152_s_at -2.831026066 2.35E-20 DDX60L 
228365_at -2.828903792 1.1E-24 CPNE8 
239552_at -2.823653202 6.72E-24 VWDE 
238440_at -2.816260391 5.65E-26 CLYBL 
204750_s_at -2.81191368 6.31E-23 DSC2 
226252_at -2.80950496 1.99E-17 NA 
205418_at -2.805670798 5.85E-27 FES 
219959_at -2.80030706 4.53E-26 MOCOS 
203058_s_at -2.79923752 1.17E-21 PAPSS2 
1555461_at -2.794082881 2.07E-23 NA 
214642_x_at -2.791302546 2.08E-21 MAGEA5 
242517_at -2.772630953 9.58E-24 KISS1R 
204015_s_at -2.7699602 3.15E-27 DUSP4 
202506_at -2.767711148 4.7E-27 SSFA2 
220638_s_at -2.758191237 4.42E-24 CBLC 
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208116_s_at -2.75817569 5.15E-21 MAN1A1 
207808_s_at -2.757112623 9.63E-21 PROS1 
227163_at -2.756119378 5.86E-31 GSTO2 
206698_at -2.756093515 4.6E-21 XK 
223611_s_at -2.755286791 1.07E-14 LNX1 
239108_at -2.755162157 9.08E-22 FAR2 
238439_at -2.747656078 3.27E-15 ANKRD22 
222433_at -2.745204447 2.32E-26 ENAH 
1558280_s_at -2.742052225 3.95E-19 ARHGAP29 
231769_at -2.738768145 5.12E-29 FBXO6 
224553_s_at -2.73060438 1.66E-23 TNFRSF18 
227204_at -2.719298401 1.61E-24 PARD6G 
215505_s_at -2.714276881 1.21E-24 STRN3 
228115_at -2.713305041 1.09E-15 NA 
229377_at -2.711026806 5.36E-25 GRTP1 
235057_at -2.710892139 3.83E-22 ITCH 
211571_s_at -2.710027617 1.41E-10 VCAN 
212762_s_at -2.704396785 2.53E-26 TCF7L2 
212093_s_at -2.700261679 2.14E-14 MTUS1 
220816_at -2.700173124 3.15E-21 LPAR3 
225911_at -2.698684704 2.1E-20 NPNT 
213110_s_at -2.687661089 6.55E-22 COL4A5 
216511_s_at -2.687525169 4.16E-26 TCF7L2 
242873_at -2.683762537 3.99E-12 NA 
209631_s_at -2.669081192 9.25E-23 GPR37 
205014_at -2.668687759 9.12E-21 FGFBP1 
215411_s_at -2.659420935 1.03E-23 TRAF3IP2 
202180_s_at -2.659001081 5.12E-20 MVP 
1552797_s_at -2.640691771 1.82E-09 PROM2 
231984_at -2.638588534 1.06E-23 MTAP 
225166_at -2.632803947 1.85E-21 ARHGAP18 
205917_at -2.631145266 1.4E-19 ZNF264 
206219_s_at -2.623368947 3.79E-22 VAV1 
212543_at -2.622852136 4.62E-18 AIM1 
204897_at -2.621565623 8.05E-19 PTGER4 
227785_at -2.616760968 1.7E-25 SDCCAG8 
229744_at -2.615904284 3.11E-30 SSFA2 
205139_s_at -2.609968595 9.9E-22 UST 
222662_at -2.608194996 2.24E-19 PPP1R3B 
212136_at -2.605979124 2.49E-21 ATP2B4 
203939_at -2.595928019 4.57E-13 NT5E 
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216035_x_at -2.588755147 3.12E-24 TCF7L2 
238681_at -2.58814915 3.64E-19 GDPD1 
224209_s_at -2.587297003 5.75E-20 GDA 
204619_s_at -2.586155238 1.26E-10 VCAN 
233562_at -2.584864607 1.74E-23 LOC84856 
226679_at -2.584847266 1.6E-19 SLC26A11 
201564_s_at -2.582499682 1.51E-24 FSCN1 
204319_s_at -2.58183463 4.73E-29 RGS10 
244246_at -2.574497798 5.91E-20 MIPOL1 
214279_s_at -2.574449097 5.81E-22 NDRG2 
244467_at -2.570876372 1.57E-20 C22:CTA-
250D10.9 
227491_at -2.564046565 1.18E-24 ELOVL6 
217820_s_at -2.562130958 1.1E-23 ENAH 
229849_at -2.560134547 4.69E-24 NA 
204014_at -2.558299779 9.62E-21 DUSP4 
201925_s_at -2.558030298 3.93E-22 CD55 
215346_at -2.552319516 5.86E-17 CD40 
200907_s_at -2.551995251 4.77E-11 PALLD 
210138_at -2.550268024 1.5E-20 RGS20 
213839_at -2.548538976 1.89E-19 CLMN 
1569025_s_at -2.547810792 4.0E-20 FAM13A 
202742_s_at -2.546225199 0.00000109 PRKACB 
228946_at -2.542925602 6.17E-21 INTU 
203130_s_at -2.541420185 6.94E-23 KIF5C 
201061_s_at -2.54131482 4.0E-22 STOM 
228551_at -2.540600024 3.84E-20 DENND5B 
206103_at -2.540167218 2.6E-25 RAC3 
219825_at -2.539667435 3.44E-18 CYP26B1 
207558_s_at -2.53932263 5.59E-20 PITX2 
227875_at -2.536752763 3.96E-23 KLHL13 
222376_at -2.525063494 8.25E-19 NA 
223125_s_at -2.524473663 9.44E-25 C1orf21 
235059_at -2.524201803 1.54E-21 RAB12 
219863_at -2.508380659 3.83E-18 HERC5 
222240_s_at -2.506488897 6.76E-25 ISYNA1 
209469_at -2.494158538 4.26E-17 GPM6A 
239468_at -2.490602425 0.0000704 MKX 
1558290_a_at -2.489411159 6.0E-29 PVT1 
239752_at -2.485450206 7.81E-15 NA 
39248_at -2.481989948 2.6E-15 AQP3 
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242909_at -2.475624144 1.98E-22 NA 
208925_at -2.47392851 4.32E-22 CLDND1 
210933_s_at -2.47288671 9.99E-25 FSCN1 
216248_s_at -2.472379771 3.55E-17 NR4A2 
204419_x_at -2.46852187 2.96E-24 HBG2 
202786_at -2.465276854 4.76E-28 STK39 
241703_at -2.462837738 1.67E-23 RUNDC3B 
203595_s_at -2.460553892 1.26E-23 IFIT5 
207723_s_at -2.457058628 1.85E-12 KLRC3 
229414_at -2.450730356 3.11E-23 PITPNC1 
210827_s_at -2.450374333 2.2E-23 ELF3 
215016_x_at -2.449757301 9.25E-19 DST 
220334_at -2.446802574 9.59E-18 RGS17 
1552334_at -2.445591258 1.26E-19 TRIOBP 
204201_s_at -2.441912187 3.58E-14 PTPN13 
204622_x_at -2.433455377 1.16E-16 NR4A2 
225541_at -2.43127256 7.31E-27 RPL22L1 
228057_at -2.424539548 1.32E-17 DDIT4L 
236281_x_at -2.423450679 8.31E-10 HTR7 
236117_at -2.42195651 8.08E-23 NA 
225295_at -2.420013443 1.52E-19 SLC39A10 
219562_at -2.41994567 3.67E-20 RAB26 
216685_s_at -2.418407723 8.44E-26 MTAP 
200897_s_at -2.413700944 4.58E-11 PALLD 
204844_at -2.411813434 4.55E-20 ENPEP 
221884_at -2.408874578 8.51E-18 EVI1 
219317_at -2.406259636 3.92E-24 POLI 
226034_at -2.405437601 2.81E-22 NA 
210517_s_at -2.403974323 2.22E-21 AKAP12 
219062_s_at -2.402414218 2.54E-23 ZCCHC2 
204798_at -2.401685117 2.55E-20 MYB 
1557302_at -2.400892598 6.56E-23 NA 
238956_at -2.39838517 2.28E-14 NA 
239078_at -2.397673309 1.64E-24 C1orf58 
212254_s_at -2.394675208 2.03E-18 DST 
235419_at -2.391357716 9.17E-20 NA 
204379_s_at -2.38948196 1.17E-16 FGFR3 
213912_at -2.387467978 3.48E-23 TBC1D30 
218970_s_at -2.384507656 1.63E-18 CUTC 
218211_s_at -2.382994542 3.37E-24 MLPH 
226559_at -2.381724319 1.45E-15 IER5L 
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238794_at -2.381364868 4.81E-25 C10orf78 
241726_at -2.380834256 7.5E-21 NA 
223541_at -2.376448189 3.97E-14 HAS3 
223721_s_at -2.373262893 8.48E-11 DNAJC12 
50965_at -2.373088131 7.47E-20 RAB26 
225974_at -2.371042464 5.98E-23 TMEM64 
210665_at -2.371023084 2.27E-18 TFPI 
242338_at -2.369495102 9.63E-23 TMEM64 
224837_at -2.362078813 8.81E-21 FOXP1 
223276_at -2.360042631 2.8E-28 MST150 
203324_s_at -2.359112619 4.51E-23 CAV2 
216037_x_at -2.358301977 3.0E-24 TCF7L2 
210942_s_at -2.355113717 4.14E-15 ST3GAL6 
220318_at -2.354217024 1.68E-17 EPN3 
204956_at -2.35136885 3.89E-20 MTAP 
228314_at -2.34298296 5.4E-19 LRRC8C 
205530_at -2.341727308 3.06E-18 ETFDH 
206023_at -2.336700825 9.56E-25 NMU 
213032_at -2.336382918 4.6E-17 NFIB 
241386_at -2.335936188 1.32E-20 NA 
206315_at -2.334084738 4.31E-18 CRLF1 
238649_at -2.332228407 4.63E-21 PITPNC1 
219501_at -2.32975691 3.77E-15 ENOX1 
203910_at -2.324574039 2.74E-22 ARHGAP29 
226857_at -2.323803698 2.77E-26 ARHGEF19 
1554149_at -2.322576045 5.36E-21 CLDND1 
225524_at -2.319532144 5.52E-13 ANTXR2 
231930_at -2.316968436 1.67E-17 ELMOD1 
219745_at -2.315155002 3.42E-17 TMEM180 
238846_at -2.310058123 2.61E-18 TNFRSF11A 
213715_s_at -2.307354435 1.03E-21 KANK3 
205442_at -2.306395681 4.09E-18 MFAP3L 
1554291_at -2.299490869 7.31E-19 UHRF1BP1
L 
239367_at -2.299091115 2.66E-09 BDNF 
213943_at -2.298439083 3.32E-20 TWIST1 
1559072_a_at -2.297135034 3.2E-17 ELFN2 
203788_s_at -2.295512365 1.59E-21 SEMA3C 
205164_at -2.295046411 9.87E-25 GCAT 
223851_s_at -2.290556897 2.02E-21 TNFRSF18 
209290_s_at -2.289841846 2.54E-18 NFIB 
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212761_at -2.28766511 5.28E-27 TCF7L2 
201860_s_at -2.287091723 7.09E-21 PLAT 
200906_s_at -2.285367635 2.52E-09 PALLD 
201510_at -2.284003238 1.48E-21 ELF3 
219403_s_at -2.281773111 2.39E-22 HPSE 
205129_at -2.281750982 6.03E-23 NPM3 
1554008_at -2.280937971 2.33E-23 OSMR 
203571_s_at -2.274123013 6.83E-21 C10orf116 
1557638_at -2.273933699 5.87E-22 NA 
235725_at -2.273083712 5.0E-23 SMAD4 
214164_x_at -2.271581144 9.77E-20 CA12 
230003_at -2.268851852 9.36E-17 NA 
211363_s_at -2.266075096 9.21E-25 MTAP 
222196_at -2.264699986 2.27E-19 LOC286434 
208146_s_at -2.257275585 1.22E-19 CPVL 
201926_s_at -2.25406707 1.0E-22 CD55 
223533_at -2.253817136 8.11E-23 LRRC8C 
211162_x_at -2.24419709 6.8E-25 SCD 
219371_s_at -2.243542755 3.03E-16 KLF2 
235046_at -2.241750319 1.55E-09 NA 
212150_at -2.240688215 2.03E-25 EFR3A 
1558111_at -2.239388205 3.03E-23 MBNL1 
206396_at -2.238842124 1.5E-19 SLC1A1 
212759_s_at -2.234653689 8.48E-22 TCF7L2 
226806_s_at -2.232823927 1.67E-17 NA 
209289_at -2.231123874 4.08E-21 NFIB 
201060_x_at -2.228081779 2.07E-23 STOM 
202887_s_at -2.226973135 7.03E-10 DDIT4 
217599_s_at -2.226474718 1.39E-21 MDFIC 
207818_s_at -2.219821009 1.48E-08 HTR7 
235429_at -2.219775815 2.32E-20 NA 
236738_at -2.215289746 4.56E-17 LOC401097 
223278_at -2.213288887 1.0E-23 GJB2 
223741_s_at -2.212339789 1.33E-22 TTYH2 
212190_at -2.207184847 4.38E-13 SERPINE2 
212192_at -2.206906628 4.81E-12 KCTD12 
238067_at -2.206885272 9.93E-18 TBC1D8B 
206108_s_at -2.206342102 4.73E-26 SFRS6 
213470_s_at -2.203941459 1.84E-24 HNRNPH1 
224391_s_at -2.203768456 5.49E-24 SIAE 
208820_at -2.202814572 7.26E-28 PTK2 
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210683_at -2.202481324 5.67E-21 NRTN 
222997_s_at -2.202198979 5.39E-25 MRPS21 
228304_at -2.20173752 2.26E-20 RBM43 
210674_s_at -2.201371666 1.94E-24 PCDHA12 
205613_at -2.199178015 9.53E-21 SYT17 
212646_at -2.197875564 6.88E-20 RFTN1 
229014_at -2.195243947 3.72E-23 FLJ42709 
237301_at -2.194549347 1.66E-12 NA 
226597_at -2.191144077 3.35E-24 REEP6 
222904_s_at -2.19096284 1.7E-14 TMC5 
221002_s_at -2.188630371 1.27E-26 TSPAN14 
238935_at -2.187654217 8.23E-20 RPS27L 
232038_at -2.186699925 5.55E-19 C6orf170 
244190_at -2.186679423 1.75E-16 PNPLA8 
225387_at -2.185394243 2.95E-24 TSPAN5 
231597_x_at -2.180740468 3.46E-18 NA 
211330_s_at -2.177374872 4.14E-21 HFE 
1555950_a_at -2.176171757 5.14E-23 CD55 
214647_s_at -2.175408957 2.17E-22 HFE 
213358_at -2.174443225 3.71E-21 KIAA0802 
236489_at -2.172194371 0.0000874 NA 
225388_at -2.168822335 2.14E-24 TSPAN5 
207753_at -2.168802352 3.88E-17 ZNF304 
201724_s_at -2.165669027 5.95E-23 GALNT1 
1568612_at -2.165363384 1.02E-16 GABRG2 
201312_s_at -2.162356546 5.56E-22 SH3BGRL 
203238_s_at -2.158115439 2.55E-21 NOTCH3 
229396_at -2.151821585 4.59E-21 OVOL1 
221577_x_at -2.151709512 2.31E-17 GDF15 
227468_at -2.149524868 6.6E-20 CPT1C 
33494_at -2.144454036 1.07E-21 ETFDH 
1558605_at -2.139598979 2.75E-13 NA 
204848_x_at -2.13747121 9.37E-22 HBG1 
1554679_a_at -2.136531549 2.14E-24 LAPTM4B 
206492_at -2.13101951 8.5E-18 FHIT 
209846_s_at -2.128564814 1.23E-21 BTN3A2 
219517_at -2.127827846 1.34E-18 ELL3 
213310_at -2.127519626 9.11E-20 EIF2C2 
208029_s_at -2.126987611 2.49E-26 LAPTM4B 
203323_at -2.123316848 2.92E-19 CAV2 
242979_at -2.123012504 1.96E-17 IRS1 
149 
218986_s_at -2.122216262 1.44E-17 DDX60 
209470_s_at -2.119516833 5.44E-16 GPM6A 
1552390_a_at -2.117108474 2.27E-18 C8orf47 
235308_at -2.115841372 3.33E-13 ZBTB20 
219358_s_at -2.114960416 4.34E-18 ADAP2 
211708_s_at -2.114304678 9.39E-25 SCD 
236045_x_at -2.111589877 3.11E-16 NA 
235004_at -2.109642594 9.67E-16 RBM24 
201311_s_at -2.101077609 2.39E-21 SH3BGRL 
219580_s_at -2.096086728 5.07E-14 TMC5 
208767_s_at -2.095274155 1.84E-26 LAPTM4B 
208818_s_at -2.091826751 1.27E-23 COMT 
210135_s_at -2.090304766 7.66E-22 SHOX2 
209615_s_at -2.088132125 3.07E-23 PAK1 
222592_s_at -2.087742598 1.25E-09 ACSL5 
230055_at -2.087483511 5.02E-19 KHDC1 
225459_at -2.085854697 1.8E-21 AMOTL1 
224838_at -2.085138059 2.64E-20 FOXP1 
202345_s_at -2.084080705 3.87E-24 FABP5 
227839_at -2.083256509 4.26E-17 MBD5 
219179_at -2.082352139 7.19E-11 DACT1 
234775_at -2.081043614 7.7E-19 OR51B5 
225959_s_at -2.079950407 2.62E-26 ZNRF1 
213603_s_at -2.079568923 7.74E-26 RAC2 
64408_s_at -2.078774794 1.24E-18 CALML4 
209890_at -2.075707099 3.42E-26 TSPAN5 
212149_at -2.075161897 3.63E-26 EFR3A 
242917_at -2.074628664 3.4E-20 RASGEF1A 
1560318_at -2.071669901 3.42E-17 ARHGAP29 
223515_s_at -2.063004351 2.51E-25 COQ3 
225666_at -2.062031945 2.02E-25 TMTC4 
218322_s_at -2.061837645 9.4E-09 ACSL5 
204621_s_at -2.061823092 1.3E-14 NR4A2 
227856_at -2.061406395 1.45E-21 C4orf32 
235259_at -2.05960176 8.58E-19 PACRGL 
228221_at -2.057100154 1.72E-19 SLC44A3 
234513_at -2.056798045 4.76E-15 ELOVL3 
227438_at -2.052855149 9.6E-24 ALPK1 
223599_at -2.051444212 1.14E-11 TRIM6 
206241_at -2.050136178 7.15E-24 KPNA5 
207821_s_at -2.049817423 1.89E-28 PTK2 
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209183_s_at -2.04766941 5.25E-19 C10orf10 
202741_at -2.046644699 0.00000455 PRKACB 
239196_at -2.045578374 1.01E-16 ANKRD22 
204820_s_at -2.044677939 5.46E-23 BTN3A3 
215321_at -2.041116616 1.47E-20 RUNDC3B 
222558_at -2.039580946 4.55E-25 RPRD1A 
204560_at -2.039232955 2.21E-21 FKBP5 
220474_at -2.034038032 3.17E-14 SLC25A21 
208817_at -2.030383448 7.1E-23 COMT 
211105_s_at -2.030065139 1.73E-20 NFATC1 
224976_at -2.02987832 1.16E-20 NFIA 
223435_s_at -2.029598288 6.64E-19 PCDHA@ 
224856_at -2.029206572 5.97E-23 FKBP5 
212253_x_at -2.024077043 1.72E-16 DST 
217847_s_at -2.023683745 9.15E-23 THRAP3 
229590_at -2.023221496 5.52E-24 RPL13 
222559_s_at -2.021994511 1.91E-26 RPRD1A 
215867_x_at -2.021876556 4.06E-15 CA12 
202457_s_at -2.020728155 2.74E-20 PPP3CA 
1557103_a_at -2.019716166 6.99E-16 LMTK3 
231768_at -2.019542023 4.48E-17 USF1 
224840_at -2.017108093 2.35E-25 FKBP5 
36475_at -2.016527424 4.66E-27 GCAT 
204040_at -2.016436312 4.74E-18 RNF144A 
235871_at -2.013394239 2.51E-17 LIPH 
235325_at -2.00983031 3.38E-20 SPG7 
212135_s_at -2.008966591 1.44E-18 ATP2B4 
230281_at -2.002073034 1.96E-21 C16orf46 
227126_at -2.000756882 6.6E-16 PTPRG 
228653_at -2.00053394 2.62E-15 SAMD5 
DOWN-REGULATED BY SMAD4  
Affymetrix 
probe 
Coef FDR 
Gene 
Symbol 
223948_s_at 2.001595545 1.13E-20 TMPRSS3 
217585_at 2.003528658 7.13E-18 NEBL 
211160_x_at 2.004615463 1.72E-24 ACTN1 
1552562_at 2.007497781 1.07E-19 ZNF570 
1552423_at 2.008817735 1.37E-17 ETV3 
1552740_at 2.009394831 6.78E-17 C2orf15 
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227013_at 2.010912568 6.69E-24 LATS2 
219440_at 2.011493007 2.29E-18 RAI2 
224204_x_at 2.012325661 1.24E-20 ARNTL2 
227808_at 2.012557765 4.40E-24 DNAJC15 
1557448_a_at 2.012567813 2.06E-18 NA 
228030_at 2.020441304 1.24E-19 RBM6 
36920_at 2.021345788 6.65E-18 MTM1 
1555852_at 2.022349974 1.28E-16 PSMB9 
208712_at 2.02402084 1.88E-24 CCND1 
235729_at 2.024360154 1.07E-17 ZNF514 
204254_s_at 2.024505089 1.41E-20 VDR 
229576_s_at 2.024874112 7.17E-23 TBX3 
208682_s_at 2.025867161 8.50E-21 MAGED2 
209710_at 2.026305792 2.03E-20 GATA2 
241418_at 2.026645289 2.56E-14 LOC344887 
230398_at 2.028443161 2.94E-19 TNS4 
201826_s_at 2.030994562 6.39E-17 SCCPDH 
213924_at 2.032093713 1.81E-20 MPPE1 
1553713_a_at 2.032228876 5.78E-20 RHEBL1 
1554576_a_at 2.033707581 1.43E-18 ETV4 
1556533_at 2.033752706 2.89E-20 C17orf52 
223616_at 2.034100611 3.53E-19 ZNF649 
219884_at 2.03499411 8.53E-24 LHX6 
243918_at 2.037096622 4.12E-17 NA 
227822_at 2.037255454 8.90E-18 ZNF605 
203627_at 2.037826204 1.21E-19 IGF1R 
219873_at 2.038049187 1.83E-15 COLEC11 
203438_at 2.039098575 7.21E-16 STC2 
223408_s_at 2.039693313 7.48E-20 FOXK2 
219565_at 2.04111855 4.20E-22 CYP20A1 
226342_at 2.04136412 1.24E-18 SPTBN1 
230352_at 2.042149583 1.42E-22 PRPS2 
210869_s_at 2.043353091 2.99E-22 MCAM 
202082_s_at 2.04459877 1.32E-20 SEC14L1 
220921_at 2.045143936 4.89E-16 SPANXA1 
243010_at 2.045331613 2.60E-23 MSI2 
204683_at 2.047862438 2.17E-19 ICAM2 
206286_s_at 2.047952074 2.16E-18 TDGF1 
1568813_at 2.047958281 3.53E-19 NA 
212549_at 2.049792864 7.68E-24 STAT5B 
226092_at 2.051485079 3.83E-22 MPP5 
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210510_s_at 2.052339859 7.65E-18 NRP1 
227897_at 2.05331385 2.78E-16 RAP2B 
207401_at 2.053682625 2.22E-18 PROX1 
202124_s_at 2.055352439 9.63E-19 TRAK2 
227566_at 2.056882796 7.44E-13 NTM 
209917_s_at 2.057188894 6.74E-20 TP53TG1 
239154_at 2.057287968 4.12E-20 NA 
212774_at 2.057394225 1.60E-19 ZNF238 
231149_s_at 2.057565784 6.60E-19 ULK4 
232088_x_at 2.059196391 2.20E-18 
hCG_20390
27 
232140_at 2.060920271 6.20E-20 
LOC100132
352 
209737_at 2.061799186 1.46E-19 MAGI2 
229826_at 2.063509151 3.04E-23 LOC440957 
209496_at 2.064566187 1.98E-18 RARRES2 
1553055_a_at 2.066659568 1.30E-15 SLFN5 
219826_at 2.067977547 1.21E-17 ZNF419 
207468_s_at 2.069248903 6.63E-25 SFRP5 
225674_at 2.069280895 2.44E-24 BCAP29 
204881_s_at 2.070045873 1.20E-20 UGCG 
244570_at 2.070129534 3.71E-22 
LOC100130
360 
200953_s_at 2.071157243 2.08E-18 CCND2 
240690_at 2.071931025 6.39E-18 NA 
233949_s_at 2.072414505 1.60E-19 MYH7B 
219389_at 2.07248453 3.26E-19 SUSD4 
228293_at 2.072505967 5.32E-20 DEPDC7 
1560156_at 2.073033034 5.95E-20 NA 
210196_s_at 2.075470397 2.53E-21 PSG1 
207413_s_at 2.076069147 8.75E-20 SCN5A 
225564_at 2.076641127 1.62E-22 SPATA13 
201830_s_at 2.077757208 1.53E-22 NET1 
220265_at 2.078674309 3.57E-20 GPR107 
226657_at 2.079603059 1.66E-21 MGC33894 
243065_at 2.082862865 3.14E-19 NA 
217707_x_at 2.08591528 2.16E-10 SMARCA2 
200660_at 2.088782815 3.93E-26 S100A11 
204831_at 2.08913978 8.25E-21 CDK8 
225677_at 2.089658537 7.74E-24 BCAP29 
215237_at 2.089948665 1.15E-18 DOCK9 
226040_at 2.090890673 4.53E-14 NA 
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226267_at 2.091210936 1.40E-17 JDP2 
239050_s_at 2.092050641 6.10E-17 NA 
202637_s_at 2.092272057 5.21E-17 ICAM1 
1555270_a_at 2.092656737 3.78E-23 WFS1 
229061_s_at 2.093069871 2.45E-18 SLC25A13 
219264_s_at 2.093702869 3.63E-19 PPP2R3B 
205500_at 2.095203785 4.31E-19 C5 
232382_s_at 2.09796432 9.34E-19 PCMTD1 
223916_s_at 2.098387577 2.43E-17 BCOR 
214021_x_at 2.101508248 5.05E-21 ITGB5 
208637_x_at 2.103540823 8.57E-25 ACTN1 
231034_s_at 2.10436072 6.78E-18 NHSL1 
223974_at 2.108570947 3.77E-18 MGC11082 
225844_at 2.10878755 5.15E-23 POLE4 
224919_at 2.11114806 4.05E-25 MRPS6 
219496_at 2.112316233 2.72E-22 ANKRD57 
230002_at 2.112740538 1.19E-22 CLCC1 
223874_at 2.113688945 6.77E-19 ARP11 
228843_at 2.114183729 2.49E-19 NA 
203279_at 2.117560595 5.97E-23 EDEM1 
212298_at 2.118482295 8.49E-16 NRP1 
204214_s_at 2.119549905 6.18E-24 RAB32 
213393_at 2.120549932 2.40E-20 NA 
220054_at 2.121974766 5.46E-20 IL23A 
240151_at 2.123985943 3.56E-21 LOC404266 
203002_at 2.128986284 1.11E-23 AMOTL2 
238624_at 2.129004934 2.15E-21 NA 
229294_at 2.12918493 7.99E-20 JPH3 
230689_at 2.129656116 1.42E-20 NA 
215238_s_at 2.131748535 7.00E-19 DOCK9 
206337_at 2.13208729 7.74E-14 CCR7 
225512_at 2.13353456 6.10E-22 ZBTB38 
203628_at 2.134682951 1.29E-19 IGF1R 
219321_at 2.136116032 6.08E-21 MPP5 
209356_x_at 2.138117527 3.63E-17 EFEMP2 
227261_at 2.138432886 3.36E-18 KLF12 
201566_x_at 2.139151764 2.14E-10 ID2 
209619_at 2.139220283 2.66E-17 CD74 
205801_s_at 2.139690005 2.71E-23 RASGRP3 
229225_at 2.140132561 2.06E-15 NRP2 
200856_x_at 2.140995159 2.13E-22 LOC100133
154 
918 
203231_s_at 2.142190856 3.23E-16 ATXN1 
223405_at 2.145369713 4.13E-18 NPL 
222902_s_at 2.146389349 2.01E-22 DEM1 
230120_s_at 2.147590245 4.86E-20 PLGLB2 
236223_s_at 2.147713742 5.30E-21 RIT1 
228638_at 2.152274214 3.70E-22 FAM76A 
206665_s_at 2.154857428 2.50E-21 BCL2L1 
228825_at 2.15547215 1.73E-19 PTGR1 
228400_at 2.157018484 4.07E-17 SHROOM3 
228290_at 2.157621704 5.01E-18 
NCRNA001
53 
1562056_at 2.157678768 6.04E-17 NA 
230434_at 2.158918924 1.69E-21 KLHL23 
209383_at 2.159584029 3.12E-19 DDIT3 
204220_at 2.159756718 7.27E-20 GMFG 
205463_s_at 2.160642566 5.79E-21 PDGFA 
226453_at 2.161034619 1.01E-26 RNASEH2C 
235094_at 2.163013073 2.15E-17 NA 
225045_at 2.16464947 4.81E-20 CCDC88A 
230954_at 2.165301557 1.95E-15 C20orf112 
227410_at 2.166369676 8.09E-22 FAM43A 
1555883_s_at 2.17037673 2.48E-21 SPIN3 
201464_x_at 2.171310811 1.69E-21 JUN 
228462_at 2.17165176 4.40E-19 IRX2 
225946_at 2.172986747 5.12E-20 RASSF8 
217966_s_at 2.173719784 9.05E-17 FAM129A 
206632_s_at 2.174145788 6.91E-19 APOBEC3B 
229512_at 2.175074274 6.07E-18 FAM120C 
236571_at 2.175346953 1.38E-19 NA 
1564413_at 2.175589441 5.12E-23 FLJ36116 
201905_s_at 2.175816402 5.69E-25 CTDSPL 
204288_s_at 2.176209802 7.95E-21 SORBS2 
206463_s_at 2.181560277 1.59E-17 DHRS2 
204345_at 2.183398049 6.40E-20 COL16A1 
1557523_at 2.185284448 2.79E-17 LOC92270 
226947_at 2.189390496 5.78E-20 GUSBL2 
209396_s_at 2.18985411 1.18E-19 CHI3L1 
201125_s_at 2.190253032 1.05E-25 ITGB5 
205761_s_at 2.191036913 3.63E-23 DUS4L 
226979_at 2.191835189 2.25E-23 MAP3K2 
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204416_x_at 2.192392719 8.69E-21 APOC1 
227452_at 2.192587304 1.81E-11 NA 
209565_at 2.192604649 3.24E-24 RNF113A 
236982_at 2.193180652 5.90E-22 NA 
1553992_s_at 2.194080028 4.19E-21 NBR2 
229835_s_at 2.195955942 3.76E-23 SLMO2 
239376_at 2.197553452 9.00E-21 NA 
230752_at 2.200905719 1.35E-17 NA 
225656_at 2.201408373 1.40E-19 EFHC1 
229332_at 2.20261466 2.48E-23 HPDL 
213229_at 2.20769639 3.82E-18 DICER1 
1553587_a_at 2.208114119 3.18E-22 POLE4 
223689_at 2.209418779 4.34E-23 IGF2BP1 
223764_x_at 2.210973597 3.14E-21 NIPSNAP3B 
209107_x_at 2.211818881 4.68E-22 NCOA1 
235589_s_at 2.212601928 1.47E-19 MDM4 
210051_at 2.213887075 2.04E-22 RAPGEF3 
1569366_a_at 2.214491667 6.87E-22 ZNF569 
232884_s_at 2.214818286 1.75E-18 ZNF853 
214022_s_at 2.215183032 2.68E-12 IFITM1 
218113_at 2.215609105 7.57E-14 TMEM2 
200739_s_at 2.215985691 3.13E-16 SUMO3 
242550_at 2.216052553 2.79E-17 EIF3B 
1565347_s_at 2.216537648 9.72E-20 TFE3 
243802_at 2.217170512 8.25E-21 DNAH12 
205600_x_at 2.217420008 2.58E-22 HOXB5 
1557128_at 2.217702135 1.34E-21 FAM111B 
226283_at 2.217711829 3.93E-18 WDR51B 
226137_at 2.21788027 5.12E-15 ZFHX3 
244174_at 2.21822943 7.70E-19 NA 
231697_s_at 2.222143822 6.69E-19 TMEM49 
233825_s_at 2.225136539 1.83E-22 CD99L2 
210249_s_at 2.22765983 1.64E-22 NCOA1 
215923_s_at 2.228127747 1.63E-22 PSD4 
219748_at 2.230102725 2.32E-19 TREML2 
1557164_a_at 2.230837534 3.13E-18 NA 
206777_s_at 2.232567152 1.17E-20 CRYBB2 
204972_at 2.233495323 5.35E-17 OAS2 
216867_s_at 2.233724387 4.64E-18 PDGFA 
229128_s_at 2.240231277 1.18E-25 ANP32E 
201721_s_at 2.241516614 8.31E-18 LAPTM5 
156 
218435_at 2.242415626 1.96E-26 DNAJC15 
220658_s_at 2.243257146 2.04E-20 ARNTL2 
219655_at 2.243716362 2.88E-18 C7orf10 
1562020_s_at 2.244373268 9.51E-16 NT5DC4 
236557_at 2.247268716 3.38E-21 ZBTB38 
1569349_at 2.248470451 3.63E-19 C11orf30 
223253_at 2.255457401 7.77E-25 EPDR1 
212285_s_at 2.255846238 1.21E-23 AGRN 
1553115_at 2.257716576 3.93E-22 NKD1 
235728_at 2.258440694 3.37E-22 ZFP3 
236313_at 2.262691633 2.80E-16 CDKN2B 
238909_at 2.264083249 2.24E-19 S100A10 
219833_s_at 2.266662965 2.72E-21 EFHC1 
237213_at 2.267957724 1.89E-22 NA 
206542_s_at 2.268495126 4.43E-11 SMARCA2 
230588_s_at 2.26893631 3.24E-22 LOC285074 
202166_s_at 2.26894137 4.09E-25 PPP1R2 
226360_at 2.270965971 7.18E-26 ZNRF3 
219594_at 2.276200112 9.30E-20 NINJ2 
225619_at 2.27933342 1.70E-20 SLAIN1 
243539_at 2.280464316 2.97E-18 KIAA1841 
212843_at 2.280821942 7.26E-21 NCAM1 
219228_at 2.281481382 1.36E-20 ZNF331 
218746_at 2.283749284 2.55E-18 TAPBPL 
206110_at 2.283753927 2.17E-16 HIST1H3H 
242133_s_at 2.284749335 8.59E-20 NA 
224917_at 2.287054718 2.25E-19 TMEM49 
206482_at 2.289575164 5.99E-18 PTK6 
1566129_at 2.292361106 1.51E-19 LIMS1 
203382_s_at 2.297054498 9.84E-21 APOE 
238530_at 2.297178011 1.08E-15 NNT 
203342_at 2.297696771 5.23E-25 TIMM17B 
215041_s_at 2.302335267 6.63E-19 DOCK9 
214182_at 2.302450885 1.27E-23 
LOC100132
430 
238017_at 2.30266678 3.00E-19 SDR16C5 
222590_s_at 2.304525182 1.34E-20 NLK 
228235_at 2.304826282 8.48E-20 MGC16121 
209663_s_at 2.305761611 1.07E-17 ITGA7 
228044_at 2.307392289 1.90E-20 SERP2 
1556769_a_at 2.308736467 3.45E-11 NA 
157 
214079_at 2.3092358 3.59E-17 DHRS2 
214257_s_at 2.317524854 4.09E-24 SEC22B 
235456_at 2.31789932 8.56E-20 NA 
212538_at 2.318434416 1.05E-19 DOCK9 
208868_s_at 2.3191494 1.61E-18 
GABARAPL
1 
201185_at 2.321616506 4.43E-19 HTRA1 
229146_at 2.334810625 2.86E-20 C7orf31 
214718_at 2.339950988 2.70E-21 GATAD1 
229347_at 2.342111401 4.01E-20 NA 
217967_s_at 2.342287847 1.60E-16 FAM129A 
213627_at 2.343989481 6.02E-22 MAGED2 
211094_s_at 2.349676385 5.48E-19 NF1 
1557470_at 2.35214077 1.74E-21 SPATA13 
205560_at 2.352471305 3.91E-22 PCSK5 
210852_s_at 2.352904467 7.40E-20 AASS 
1557129_a_at 2.355912134 5.23E-17 FAM111B 
235287_at 2.356216674 3.70E-18 CDK6 
213788_s_at 2.356276173 1.72E-22 BRD3 
214071_at 2.356849843 5.05E-20 GNAL 
225927_at 2.359979205 6.73E-23 MAP3K1 
222900_at 2.362214604 1.80E-22 NA 
204072_s_at 2.362433975 2.33E-15 FRY 
239186_at 2.366138856 1.21E-17 MGC39372 
1553539_at 2.368424487 1.64E-21 KRT74 
204417_at 2.372461661 3.51E-17 GALC 
218031_s_at 2.373123466 1.22E-21 FOXN3 
218625_at 2.37475004 1.05E-19 NRN1 
230454_at 2.375836886 3.37E-18 ICA1L 
205559_s_at 2.376415248 7.13E-22 PCSK5 
227396_at 2.376681062 4.62E-20 PTPRJ 
230333_at 2.377484203 8.53E-18 NA 
235174_s_at 2.378567624 4.40E-17 
LOC100128
822 
224279_s_at 2.37939089 5.20E-21 CABYR 
1552846_s_at 2.380488849 1.13E-16 RAB42 
1555486_a_at 2.380667612 6.67E-22 FLJ14213 
242005_at 2.381646968 8.49E-09 NA 
203851_at 2.386195698 2.97E-16 IGFBP6 
1562722_at 2.386480515 5.89E-18 PRR20 
202688_at 2.386891314 3.07E-24 TNFSF10 
222877_at 2.387693277 9.24E-20 NA 
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206154_at 2.389289678 3.16E-19 RLBP1 
1568838_at 2.390377891 2.91E-19 
LOC100132
169 
1569157_s_at 2.390953677 4.47E-20 ZNF846 
223690_at 2.39209856 3.23E-20 LTBP2 
212807_s_at 2.392381239 1.79E-20 SORT1 
218359_at 2.393447801 1.13E-19 NRSN2 
210948_s_at 2.396963985 2.17E-21 LEF1 
213931_at 2.397088384 9.10E-12 ID2 
203008_x_at 2.400463233 1.75E-24 TXNDC9 
1569194_at 2.400501605 5.29E-23 ZNF789 
236616_at 2.401208101 2.66E-20 NA 
203849_s_at 2.405282122 5.29E-22 KIF1A 
235033_at 2.40613372 3.05E-22 NPEPL1 
1557169_x_at 2.407279654 4.04E-20 HCG11 
219342_at 2.40841727 1.64E-21 CASD1 
218691_s_at 2.408811819 5.68E-23 PDLIM4 
219704_at 2.411197714 4.27E-18 YBX2 
209185_s_at 2.411377875 9.94E-21 IRS2 
1558953_s_at 2.416290339 3.41E-22 CEP164 
235106_at 2.416651379 2.50E-25 MAML2 
244819_x_at 2.417623502 8.57E-20 PSPH 
223223_at 2.424008178 2.72E-24 ARV1 
228083_at 2.427311316 1.50E-24 CACNA2D4 
202778_s_at 2.428996215 3.76E-22 ZMYM2 
212531_at 2.429591585 
0.0025938
8 
LCN2 
232579_at 2.431224355 5.92E-22 
LOC100134
229 
211758_x_at 2.43151623 1.34E-23 TXNDC9 
224687_at 2.431689668 6.22E-23 ANKIB1 
206523_at 2.432252009 4.38E-22 CYTH3 
212848_s_at 2.433040461 4.37E-26 C9orf3 
227444_at 2.433107577 8.87E-24 ARMCX4 
231102_at 2.434022619 3.73E-20 CROT 
217248_s_at 2.441686527 4.84E-19 SLC7A8 
220945_x_at 2.441891651 2.20E-21 MANSC1 
216242_x_at 2.442773935 3.65E-28 POLR2J2 
240436_at 2.442979333 2.90E-20 LOC650794 
231215_at 2.447110217 1.04E-19 NA 
202165_at 2.447219345 5.31E-26 PPP1R2 
243362_s_at 2.447771709 1.81E-25 LOC641518 
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225469_at 2.448593445 2.44E-22 LYRM5 
1553112_s_at 2.448684642 2.53E-21 CDK8 
230233_at 2.450919218 1.04E-20 NA 
218656_s_at 2.451324483 3.32E-18 LHFP 
201124_at 2.455181162 1.19E-21 ITGB5 
212845_at 2.458030326 8.27E-23 SAMD4A 
214830_at 2.458110752 5.50E-20 SLC38A6 
229376_at 2.458315358 2.74E-18 PROX1 
1553430_a_at 2.45967347 5.72E-23 EDARADD 
217867_x_at 2.461823473 2.74E-26 BACE2 
211029_x_at 2.462131571 4.47E-21 FGF18 
211518_s_at 2.462756098 5.24E-19 BMP4 
234300_s_at 2.466006077 5.91E-24 ZFP28 
230493_at 2.467010452 3.12E-20 SHISA2 
228222_at 2.470152644 1.45E-28 PPP1CB 
238692_at 2.471620829 5.90E-20 BTBD11 
225142_at 2.473334323 8.04E-20 JHDM1D 
228415_at 2.481084749 4.98E-24 AP1S2 
221552_at 2.482259348 4.01E-23 ABHD6 
208291_s_at 2.484371863 2.13E-22 TH 
45288_at 2.484689693 5.32E-23 ABHD6 
225782_at 2.4885047 5.62E-17 MSRB3 
242940_x_at 2.488792755 8.27E-17 DLX6 
238790_at 2.49042345 1.26E-18 LOC374443 
1556029_s_at 2.492654079 3.77E-21 NMNAT2 
202458_at 2.493320695 8.91E-18 PRSS23 
223824_at 2.497765348 5.41E-23 C10orf59 
229071_at 2.5040351 5.99E-21 C17orf100 
227401_at 2.505415699 2.23E-22 IL17D 
228606_at 2.507506499 1.92E-24 TM4SF19 
219282_s_at 2.507967101 4.90E-22 TRPV2 
228846_at 2.508651133 2.25E-22 MXD1 
203736_s_at 2.50875283 4.25E-18 PPFIBP1 
1552566_at 2.509456886 1.30E-23 BTBD16 
224938_at 2.509850856 4.06E-18 NUFIP2 
210762_s_at 2.512737366 1.08E-20 DLC1 
207279_s_at 2.516595637 5.77E-19 NEBL 
206669_at 2.516792867 2.16E-23 GAD1 
224848_at 2.523164821 2.19E-15 CDK6 
227272_at 2.526906819 1.68E-20 C15orf52 
210915_x_at 2.530172079 4.55E-23 IL23A 
160 
229588_at 2.534369092 1.51E-19 DNAJC10 
202083_s_at 2.538327568 3.87E-22 SEC14L1 
223739_at 2.538742913 6.71E-24 PADI1 
210657_s_at 2.545125308 4.43E-19 4-Sep 
204929_s_at 2.546628907 2.02E-23 VAMP5 
220936_s_at 2.547772759 3.12E-20 H2AFJ 
214708_at 2.553155318 1.45E-22 SNTB1 
230149_at 2.555232646 1.52E-19 NA 
206544_x_at 2.555600954 2.93E-13 SMARCA2 
204588_s_at 2.558845817 7.98E-20 SLC7A7 
209184_s_at 2.559764509 1.12E-20 IRS2 
227062_at 2.563096141 4.82E-18 
NCRNA000
84 
201466_s_at 2.56324932 6.42E-19 JUN 
229733_s_at 2.56495409 3.65E-24 NA 
209525_at 2.565347936 4.24E-22 HDGFRP3 
215303_at 2.567164893 1.11E-23 DCLK1 
217591_at 2.570261733 1.59E-25 NA 
208869_s_at 2.573823294 1.00E-18 
GABARAPL
1 
201109_s_at 2.573994148 4.04E-22 THBS1 
205978_at 2.57408841 3.16E-16 KL 
205932_s_at 2.576250783 3.08E-18 MSX1 
219147_s_at 2.577576972 1.94E-24 C9orf95 
242775_at 2.577963951 5.99E-21 NA 
1558834_s_at 2.578003331 1.35E-20 C1orf62 
229986_at 2.584916186 6.55E-20 ZNF717 
222451_s_at 2.588591474 1.65E-28 ZDHHC9 
210495_x_at 2.592240002 6.08E-21 FN1 
214502_at 2.592304165 2.67E-15 HIST1H2BJ 
229972_at 2.594771252 9.40E-20 NA 
207198_s_at 2.595742123 1.49E-27 LIMS1 
1555613_a_at 2.596414903 3.81E-21 ZAP70 
241782_at 2.596834913 4.54E-18 NEBL 
205365_at 2.598157886 3.32E-20 HOXB6 
205453_at 2.601337422 2.88E-25 HOXB2 
238493_at 2.602519404 2.39E-24 ZNF506 
200740_s_at 2.602629908 5.91E-20 SUMO3 
220663_at 2.605479691 4.84E-20 IL1RAPL1 
212415_at 2.608578786 3.59E-27 SEPT6 
215596_s_at 2.611561549 5.20E-25 RNF160 
226546_at 2.611601139 4.78E-22 NA 
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1559957_a_at 2.61293232 5.46E-26 LOC642852 
213496_at 2.614702672 1.68E-18 LPPR4 
227976_at 2.615452007 5.14E-25 LOC644538 
223827_at 2.615606039 2.54E-22 TNFRSF19 
225273_at 2.616880947 2.38E-18 WWC3 
231152_at 2.617052743 3.71E-19 INO80D 
224847_at 2.617239964 7.22E-16 CDK6 
229667_s_at 2.617988155 1.75E-13 HOXB8 
217551_at 2.624708864 2.74E-19 LOC441453 
235534_at 2.626553245 2.21E-23 NA 
213711_at 2.6270004 1.25E-20 KRT81 
212687_at 2.628671505 1.48E-25 LIMS1 
218996_at 2.630093152 6.52E-25 TFPT 
1570253_a_at 2.632084155 2.62E-20 RHEBL1 
202638_s_at 2.632396737 5.56E-20 ICAM1 
213167_s_at 2.633073058 1.29E-22 MRPS6 
235371_at 2.633729214 6.39E-23 GLT8D4 
1553082_at 2.638987331 5.35E-22 CRYGN 
211534_x_at 2.639368024 5.39E-22 PTPRN2 
229481_at 2.646663455 1.72E-23 NKD1 
200857_s_at 2.647355601 6.47E-23 NCOR1 
206648_at 2.647885848 7.40E-21 ZNF571 
219856_at 2.651534227 4.94E-20 C1orf116 
235721_at 2.651585801 3.95E-23 DTX3 
213619_at 2.652091616 1.30E-26 HNRNPH1 
216092_s_at 2.655620029 2.11E-22 SLC7A8 
225908_at 2.661959797 1.29E-20 IAH1 
211817_s_at 2.665448517 2.33E-26 KCNJ5 
219569_s_at 2.666397326 6.30E-25 TMEM22 
222553_x_at 2.670001961 2.75E-23 OXR1 
217868_s_at 2.670411347 1.20E-26 METTL9 
235433_at 2.671279443 3.16E-23 APOOL 
228095_at 2.67185217 1.99E-25 PHF14 
229344_x_at 2.675173631 4.78E-23 RIMKLB 
214375_at 2.679820282 2.47E-20 PPFIBP1 
208916_at 2.687475864 9.33E-27 SLC1A5 
211458_s_at 2.687822464 3.64E-19 
GABARAPL
3 
222589_at 2.690853033 9.39E-25 NLK 
222453_at 2.691637451 1.13E-22 CYBRD1 
209189_at 2.70318444 2.14E-20 FOS 
162 
219928_s_at 2.703674363 2.19E-23 CABYR 
243752_s_at 2.705237358 6.85E-22 CYTH3 
219520_s_at 2.705766291 6.61E-22 WWC3 
226001_at 2.707334474 5.62E-18 KLHL5 
227200_at 2.709102953 5.28E-27 NA 
231101_at 2.709451736 2.47E-26 PPP2R5E 
201009_s_at 2.711959391 1.10E-22 TXNIP 
212565_at 2.714181192 9.57E-23 STK38L 
219383_at 2.714389113 2.14E-21 FLJ14213 
212915_at 2.715503393 5.02E-18 PDZRN3 
214374_s_at 2.716634372 1.13E-19 PPFIBP1 
218318_s_at 2.718494575 3.10E-22 NLK 
1558733_at 2.720284614 3.29E-25 ZBTB38 
204255_s_at 2.720440918 1.66E-23 VDR 
202752_x_at 2.72675246 3.83E-23 SLC7A8 
219561_at 2.727281932 5.46E-20 COPZ2 
206987_x_at 2.733241904 8.93E-23 FGF18 
210886_x_at 2.734013152 1.18E-22 TP53TG1 
202086_at 2.734053393 1.34E-20 MX1 
218182_s_at 2.734588961 1.43E-23 CLDN1 
211538_s_at 2.736931126 1.87E-20 HSPA2 
221969_at 2.739111186 9.26E-25 NA 
218831_s_at 2.74041632 3.51E-23 FCGRT 
204867_at 2.740742067 1.12E-22 GCHFR 
226388_at 2.740900213 2.69E-19 TCEA3 
222446_s_at 2.741084196 1.09E-29 BACE2 
214577_at 2.744038735 7.56E-19 MAP1B 
228570_at 2.744539538 8.28E-23 BTBD11 
235567_at 2.746922896 1.03E-25 RORA 
207156_at 2.74706823 8.98E-21 HIST1H2AG 
1554711_at 2.747710605 6.88E-24 CALHM3 
239253_at 2.748044295 8.25E-21 NA 
226880_at 2.750824571 3.51E-29 NUCKS1 
234937_x_at 2.751097385 2.70E-23 ZFP28 
242218_at 2.759858224 2.16E-22 PPARD 
211259_s_at 2.760066972 1.86E-25 BMP7 
228642_at 2.763479147 2.92E-21 NA 
235652_at 2.765957674 1.66E-21 NA 
219682_s_at 2.769690004 1.30E-23 TBX3 
201289_at 2.770069888 6.99E-22 CYR61 
206670_s_at 2.771756305 3.63E-26 GAD1 
163 
215143_at 2.777088868 2.86E-27 DPY19L2P2 
206027_at 2.777527968 2.63E-18 S100A3 
223879_s_at 2.778035041 2.40E-24 OXR1 
219956_at 2.778433201 6.63E-25 GALNT6 
234921_at 2.779834627 1.67E-25 ZNF470 
209882_at 2.780056048 8.17E-22 RIT1 
221679_s_at 2.783758889 2.15E-25 ABHD6 
1554588_a_at 2.787018053 5.53E-23 TTC30B 
205278_at 2.787437337 8.43E-25 GAD1 
204249_s_at 2.78859104 6.91E-20 LMO2 
235085_at 2.788616539 1.87E-25 PRAGMIN 
206529_x_at 2.790086911 3.97E-18 SLC26A4 
230921_s_at 2.792987468 2.90E-23 PCBP2 
210105_s_at 2.798231022 2.73E-19 FYN 
223380_s_at 2.800396774 1.20E-27 LATS2 
225147_at 2.806400148 1.62E-26 CYTH3 
222471_s_at 2.807653539 1.75E-25 KCMF1 
236646_at 2.81320894 5.58E-25 C12orf59 
226558_at 2.813509149 1.95E-24 MAFIP 
204890_s_at 2.815517589 3.15E-23 LCK 
230621_at 2.817255849 7.34E-25 IAH1 
238694_at 2.818601233 2.38E-24 NA 
218747_s_at 2.820068988 7.00E-24 TAPBPL 
238657_at 2.82400144 4.47E-22 UBXN10 
227949_at 2.825372558 4.84E-25 PHACTR3 
210281_s_at 2.828039059 8.43E-24 ZMYM2 
37966_at 2.831967027 7.81E-25 PARVB 
222447_at 2.840431917 3.13E-25 METTL9 
227931_at 2.847320339 2.61E-21 INO80D 
233555_s_at 2.847941069 1.21E-24 SULF2 
1558762_a_at 2.848265911 2.08E-26 ZNF789 
203962_s_at 2.850394472 2.11E-17 NEBL 
201110_s_at 2.852335514 1.58E-20 THBS1 
233078_at 2.8544519 2.09E-25 API5 
224558_s_at 2.854875645 6.10E-22 MALAT1 
228443_s_at 2.856889863 1.25E-27 SETD8 
223761_at 2.85812778 1.20E-21 FGF19 
236266_at 2.858944632 6.05E-23 RORA 
213170_at 2.861273196 1.65E-24 GPX7 
1557167_at 2.862626168 1.08E-27 HCG11 
1555882_at 2.863408774 9.28E-21 SPIN3 
164 
216442_x_at 2.864553299 8.49E-22 FN1 
214285_at 2.864898698 6.56E-22 FABP3 
219471_at 2.875115171 1.22E-21 C13orf18 
210764_s_at 2.875186002 3.15E-21 CYR61 
215779_s_at 2.878489324 8.14E-21 HIST1H2BG 
218704_at 2.879029597 4.53E-12 RNF43 
220120_s_at 2.879997514 7.85E-21 EPB41L4A 
202196_s_at 2.883172702 7.85E-21 DKK3 
203780_at 2.891948589 2.12E-21 MPZL2 
205896_at 2.897695863 8.50E-23 SLC22A4 
219229_at 2.904763308 1.64E-22 SLCO3A1 
229138_at 2.914177929 7.07E-26 PARP11 
239201_at 2.92142664 4.56E-25 PFTK2 
216033_s_at 2.926287099 1.24E-18 FYN 
209684_at 2.926710608 1.72E-21 RIN2 
218197_s_at 2.927985173 3.53E-26 OXR1 
217875_s_at 2.928532323 5.16E-23 PMEPA1 
220198_s_at 2.930982355 4.69E-17 EIF5A2 
225999_at 2.936788241 6.42E-25 RIMKLB 
207819_s_at 2.940537895 9.51E-22 ABCB4 
229715_at 2.942281878 1.85E-23 NA 
229374_at 2.944915381 2.32E-19 EPHA4 
236224_at 2.945667905 1.34E-24 RIT1 
212810_s_at 2.951099474 7.94E-21 SLC1A4 
206094_x_at 2.953284642 3.30E-22 UGT1A6 
203726_s_at 2.957757615 3.05E-21 LAMA3 
211685_s_at 2.96149178 1.05E-23 NCALD 
221210_s_at 2.96479409 3.44E-23 NPL 
206018_at 2.965856536 7.22E-27 FOXG1 
202520_s_at 2.966266328 1.86E-29 MLH1 
235296_at 2.96673825 1.28E-17 EIF5A2 
205027_s_at 2.96787861 1.54E-19 MAP3K8 
221701_s_at 2.969423295 1.34E-24 STRA6 
204532_x_at 2.97400928 1.90E-23 UGT1A9 
212464_s_at 2.974592447 2.25E-21 FN1 
218959_at 2.978045777 9.68E-24 HOXC10 
208523_x_at 2.983316263 6.20E-23 HIST1H2BI 
208359_s_at 2.988707177 3.11E-25 KCNJ4 
209678_s_at 2.990360354 1.67E-27 PRKCI 
207433_at 2.992147196 4.72E-27 IL10 
209738_x_at 2.992733224 2.80E-24 PSG6 
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213304_at 2.994941365 1.24E-23 FAM179B 
223821_s_at 3.007094886 2.34E-25 SUSD4 
222772_at 3.007656919 1.50E-24 MYEF2 
204682_at 3.009389542 1.25E-23 LTBP2 
207457_s_at 3.010484146 2.24E-25 LY6G6D 
1555935_s_at 3.011664905 1.27E-25 HUNK 
230659_at 3.014414171 4.62E-24 NA 
212678_at 3.018656696 1.64E-22 NF1 
1557051_s_at 3.01880922 1.81E-22 NA 
212486_s_at 3.021382261 8.28E-21 FYN 
239302_s_at 3.022161904 2.52E-23 NA 
1569003_at 3.023956205 3.13E-25 TMEM49 
236893_at 3.027199566 1.57E-21 LOC404266 
242053_at 3.029760682 2.21E-27 TSGA10 
203973_s_at 3.033407815 1.60E-27 CEBPD 
207126_x_at 3.034107725 2.01E-23 UGT1A1 
204702_s_at 3.037002154 1.26E-23 NFE2L3 
226985_at 3.03917817 2.59E-22 FGD5 
230543_at 3.039482654 1.06E-21 USP9X 
219414_at 3.042323841 3.44E-24 CLSTN2 
242919_at 3.042397123 3.76E-25 ZNF253 
226368_at 3.044476729 2.41E-26 CHST11 
229889_at 3.049284265 2.25E-24 C17orf76 
226438_at 3.05300151 6.45E-25 SNTB1 
222787_s_at 3.054226348 9.72E-22 TMEM106B 
226462_at 3.058577494 9.73E-22 STXBP6 
212624_s_at 3.058729751 1.93E-15 CHN1 
205031_at 3.066126601 5.28E-27 EFNB3 
222833_at 3.067725068 3.50E-25 LPCAT2 
229307_at 3.067819733 5.74E-26 ANKRD28 
218559_s_at 3.068188107 7.24E-24 MAFB 
224341_x_at 3.069047039 4.37E-24 TLR4 
1553169_at 3.069946087 9.10E-26 LRRN4 
206377_at 3.078103353 3.17E-23 FOXF2 
242358_at 3.07827769 4.73E-26 NA 
213317_at 3.078925255 1.28E-24 CLIC5 
205569_at 3.080914454 1.49E-18 LAMP3 
225227_at 3.084100368 2.93E-22 NA 
210241_s_at 3.088168138 8.27E-27 TP53TG1 
207173_x_at 3.088815133 2.98E-19 CDH11 
201904_s_at 3.091204573 3.51E-29 CTDSPL 
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215821_x_at 3.091464394 4.46E-25 PSG3 
209395_at 3.099208694 8.28E-24 CHI3L1 
242277_at 3.101355236 3.39E-26 NA 
1553708_at 3.103480987 4.81E-27 MGC16075 
239503_at 3.103590838 1.88E-19 NA 
209755_at 3.104083386 5.00E-27 NMNAT2 
235749_at 3.104584658 1.90E-20 UGCGL2 
216604_s_at 3.106659642 5.35E-27 SLC7A8 
202007_at 3.110914043 9.98E-22 NID1 
219044_at 3.111074496 5.26E-24 THNSL2 
229026_at 3.118641983 1.29E-28 CDC42SE2 
212944_at 3.119559517 7.76E-20 SLC5A3 
227377_at 3.119606163 3.02E-23 IGF2BP1 
239598_s_at 3.120525058 5.40E-25 LPCAT2 
211596_s_at 3.124352767 5.91E-22 LRIG1 
230413_s_at 3.124654725 8.64E-21 NA 
210387_at 3.124719238 2.65E-25 HIST1H2BG 
211719_x_at 3.128023957 1.55E-22 FN1 
219221_at 3.128483641 3.35E-28 ZBTB38 
203779_s_at 3.130956385 8.77E-25 MPZL2 
205295_at 3.134799125 4.01E-23 CKMT2 
241359_at 3.144879456 1.99E-24 NA 
221795_at 3.146945213 5.05E-26 NTRK2 
202687_s_at 3.147073082 3.88E-25 TNFSF10 
214519_s_at 3.148534536 1.25E-23 RLN2 
228425_at 3.148587345 1.70E-24 LOC654433 
201906_s_at 3.151942859 1.08E-28 CTDSPL 
228291_s_at 3.152102348 1.34E-28 
NCRNA001
53 
242414_at 3.160941765 9.27E-26 QPRT 
222067_x_at 3.164923606 6.51E-23 HIST1H2BD 
225224_at 3.167873628 7.19E-25 C20orf112 
228260_at 3.167937441 1.93E-23 ELAVL2 
202150_s_at 3.169633642 1.48E-24 NEDD9 
209930_s_at 3.175048161 7.98E-24 NFE2 
235027_at 3.176345734 2.49E-22 NA 
213916_at 3.18346116 1.53E-23 ZNF20 
222760_at 3.188897031 4.01E-25 ZNF703 
210195_s_at 3.189117192 4.06E-21 PSG1 
225799_at 3.190146974 7.81E-24 LOC541471 
228496_s_at 3.191692441 2.44E-24 CRIM1 
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204268_at 3.194336992 2.70E-12 S100A2 
208527_x_at 3.197008809 1.13E-20 HIST1H2BE 
214469_at 3.197656593 2.54E-21 HIST1H2AE 
211819_s_at 3.202997316 3.66E-26 SORBS1 
228834_at 3.210596069 1.84E-28 TOB1 
214012_at 3.215036503 9.45E-27 ERAP1 
242931_at 3.219085974 3.83E-21 LONRF3 
229464_at 3.220409334 1.06E-24 MYEF2 
241710_at 3.238456722 3.97E-26 
hCG_16452
20 
209594_x_at 3.249023467 3.30E-23 PSG9 
1554241_at 3.250334949 6.28E-28 COCH 
205366_s_at 3.251242849 1.50E-25 HOXB6 
206404_at 3.25327442 8.87E-23 FGF9 
226381_at 3.255810971 3.17E-24 PS1TP4 
212676_at 3.259798167 2.42E-28 NF1 
203892_at 3.260253426 8.91E-26 WFDC2 
227145_at 3.261117526 1.73E-26 LOXL4 
230508_at 3.268772847 9.99E-22 DKK3 
207210_at 3.272731269 3.25E-20 GABRA3 
205258_at 3.273248638 3.05E-26 INHBB 
209904_at 3.277786804 5.07E-20 TNNC1 
226779_at 3.280685382 9.71E-23 NA 
209815_at 3.281610512 2.66E-21 PTCH1 
228915_at 3.285719453 1.55E-23 DACH1 
231583_at 3.290446809 4.08E-27 KRT74 
231382_at 3.291539204 4.79E-24 FGF18 
206114_at 3.292026783 5.59E-18 EPHA4 
222484_s_at 3.29309274 2.32E-28 CXCL14 
226400_at 3.297416583 1.23E-29 CDC42 
208490_x_at 3.302425158 1.54E-22 HIST1H2BF 
214343_s_at 3.303704979 1.50E-23 ATXN7L1 
1558103_a_at 3.304902938 1.27E-26 NA 
212811_x_at 3.305983632 1.97E-23 SLC1A4 
214051_at 3.312024364 7.00E-24 TMSB15B 
205591_at 3.313182374 2.55E-22 OLFM1 
215071_s_at 3.31669792 3.19E-20 HIST1H2AC 
1562019_at 3.321844815 9.45E-26 NT5DC4 
218137_s_at 3.32409875 1.09E-26 SMAP1 
204724_s_at 3.328063372 2.06E-22 COL9A3 
226235_at 3.328312862 5.92E-27 LOC339290 
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204044_at 3.331959558 3.91E-24 QPRT 
236193_at 3.332513301 1.50E-19 HIST1H2BC 
209806_at 3.343591279 1.58E-25 HIST1H2BK 
208257_x_at 3.34607547 1.01E-24 PSG1 
219961_s_at 3.354413029 2.87E-29 
NCRNA001
53 
237186_at 3.356912568 6.01E-26 NA 
205738_s_at 3.362927631 6.21E-21 FABP3 
209269_s_at 3.365373432 3.08E-24 SYK 
219848_s_at 3.368954135 2.70E-27 ZNF432 
224833_at 3.370488127 2.52E-18 ETS1 
225728_at 3.379041546 1.64E-26 SORBS2 
203961_at 3.379333563 1.24E-17 NEBL 
200854_at 3.379639302 1.86E-26 NCOR1 
202208_s_at 3.390133072 9.55E-27 ARL4C 
209911_x_at 3.390447922 9.77E-25 HIST1H2BD 
227051_at 3.393997025 1.21E-24 NA 
219557_s_at 3.394651404 4.89E-24 NRIP3 
228256_s_at 3.395902027 8.56E-19 EPB41L4A 
240277_at 3.397874068 5.77E-25 NA 
229125_at 3.404690429 1.24E-24 KANK4 
230518_at 3.407325711 1.56E-25 MPZL2 
201147_s_at 3.408915494 4.18E-22 TIMP3 
218002_s_at 3.413670852 4.90E-26 CXCL14 
236180_at 3.413725375 2.04E-24 NA 
209994_s_at 3.417156665 5.50E-24 ABCB1 
208180_s_at 3.418227421 1.66E-19 HIST1H4H 
206115_at 3.419306335 5.05E-20 EGR3 
204872_at 3.426118643 1.26E-26 TLE4 
203946_s_at 3.429296488 1.06E-23 ARG2 
242722_at 3.43132621 1.27E-26 LMO7 
221609_s_at 3.431766211 1.10E-25 WNT6 
218280_x_at 3.43358477 1.91E-21 
HIST2H2AA
3 
1553185_at 3.436712669 1.94E-26 RASEF 
205234_at 3.438681084 6.08E-28 SLC16A4 
229400_at 3.442130704 1.66E-24 HOXD10 
214175_x_at 3.442659003 2.87E-29 PDLIM4 
211084_x_at 3.447692676 7.57E-20 PRKD3 
203423_at 3.451237788 1.41E-20 RBP1 
204973_at 3.462579662 5.20E-26 GJB1 
214639_s_at 3.464284098 3.96E-23 HOXA1 
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226279_at 3.465148945 4.47E-26 PRSS23 
1553186_x_at 3.468866127 8.93E-28 RASEF 
219634_at 3.472907883 3.71E-28 CHST11 
224498_x_at 3.474353316 4.05E-24 AXIN2 
209032_s_at 3.483990832 2.30E-25 CADM1 
201162_at 3.486300954 3.21E-29 IGFBP7 
224724_at 3.486464188 6.31E-28 SULF2 
229534_at 3.487454536 1.20E-28 ACOT4 
243018_at 3.49147799 2.47E-24 NA 
1559584_a_at 3.493709322 6.23E-28 C16orf54 
229623_at 3.499105535 2.87E-29 FLJ12993 
212098_at 3.499524574 1.75E-31 LOC151162 
209590_at 3.504695514 2.55E-23 BMP7 
1555673_at 3.513525839 2.13E-16 KRTAP2-1 
222565_s_at 3.514912198 3.25E-18 PRKD3 
213131_at 3.516221723 7.26E-20 OLFM1 
206022_at 3.518190011 1.95E-26 NDP 
238695_s_at 3.521733381 6.95E-23 RAB39B 
223949_at 3.53259321 3.39E-27 TMPRSS3 
1558801_at 3.533063313 9.99E-29 NA 
209610_s_at 3.533881544 2.21E-24 SLC1A4 
210004_at 3.549781842 1.19E-21 OLR1 
235056_at 3.551035745 3.53E-24 ETV6 
227819_at 3.555562288 1.67E-24 LGR6 
240633_at 3.555740535 9.45E-27 DOK7 
222921_s_at 3.567858989 2.32E-26 HEY2 
238183_at 3.56870017 3.75E-24 NA 
212233_at 3.580045163 3.47E-21 MAP1B 
1553171_x_at 3.583225164 1.05E-29 LRRN4 
220122_at 3.587221935 6.69E-21 MCTP1 
214290_s_at 3.593323297 2.62E-22 
HIST2H2AA
3 
208608_s_at 3.593706296 1.16E-25 SNTB1 
242844_at 3.60342123 8.37E-29 PGGT1B 
1559283_a_at 3.60354118 1.55E-27 CNPY1 
214091_s_at 3.604606747 3.33E-27 GPX3 
228964_at 3.606325636 2.14E-22 PRDM1 
226372_at 3.615380692 1.81E-27 CHST11 
1557094_at 3.618353821 1.02E-24 LOC728449 
222747_s_at 3.62329679 9.18E-22 SCML1 
230372_at 3.624822182 3.35E-27 HAS2 
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213069_at 3.626213628 1.24E-25 HEG1 
238969_at 3.629876991 1.19E-27 C3orf55 
228948_at 3.631920862 7.17E-18 EPHA4 
227850_x_at 3.637266729 1.18E-26 CDC42EP5 
220994_s_at 3.639351184 3.26E-21 STXBP6 
235649_at 3.64769918 4.33E-24 ADAMTS8 
48106_at 3.656384257 2.87E-29 SLC48A1 
225841_at 3.65684861 9.99E-29 C1orf59 
235289_at 3.657854186 7.15E-22 EIF5A2 
237313_at 3.662435127 1.21E-27 NA 
212338_at 3.664925421 3.31E-25 MYO1D 
233819_s_at 3.669702757 5.04E-27 RNF160 
228865_at 3.669830923 5.52E-19 C1orf116 
204830_x_at 3.677088958 5.97E-26 PSG5 
238096_at 3.679980581 4.42E-26 LOC284023 
218416_s_at 3.68025929 6.90E-27 SLC48A1 
205646_s_at 3.680578535 6.28E-26 PAX6 
230748_at 3.692286047 4.72E-12 SLC16A6 
214696_at 3.699585888 7.46E-25 C17orf91 
220494_s_at 3.708426655 7.21E-30 NA 
206432_at 3.709321911 2.19E-25 HAS2 
225872_at 3.71195561 1.41E-28 SLC35F5 
228904_at 3.713381355 7.66E-30 HOXB3 
236235_at 3.718283344 1.83E-28 ITCH 
228345_at 3.726095245 4.01E-27 CHIC1 
1555355_a_at 3.729906852 5.07E-22 ETS1 
226085_at 3.738869522 1.80E-28 CBX5 
221214_s_at 3.743771322 4.89E-29 NELF 
232203_at 3.745645043 9.29E-32 NA 
202146_at 3.750056622 1.10E-26 IFRD1 
230075_at 3.755303862 7.34E-25 RAB39B 
208546_x_at 3.759832814 9.32E-22 HIST1H2BH 
205632_s_at 3.761877371 2.25E-28 PIP5K1B 
201150_s_at 3.762011986 5.12E-23 TIMP3 
205201_at 3.772931511 9.23E-27 GLI3 
208579_x_at 3.780347319 4.57E-22 H2BFS 
205531_s_at 3.79027671 3.22E-27 GLS2 
206002_at 3.792491392 4.65E-27 GPR64 
207540_s_at 3.799417725 2.05E-23 SYK 
220102_at 3.805958165 3.23E-26 FOXL2 
218952_at 3.814312485 3.19E-30 PCSK1N 
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207060_at 3.823088997 9.94E-28 EN2 
220394_at 3.823936895 1.39E-27 FGF20 
214660_at 3.824036967 2.61E-26 ITGA1 
204790_at 3.826606855 2.00E-27 SMAD7 
202147_s_at 3.828678788 1.32E-27 IFRD1 
239647_at 3.838528607 2.70E-27 CHST13 
219778_at 3.844163234 1.36E-26 ZFPM2 
204584_at 3.849827547 8.78E-27 L1CAM 
240211_at 3.851610171 3.39E-29 
LOC100130
468 
201249_at 3.864588999 1.09E-26 SLC2A1 
218793_s_at 3.869769929 3.45E-14 SCML1 
243179_at 3.870345274 1.08E-27 
LOC100130
360 
238937_at 3.88472757 3.24E-26 ZNF420 
218330_s_at 3.885973773 2.99E-21 NAV2 
236083_at 3.897142097 6.89E-25 BCL2L15 
1553972_a_at 3.900856051 2.03E-23 CBS 
232035_at 3.907804241 1.13E-20 HIST4H4 
204469_at 3.91159933 5.31E-26 PTPRZ1 
208596_s_at 3.913039415 1.02E-24 UGT1A3 
226731_at 3.926404968 6.57E-28 PELO 
209493_at 3.931165422 1.09E-26 PDZD2 
236420_s_at 3.954543082 3.21E-29 ANO4 
210479_s_at 3.967363693 5.75E-28 RORA 
225978_at 3.96824882 2.85E-29 RIMKLB 
201008_s_at 3.971573101 7.15E-31 TXNIP 
202627_s_at 3.973616853 4.46E-23 SERPINE1 
213620_s_at 3.975647758 1.10E-25 ICAM2 
227565_at 3.975884347 2.98E-23 NA 
1564706_s_at 3.980337827 6.41E-27 GLS2 
222695_s_at 3.989645196 3.80E-26 AXIN2 
218417_s_at 4.004491731 9.46E-29 SLC48A1 
212816_s_at 4.010155616 3.38E-23 CBS 
228600_x_at 4.027358429 9.54E-25 C7orf46 
209201_x_at 4.028777862 7.41E-25 CXCR4 
208607_s_at 4.034989312 9.99E-29 SAA2 
224851_at 4.035295105 3.92E-20 CDK6 
222925_at 4.03948058 8.30E-32 DCDC2 
232297_at 4.039491621 4.65E-24 NA 
226068_at 4.041592156 4.09E-21 SYK 
213048_s_at 4.041706887 3.33E-29 NA 
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44790_s_at 4.042203229 1.50E-25 C13orf18 
227889_at 4.046036821 7.95E-28 LPCAT2 
229912_at 4.075280266 1.33E-26 SDK1 
226875_at 4.078960786 9.35E-27 DOCK11 
203381_s_at 4.097717865 3.23E-26 APOE 
242761_s_at 4.100822533 2.58E-25 ZNF420 
210140_at 4.103643002 6.80E-30 CST7 
211002_s_at 4.11660951 3.08E-28 TRIM29 
235740_at 4.11663046 2.81E-23 NA 
242383_at 4.12562674 7.51E-25 NA 
1558102_at 4.130863136 5.43E-28 NA 
219476_at 4.144578882 5.94E-22 C1orf116 
218236_s_at 4.150359247 2.32E-15 PRKD3 
211919_s_at 4.163901543 7.34E-25 CXCR4 
227647_at 4.164212433 2.89E-25 KCNE3 
229613_at 4.165578886 1.21E-30 NA 
204891_s_at 4.181607846 3.89E-29 LCK 
236917_at 4.181801964 7.60E-30 LRRC34 
210426_x_at 4.205522322 4.53E-30 RORA 
216603_at 4.210926725 3.24E-28 SLC7A8 
206224_at 4.213573867 1.03E-24 CST1 
243495_s_at 4.216301839 3.78E-27 NA 
208481_at 4.216352669 2.92E-29 ASB4 
227449_at 4.217585021 2.97E-13 EPHA4 
1554026_a_at 4.236308926 9.46E-25 MYO10 
235795_at 4.248285776 3.31E-24 PAX6 
213479_at 4.252895427 1.08E-27 NPTX2 
218803_at 4.260248536 7.66E-30 CHFR 
202982_s_at 4.265488808 7.10E-29 ACOT2 
207038_at 4.27226843 2.34E-15 SLC16A6 
214455_at 4.273043763 5.91E-21 HIST1H2BC 
201250_s_at 4.282654706 2.16E-24 SLC2A1 
226084_at 4.283899123 1.96E-23 MAP1B 
218454_at 4.285978428 1.30E-27 PLBD1 
214995_s_at 4.287614379 1.42E-30 APOBEC3F 
240572_s_at 4.288868869 2.99E-27 LOC374443 
228920_at 4.299633496 2.07E-29 ZNF260 
227099_s_at 4.300338886 7.49E-28 LOC387763 
219117_s_at 4.301041604 1.54E-29 FKBP11 
236471_at 4.308036167 7.46E-24 NFE2L3 
203815_at 4.310438056 7.98E-31 GSTT1 
173 
217228_s_at 4.315831944 1.11E-28 ASB4 
219118_at 4.320368737 1.67E-27 FKBP11 
235457_at 4.330850064 4.13E-30 MAML2 
213285_at 4.334974113 4.48E-27 TMEM30B 
231849_at 4.341804272 1.60E-30 KRT80 
211071_s_at 4.348007242 5.99E-25 MLLT11 
202783_at 4.363360503 2.22E-32 NNT 
221648_s_at 4.395444773 7.37E-29 NA 
204042_at 4.406209156 6.76E-25 WASF3 
205003_at 4.411778434 1.81E-19 DOCK4 
228266_s_at 4.418838091 2.73E-29 HDGFRP3 
215125_s_at 4.423254251 1.19E-27 UGT1A@ 
202207_at 4.430268677 6.79E-26 ARL4C 
212143_s_at 4.4325135 9.68E-31 IGFBP3 
203508_at 4.45742527 8.66E-28 TNFRSF1B 
212776_s_at 4.462552662 3.47E-28 OBSL1 
222771_s_at 4.466520226 1.28E-29 MYEF2 
206029_at 4.488030927 3.18E-28 ANKRD1 
229215_at 4.495802842 1.23E-30 ASCL2 
236979_at 4.506821068 6.37E-31 BCL2L15 
205110_s_at 4.514206803 3.13E-27 FGF13 
219109_at 4.51482857 3.96E-30 SPAG16 
1558388_a_at 4.519733027 9.21E-25 NA 
222449_at 4.524503386 1.64E-30 PMEPA1 
203559_s_at 4.524531879 7.53E-30 ABP1 
227753_at 4.532066865 1.50E-27 TMEM139 
222150_s_at 4.5404784 2.07E-30 PION 
221666_s_at 4.544133022 1.88E-31 PYCARD 
222513_s_at 4.572953768 1.11E-28 SORBS1 
226829_at 4.579320075 4.97E-29 AFAP1L2 
214571_at 4.581354757 8.54E-30 FGF3 
213789_at 4.584017391 3.35E-28 EBP 
205858_at 4.608291805 2.45E-26 NGFR 
204523_at 4.612446101 3.79E-32 ZNF140 
209591_s_at 4.628920548 1.66E-25 BMP7 
237720_at 4.629160973 1.69E-25 ASB4 
220048_at 4.632384526 9.52E-30 EDAR 
209030_s_at 4.633525554 1.96E-28 CADM1 
1569342_at 4.654604987 1.19E-31 GLI3 
243489_at 4.662489597 2.54E-25 NA 
221024_s_at 4.68438753 4.03E-30 SLC2A10 
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213142_x_at 4.686111868 1.13E-30 PION 
214456_x_at 4.703079815 4.23E-29 SAA2 
239791_at 4.709513144 1.07E-29 LOC404266 
211840_s_at 4.711666435 4.73E-29 PDE4D 
239153_at 4.720703792 4.89E-29 HOTAIR 
219563_at 4.726677676 1.36E-24 C14orf139 
209822_s_at 4.729414324 1.10E-30 VLDLR 
203799_at 4.730316936 1.86E-32 CD302 
202708_s_at 4.730427145 1.75E-25 HIST2H2BE 
227812_at 4.738529483 1.33E-28 TNFRSF19 
227279_at 4.746540064 1.87E-31 TCEAL3 
201010_s_at 4.759053982 5.51E-30 TXNIP 
1553602_at 4.762446302 1.53E-21 MUCL1 
209040_s_at 4.768668189 5.51E-30 PSMB8 
223434_at 4.770714033 1.50E-29 GBP3 
209101_at 4.777273007 9.79E-30 CTGF 
203030_s_at 4.78142293 4.93E-28 PTPRN2 
213164_at 4.784594136 4.26E-26 SLC5A3 
221796_at 4.785325049 3.61E-31 NTRK2 
211796_s_at 4.787469259 1.56E-28 IL23A 
201348_at 4.802407705 1.98E-29 GPX3 
229095_s_at 4.809985359 1.01E-28 LIMS3 
229634_at 4.810504894 1.08E-30 TMEM139 
201825_s_at 4.820029158 1.18E-29 SCCPDH 
229963_at 4.828070892 2.58E-30 BEX5 
202206_at 4.833388086 1.83E-28 ARL4C 
1553681_a_at 4.83503507 3.05E-30 PRF1 
1552626_a_at 4.843176559 6.32E-29 TMEM163 
202784_s_at 4.85124007 4.02E-30 NNT 
230560_at 4.856434044 3.43E-25 STXBP6 
235182_at 4.866079067 2.32E-26 ISM1 
211966_at 4.879895185 9.03E-31 COL4A2 
232676_x_at 4.883374704 1.56E-33 MYEF2 
231940_at 4.893912693 1.75E-31 ZNF529 
201508_at 4.90618738 3.14E-28 IGFBP4 
228262_at 4.910615305 1.86E-28 MAP7D2 
209598_at 4.918544008 2.29E-31 PNMA2 
211549_s_at 4.938244818 3.08E-30 HPGD 
202283_at 4.943811341 6.40E-31 SERPINF1 
240687_at 4.951694879 2.11E-31 PASD1 
224176_s_at 4.964145784 1.71E-28 AXIN2 
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229830_at 4.969258134 4.21E-29 PDGFA 
222450_at 4.977795355 5.32E-31 PMEPA1 
227236_at 5.024594887 8.77E-30 TSPAN2 
1558700_s_at 5.038946702 3.00E-31 ZNF260 
216693_x_at 5.054395533 1.21E-29 HDGFRP3 
204045_at 5.054625784 9.95E-33 TCEAL1 
209387_s_at 5.060435864 7.03E-32 TM4SF1 
231867_at 5.065919831 5.32E-31 ODZ2 
214247_s_at 5.076833805 3.89E-29 DKK3 
238780_s_at 5.077502968 2.44E-28 NA 
204932_at 5.102161875 6.22E-26 
TNFRSF11
B 
228523_at 5.106581599 1.84E-26 NANOS1 
242013_at 5.114226909 1.55E-31 BCL2L15 
218963_s_at 5.114492799 8.34E-14 KRT23 
203029_s_at 5.12017628 2.12E-26 PTPRN2 
202286_s_at 5.137666 3.47E-17 TACSTD2 
222803_at 5.152802825 1.99E-31 PRTFDC1 
209526_s_at 5.15724731 7.00E-33 HDGFRP3 
222549_at 5.167696239 1.70E-33 CLDN1 
240055_at 5.174996434 3.92E-31 NA 
206560_s_at 5.178857464 2.57E-33 MIA 
218723_s_at 5.196995571 1.44E-27 C13orf15 
202628_s_at 5.213883908 2.83E-25 SERPINE1 
221558_s_at 5.248422657 2.73E-29 LEF1 
237721_s_at 5.275233137 3.34E-29 ASB4 
231227_at 5.278884299 9.59E-35 NA 
204933_s_at 5.302809105 1.66E-29 
TNFRSF11
B 
226682_at 5.31364024 5.80E-33 RORA 
201506_at 5.320158709 1.31E-30 TGFBI 
211429_s_at 5.323447734 4.90E-27 SERPINA1 
236918_s_at 5.339461334 2.16E-32 LRRC34 
230795_at 5.340692109 8.14E-27 NA 
209213_at 5.428561762 6.04E-33 CBR1 
203798_s_at 5.457496327 1.43E-31 VSNL1 
235940_at 5.463010338 9.49E-34 C9orf64 
203304_at 5.483975709 2.16E-22 BAMBI 
203797_at 5.509456097 3.95E-31 VSNL1 
219836_at 5.514210182 1.11E-29 ZBED2 
235845_at 5.52188532 3.92E-31 SP5 
218087_s_at 5.527335081 2.82E-28 SORBS1 
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226226_at 5.540056241 1.72E-32 TMEM45B 
203914_x_at 5.58234348 9.02E-31 HPGD 
223503_at 5.605728792 2.31E-30 TMEM163 
222696_at 5.615989091 1.36E-30 AXIN2 
210095_s_at 5.619119696 3.65E-31 IGFBP3 
209031_at 5.62842311 9.01E-32 CADM1 
214617_at 5.6378784 4.20E-29 PRF1 
210836_x_at 5.702551823 2.41E-32 PDE4D 
202504_at 5.717674814 5.82E-32 TRIM29 
212775_at 5.732467036 1.61E-34 OBSL1 
209386_at 5.755728019 2.29E-31 TM4SF1 
210837_s_at 5.771365504 9.54E-32 PDE4D 
211548_s_at 5.797156674 1.42E-30 HPGD 
202149_at 5.83374799 6.28E-31 NEDD9 
203474_at 5.838363348 4.93E-30 IQGAP2 
205399_at 5.885915621 9.99E-29 DCLK1 
211564_s_at 5.891723978 9.54E-32 PDLIM4 
221011_s_at 5.901510021 3.08E-30 LBH 
202833_s_at 5.906131804 8.46E-27 SERPINA1 
211003_x_at 5.906561411 2.07E-33 TGM2 
229580_at 5.970583176 5.37E-34 NA 
215034_s_at 6.072809343 7.03E-32 TM4SF1 
211573_x_at 6.081013458 5.83E-34 TGM2 
237974_at 6.093435795 4.30E-35 ABHD12B 
213425_at 6.10880796 7.00E-33 WNT5A 
211964_at 6.126274623 6.51E-32 COL4A2 
209655_s_at 6.202016916 3.69E-33 TMEM47 
217028_at 6.218488412 1.66E-25 CXCR4 
209524_at 6.247652627 8.35E-34 HDGFRP3 
205990_s_at 6.30708769 1.81E-34 WNT5A 
204205_at 6.331443474 6.93E-30 APOBEC3G 
203913_s_at 6.452092708 1.34E-34 HPGD 
232231_at 6.49125603 7.28E-16 RUNX2 
235619_at 6.531240266 5.60E-35 LOC285986 
229800_at 6.665510164 1.81E-35 DCLK1 
228962_at 6.692436894 4.08E-33 PDE4D 
204115_at 6.719502089 1.61E-34 GNG11 
230323_s_at 6.831382501 9.04E-35 TMEM45B 
207935_s_at 6.88218859 1.96E-34 KRT13 
201042_at 6.970819459 7.13E-35 TGM2 
236892_s_at 7.016783909 5.91E-36 LOC404266 
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201426_s_at 7.036826527 5.91E-30 VIM 
203413_at 7.099925614 6.04E-33 NELL2 
227376_at 7.130645468 6.10E-35 GLI3 
204491_at 7.24870063 8.28E-37 PDE4D 
214023_x_at 7.270976799 3.97E-36 TUBB2B 
201163_s_at 7.309927506 5.60E-35 IGFBP7 
216236_s_at 7.387604268 9.53E-28 SLC2A14 
228335_at 7.391273205 7.80E-38 CLDN11 
205174_s_at 7.717056894 8.70E-37 QPCT 
202497_x_at 7.75240915 3.31E-26 SLC2A3 
201820_at 7.777504885 7.14E-36 KRT5 
200799_at 7.801303143 1.24E-33 HSPA1A 
223800_s_at 7.804629034 1.05E-32 LIMS3 
202498_s_at 7.843883924 2.75E-27 SLC2A3 
222088_s_at 7.847920371 6.59E-27 SLC2A14 
227475_at 7.989488515 3.57E-34 FOXQ1 
202499_s_at 8.332857437 3.30E-24 SLC2A3 
209656_s_at 8.729730884 5.08E-35 TMEM47 
225016_at 9.310729468 2.09E-36 APCDD1 
 
Global gene expression analysis of SW480vector and SW480Smad4 colon 
cancer cells by microarray was performed to assess changes in gene 
expression caused by restored Smad4 expression.  We used the 
following stringent criteria to determine differential expression of 
SW480vector compared with SW480Smad4 colon cancer cells:  FDR<0.005 
and fold-change >4 (see Materials and Methods) to obtain an epithelial 
specific, Smad4 expression profile.  Up-regulated and down-regulated 
Affymetrix probesets are displayed along with the log2 coefficient, FDR 
and gene symbol.   A negative coefficient in this analysis indicates up-
regulation in the presence of Smad4 and a positive coefficient indicates 
down-regulation in the presence of Smad4. 
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TABLE 12 
 
WNT TARGET LIST GENE IDENTIFIERS 
 
 
 
Gene ID Gene 
Gene 
Symbol 
Cells or tissue 
validation 
Reference 1:  PMID Reference 2:  PMID 
4609 c-myc MYC human colon cancer  He 1998:  9727977  
4613 n-myc MYCN mesenchyme limbs 
Ten Berge 2008:  
18776145 
 
595 Cyclin D CCND1 human colon cancer Tetsu 1999: 10201372 
Shtutman 1999:  
10318916 
6932  Tcf-1 TCF7 human colon cancer  Roose 1999:  10489374  
51176 LEF1 LEF1 human colon cancer 
Hovanes, 2001:  
11326276 
Filali 2002:  12052822 
5467  PPARdelta PPARD human colon cancer  He TC,1999:  10555149   
3725  c-jun JUN human colon cancer  Mann B, 1999:  9990071  
8061  fra-1 FOSL1 human colon cancer  Mann B, 1999:  9990071  
5329  uPAR PLAUR human colon cancer  Mann B, 1999:  9990071  
4316 
matrix metalloproteinase 
MMP-7 
MMP7 human colon cancer Brabletz 1999:  10514384 
Crawford 1999:  
10362259 
8313 Axin-2 AXIN2 human colon cancer Yan, 2001:  11752446 Lustig, 2002:  11809809 
4897 Nr-CAM NRCAM human colon cancer 
Conacci-Sorrell 2002:  
12183361 
 
6925 ITF-2 TCF4 human colon cancer Kolligs, 2002:  12086873  
2520 Gastrin GAST human colon cancer Koh, 2000:  10953028  
960 CD44 CD44 human colon cancer 
Wielenga 1999:  
10027409 
 
1948 EphB/ephrin-B EFNB2 human colon cancer Batlle, 2002:  12408869  
1947 EphB/ephrin-B EFNB1 human colon cancer Batlle, 2002:  12408869  
1949 EphB/ephrin-B EFNB3 human colon cancer Batlle, 2002:  12408869  
652 BMP4 BMP4 human colon cancer Kim 2002:  12019147  
9076 claudin-1 CLDN1 human colon cancer Miwa 2002:  11939410  
332 Survivin BIRC5 human colon cancer Zhang, 2001:  11751382  
7422 VEGF VEGFA human colon cancer Zhang, 2001:  11507052  
8817 FGF18 FGF18 human colon cancer 
Shimokawa 2003:  
14559787 
 
474 Hath1 ATOH1 human colon cancer Leow 2004:  15342386  
4233 Met MET human colon cancer Boon 2002:  12234972  
1906 endothelin-1 EDN1 human colon cancer Kim 2005:  15558022  
26292 c-myc binding protein MYCBP human colon cancer Jung 2005:  15979100  
3897 L1 neural adhesion L1CAM human colon cancer Gavert 2005:  15716380  
3398 Id2 ID2 human colon cancer 
Rockman 2001:  
11572874 
Willert 2002:  12095419 
(see this paper for others) 
182 Jagged JAG1 human colon cancer Rodilla, 2009:  19325125  
7074 Tiam1 TIAM1  Colon tumors Malliri 2005:  16249175  
4843 Nitric Oxide Synthase 2 NOS2 
Hepg2, Hct116  and dld-
1 cells 
Du, 2006  
22943 Dickkopf DKK1 Various cells, tumors Niida 2004:  15378020  
Gonzalez-Sancho 2004:  
15592505 
2254 FGF9 FGF9 
ovarian endometrioid 
adenocarcinoma 
Hendrix, 2006:  16452189  
26281 FGF20 FGF20 Various cells, tumors 
Chamorro 2004:  
15592430 
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8549 LGR5/GPR49 LGR5 Intestine Barker, 2007:  17934449  
6662 Sox9 SOX9 Intestine Blache 2004:  15240568  
6662 Sox9 SOX9 mesenchyme Hill, 2005:  15866163 Day 2005:  15866164 
860 Runx2 RUNX2 chondrocytes Dong 2006 Hill, 2005:  15866163 
64388 Gremlin GREM2 fibroblasts 
Klapholz-Brown 2007:  
17895986 
 
57167 SALL4 SALL4  Bohm, 2006:  16899215  
8792 RANK ligand TNFRSF11A Osteoblasts Spencer 2006  
3491 CCN1/Cyr61 CYR61 Osteoblasts Si, 2006:  16581771  
6657 Sox2 SOX2 Xenopus retina 
Van Raay, 2005:  
15820691 
 
9232 
Pituitary tumor transforming 
gene (PTTG) 
PTTG1 
esophageal squamous cell 
carcinoma 
Zhou 2004:  15514942  
28514 Delta-like 1 DLL1 somites 
Galceran, 2004:  
15545629 
Hofmann 2004:  
15545628 
8456 FoxN1 FOXN1 thymus 
Balciunaite 2002:  
12379851 
 
56547 matrix metalloproteinase-26 MMP26 Human 
Marchenko 2002:  
11931652 
 
79923 nanog NANOG ES Pereira, 2006:  16894029 Cole 2008:  18347094 
5460 POU5F1 (aka oct4) POU5F1 ES Cole 2008:  18347094  
6615 snail SNAI1 ES/EB 
Ten Berge 2008:  
18983966 
 
2335 Fibronectin FN1 ES/EB 
Ten Berge 2008:  
18983966 
 
8324 Frizzled 7 FZD7 EC cells Willert 2002:  12095419  
10468 Follistatin FST EC cells, ovary Willert 2002:  12095419 Yao 2004:  15162500  
89780 Wnt3a WNT3A EC cells Zhang 2009:  19109969  
2335 Fibronectin FN1 Mouse lung 
De Langhe 2005:  
15617677 
 
3670 Islet1 ISL1 Cardiac cells Lin 2007:  17519333  
4313 MMP2 MMP2 T cells Wu 2007:  17306568  
4318 MMP9 MMP9 T cells Wu 2007:  17306568  
2335  fibronectin FN1  Xenopus  Gradl 1999:  10409747  
652  BMP4 BMP4  Xenopus  Baker 1999:  10601040  
n/a  myogenic bHLH MYOD1  Xenopus 
 Munsterberg 1995:  
7498788 
 
2020  engrailed-2 EN2  Xenopus 
 McGrew 1999:  
10495268 
 
2697  connexin43 GJA1  Xenopus, Mouse 
 van der Heyden 1998:  
9601103 
 
10804  connexin 30 GJB6  Xenopus 
 McGrew 1999:  
10495268 
 
5916  retinoic acid receptor gamma RARG  Xenopus 
 McGrew 1999:  
10495268 
 
4286  MITF/nacre MITF  Zebrafish  Dorsky, 2000:  10652270 Saito 2002:  12048204 
64220 Stra6 STRA6 
Wnt-1 transformed 
mouse cells 
Szeto 2001:  11358845  
58480 Wrch-1 RHOU 
Wnt-1 transformed 
mouse cells 
Tao, 2001:  11459829  
3604 TNF family 41BB ligand TNFRSF9 
Wnt-1 transformed 
mouse cells 
Tice 2002:  11832495  
1947 ephrinB1 EFNB1 
Wnt-1 transformed 
mouse cells 
Tice 2002:  11832495  
64220 Stra6 STRA6 
Wnt-1 transformed 
mouse cells 
Tice 2002:  11832495  
5168 autotaxin  ENPP2 
Wnt-1 transformed 
mouse cells 
Tice 2002:  11832495  
3671  ISLR ISLR 
Wnt-1 transformed 
mouse cells 
Tice 2002:  11832495  
7291 Twist TWIST1 
Wnt1 induced mammary 
cancer 
Howe, 2003:  12702582  
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4314 Stromelysin MMP3 
Wnt-1 transformed 
mouse cells 
Prieve, 2003:  12697065  
51429  WISP SNX9 
Wnt-1 transformed 
mouse cells 
Xu, 2000:  10716946  
2641 Proglucagon GCG Mouse Ni 2003:  12421827  
632 Osteocalcin BGLAP Mouse Kahler 2003:  12551949  
1044 Cdx1 CDX1 Mouse embryo Pilon 2007:  17537796  
5743 cyclooxygenase-2 PTGS2 mouse (Wnt-1) Howe 1999:  10197631 
Haertel-Wiesmann 
2000:  10884377 
79191 Irx3 IRX3 Mouse brain Braun 2003:  14522868  
6496 Six3 SIX3 Mouse brain Braun 2003:  14522868  
4762 neurogenin 1 NEUROG1 Mouse brain 
Hirabayashi 2004:  
15142975 
 
389058 SP5 SP5 Mouse brain 
Weidinger 2005:  
15797017 
 Fujimura 2007:  
17090534 
4821 Nkx2.2 NKX2-2 Neural tube Lei, 2006:  16950124  
3569 IL-6 IL6 3T3-L1 Preadipocytes Longo, 2002:  12154096  
420322 WISP-1 WISP1 3T3-L1 Preadipocytes Longo, 2002:  12154096  
8839 WISP-2 WISP2 3T3-L1 Preadipocytes Longo, 2002:  12154096  
3481 IGF-II  IGF2 3T3-L1 Preadipocytes Longo, 2002:  12154096  
10296 Emp MAEA 3T3-L1 Preadipocytes Longo, 2002:  12154096  
3479  IGF-I IGF1 3T3-L1 Preadipocytes Longo, 2002:  12154096  
7424  VEGF-C VEGFC 3T3-L1 Preadipocytes Longo, 2002:  12154096  
5243 MDR1 ABCB1 3T3-L1 Preadipocytes Longo, 2002:  12154096  
10631 Â periostin POSTN  Mouse Wnt-3 
Haertel-Wiesmann 2000:  
10884377 
 
1044 Cdx1 CDX1  Mouse Wnt-3A  Lickert 2000:  10934025  
1046 Cdx4 CDX4 Mouse Wnt-3A Pilon, 2006:  16309666  
1046 Cdx4 CDX4 Zebrafish HSC 
Davidson 2003:  
13679919? 
 
8945 betaTRCP BTRC 293T and HeLa cells 
 Spiegelman 2000:  
10882123 
 
6423  sFRP-2 SFRP2  Mouse (Wnt-4) Lescher 1998:  9853965  
5308 Pitx2 PITX2 pituitary Kioussi 2002:  12464179  
1956 EGF receptor EGFR Liver Tan 2005:  16012954  
1896 Eda (TNF-related) EDA Mouse hair follicle 
Laurikkala 2002:  
11973284 
Durmowicz 2002:  
12039047 
999 E-cadherin CDH1 Mouse hair follicle Jamora, 2003:  12646922  
999 E-cadherin CDH1 ES/EB 
Ten Berge 2008:  
18983966 
 
3852 Keratin KRT5 Mouse hair follicle 
Dasgupta 1999:  
10498690 
 
182 Jagged1 JAG1 Mouse hair follicle Estrach, 2006:  17035290  
1029 P16ink4A CDKN2A Melanocytes Delmas, 2007:  18006687  
1493 CTLA-4 CTLA4 Melanomas Shah 2008:  18563180  
688 mBTEB2 KLF5  Mouse Ziemer 2001:  11134343  
2249 FGF4 FGF4 Mouse tooth bud 
Kratochwil 2002:  
12502739 
 
3576 Interleukin8 IL8 Endothelial cells 
Masckauchan 2005:  
16132617 
 
5979 ret RET rat PC12 Zheng, 1996:  8637712  
2697  connexin43 GJA1  rat cardiomyocytes Ai 2000:  10642594  
1462 versican VCAN 
vascular smooth muscle 
cells 
Rahmani 2005:  
15668231 
 
55504 Tnfrsf19 TNFRSF19 Somitic mesoderm Buttitta 2003:  12781685  
51035 Ubx UBXN1  Drosophila  Riese 1997:  9118221  
127733 Ubx UBXN10  Drosophila  Riese 1997: 9118221  
7993 Ubx UBXN8  Drosophila  Riese 1997:  9118221  
181 
7471 wingless WNT1  Drosophila  Yu 1998:  9835654  
655 BMP7 BMP7 
human colon cancer 
cells 
Hatzis MCB 2008:   
Beites CL:  19474151 
(weaker indirect evidence) 
652 Dpp BMP4 Drosophila  Yang, 2000:  10934014  
2019 Engrailed 1 EN1 human epithelial cells 
Bachar-Dahan, 2006:  
16571670 
 
8325  Dfrizzled2 FZD8  Drosophila 
 Cadigan 1998(Dfz2 human 
homolog=fz8):  9630221 
 
3219 HOXB9 homeobox B9 HOXB9 lung cancer cells 
Nguyen DX, 2009:  
19576624 
 
9314 KLF4 KLF4 intestinal cells 
Evans PM, 2009:  
19901072 
 
 
 
 
A table of annotated Wnt target genes is shown.  This list was used for Affymetrix input 
to obtain 282 resultant Affymetrix probes (not shown).  Gene identifier (ID), gene name 
and gene symbol are displayed in addition to validated cells/tissues as noted in the 
published literature.  The first author and PubMed Identifier (PMID) are listed for at least 
two references.  Source for the original list: 
http://www.stanford.edu/~rnusse/pathways/targets.html 
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Figure. 22:  (A) Smad4 colon cancer expression profile determination:  flow diagram.  The figure shows a 
flow-diagram of the development of a Smad4 gene expression profile in SW480 colon cancer cells 
(FDR<0.005 and fold-change>4).  1668 probesets were implicated which consisted of up-regulated (n=593) 
and down-regulated probesets (n=1075).  (B) Schema for determination of Wnt target gene enrichment in 
the Smad4 expression profile.  The SW480 Smad4 global expression profile (black circle, n=1668 
probesets) was used to determine if there was a significant enrichment of an annotated list of published Wnt 
target genes (gray circle, n=282 probesets) (see Table 12).  The table containing the enriched Smad4-
modulated Wnt targets is Table 13 (dark gray overlap, n=150 probe sets). 
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TABLE 13 
 
SMAD4-MODULATED, WNT ENRICHED TARGETS 
 
Affymetrix 
probe 
Coef FDR Gene Symbol 
213816_s_at -5.208338904 5.32E-31 MET 
221731_x_at -4.455090423 5.36E-15 VCAN 
203510_at -4.437460842 1.19E-27 MET 
204620_s_at -4.349783568 2.54E-15 VCAN 
213807_x_at -3.143497429 5.00E-27 MET 
215646_s_at -3.086916374 6.75E-11 VCAN 
204602_at -3.075203281 7.58E-13 DKK1 
211599_x_at -3.014005885 5.87E-27 MET 
211571_s_at -2.710027617 1.41E-10 VCAN 
204619_s_at -2.586155238 1.26E-10 VCAN 
207558_s_at -2.53932263 5.59E-20 PITX2 
238846_at -2.310058123 2.61E-18 TNFRSF11A 
213943_at -2.298439083 3.32E-20 TWIST1 
215983_s_at -1.755190399 3.48E-22 UBXN8 
212063_at -1.669196296 5.85E-19 CD44 
204489_s_at -1.47796131 1.43E-19 CD44 
202668_at -1.320836633 2.00E-14 EFNB2 
212014_x_at -1.218341893 6.15E-17 CD44 
202669_s_at -1.204038673 4.41E-12 EFNB2 
224471_s_at -1.198348701 6.04E-18 BTRC 
210512_s_at -1.191362159 6.80E-15 VEGFA 
202095_s_at -1.131580202 1.75E-17 BIRC5 
201130_s_at -1.119648171 3.52E-13 CDH1 
209835_x_at -1.092351031 3.57E-17 CD44 
204490_s_at -1.0777488 1.35E-16 CD44 
210916_s_at -1.073401268 2.69E-18 CD44 
204188_s_at -1.0290679 6.19E-17 RARG 
210513_s_at -1.018637972 5.13E-15 VEGFA 
211527_x_at -1.003293473 4.59E-15 VEGFA 
210334_x_at -0.983871923 2.44E-15 BIRC5 
1557905_s_at -0.921889157 1.15E-16 CD44 
211421_s_at -0.884091927 1.17E-09 RET 
217523_at -0.883786496 2.54E-07 CD44 
212171_x_at -0.868778847 5.80E-13 VEGFA 
201131_s_at -0.868599892 2.04E-11 CDH1 
216091_s_at -0.857392319 6.76E-14 BTRC 
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207037_at -0.819544417 7.66E-09 TNFRSF11A 
207922_s_at -0.769870439 3.69E-16 MAEA 
204189_at -0.682444519 1.54E-11 RARG 
202094_at -0.653995507 1.08E-10 BIRC5 
1565483_at -0.653204532 7.18E-05 EGFR 
204901_at -0.621820525 1.25E-11 BTRC 
205879_x_at -0.589409335 3.89E-10 RET 
203361_s_at -0.550288811 2.98E-11 MYCBP 
1565484_x_at -0.487337782 1.40E-06 EGFR 
203359_s_at -0.480112291 6.11E-10 MYCBP 
229221_at -0.476320032 7.40E-05 CD44 
219480_at -0.462653661 2.48E-05 SNAI1 
206634_at -0.412215743 8.90E-05 SIX3 
215771_x_at -0.397667812 1.19E-05 RET 
203360_s_at -0.331871568 4.56E-08 MYCBP 
221331_x_at -0.316135616 1.34634E-04 CTLA4 
220184_at -0.298162725 2.55565E-04 NANOG 
203936_s_at -0.273585702 1.88495E-04 MMP9 
207233_s_at 0.282372198 3.80852E-04 MITF 
209644_x_at 0.308520031 3.50E-07 CDKN2A 
223028_s_at 0.332644354 3.72E-06 SNX9 
209540_at 0.333169751 2.90847E-04 IGF1 
203554_x_at 0.363779621 1.07E-06 PTTG1 
210636_at 0.383131464 2.09E-06 PPARD 
223027_at 0.432717882 8.48E-10 SNX9 
211260_at 0.49250662 5.61E-08 BMP7 
204748_at 0.523747577 3.26E-05 PTGS2 
224325_at 0.581595283 2.83E-07 FZD8 
228038_at 0.595555086 6.04E-09 SOX2 
214701_s_at 0.601019473 1.18E-07 FN1 
221557_s_at 0.610681431 4.69E-07 LEF1 
211577_s_at 0.622106274 3.20E-06 IGF1 
221282_x_at 0.656272386 5.13E-08 RUNX2 
226066_at 0.664734161 3.36E-06 MITF 
204420_at 0.675402303 3.18E-07 FOSL1 
227405_s_at 0.686961958 2.83E-08 FZD8 
213281_at 0.700658487 2.24E-11 JUN 
201871_s_at 0.732825908 1.61E-13 UBXN1 
208044_s_at 0.739911957 2.13E-08 PPARD 
1569334_at 0.748543991 5.49E-11 STRA6 
218995_s_at 0.766521861 4.18E-10 EDN1 
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37152_at 0.842712279 8.64E-12 PPARD 
210984_x_at 0.858900718 5.11E-12 EGFR 
211607_x_at 0.863360829 9.39E-08 EGFR 
209541_at 0.869308094 2.14E-11 IGF1 
209542_x_at 0.952747647 1.05E-09 IGF1 
1569335_a_at 0.955531689 5.00E-12 STRA6 
223168_at 0.963972173 2.87E-06 RHOU 
201984_s_at 0.984776338 5.53E-09 EGFR 
205255_x_at 1.01704237 1.38E-14 TCF7 
205254_x_at 1.026916058 5.09E-14 TCF7 
201069_at 1.068712668 1.29E-11 MMP2 
232109_at 1.167483103 2.81E-13 UBXN10 
222802_at 1.199330545 1.62E-14 EDN1 
202936_s_at 1.293576102 4.93E-10 SOX9 
216417_x_at 1.298462572 1.13E-18 HOXB9 
226461_at 1.349730726 1.71E-19 HOXB9 
239178_at 1.439091976 1.24E-14 FGF9 
201983_s_at 1.446036871 2.78E-10 EGFR 
230092_at 1.459946709 1.42E-15 UBXN10 
206104_at 1.51025451 2.37E-12 ISL1 
201465_s_at 1.524742241 8.14E-16 JUN 
202935_s_at 1.54400712 4.70E-11 SOX9 
203705_s_at 1.582594184 1.73E-18 FZD7 
208711_s_at 1.588606808 7.87E-24 CCND1 
209993_at 1.73480427 3.59E-14 ABCB1 
211485_s_at 1.74932923 2.77E-20 FGF18 
202711_at 1.834688368 6.23E-19 EFNB1 
216994_s_at 1.873677384 7.74E-17 RUNX2 
209211_at 1.882266539 9.29E-18 KLF5 
224090_s_at 1.906822818 1.12E-20 TNFRSF19 
203706_s_at 1.940917236 3.28E-18 FZD7 
209212_s_at 1.97330756 7.51E-23 KLF5 
201565_s_at 1.982069503 6.20E-10 ID2 
208712_at 2.02402084 1.88E-24 CCND1 
201566_x_at 2.139151764 2.14E-10 ID2 
201464_x_at 2.171310811 1.69E-21 JUN 
210948_s_at 2.396963985 2.17E-21 LEF1 
213931_at 2.397088384 9.10E-12 ID2 
211029_x_at 2.462131571 4.47E-21 FGF18 
211518_s_at 2.462756098 5.24E-19 BMP4 
201466_s_at 2.56324932 6.42E-19 JUN 
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210495_x_at 2.592240002 6.08E-21 FN1 
223827_at 2.615606039 2.54E-22 TNFRSF19 
206987_x_at 2.733241904 8.93E-23 FGF18 
218182_s_at 2.734588961 1.43E-23 CLDN1 
242218_at 2.759858224 2.16E-22 PPARD 
211259_s_at 2.760066972 1.86E-25 BMP7 
201289_at 2.770069888 6.99E-22 CYR61 
238657_at 2.82400144 4.47E-22 UBXN10 
216442_x_at 2.864553299 8.49E-22 FN1 
210764_s_at 2.875186002 3.15E-21 CYR61 
221701_s_at 2.969423295 1.34E-24 STRA6 
212464_s_at 2.974592447 2.25E-21 FN1 
205031_at 3.066126601 5.28E-27 EFNB3 
211719_x_at 3.128023957 1.55E-22 FN1 
206404_at 3.25327442 8.87E-23 FGF9 
231382_at 3.291539204 4.79E-24 FGF18 
209994_s_at 3.417156665 5.50E-24 ABCB1 
224498_x_at 3.474353316 4.05E-24 AXIN2 
209590_at 3.504695514 2.55E-23 BMP7 
207060_at 3.823088997 9.94E-28 EN2 
220394_at 3.823936895 1.39E-27 FGF20 
204584_at 3.849827547 8.78E-27 L1CAM 
222695_s_at 3.989645196 3.80E-26 AXIN2 
209591_s_at 4.628920548 1.66E-25 BMP7 
227812_at 4.738529483 1.33E-28 TNFRSF19 
224176_s_at 4.964145784 1.71E-28 AXIN2 
222549_at 5.167696239 1.70E-33 CLDN1 
221558_s_at 5.248422657 2.73E-29 LEF1 
235845_at 5.52188532 3.92E-31 SP5 
222696_at 5.615989091 1.36E-30 AXIN2 
232231_at 6.49125603 7.28E-16 RUNX2 
201820_at 7.777504885 7.14E-36 KRT5 
Smad4-modulated, Wnt enriched target genes and their 
Affymetrix probe identifiers (IDs) are displayed.  Fold-change 
on a log2-scale, False Discovery Rate (FDR) and Gene 
Symbol are also displayed. A negative coefficient in this 
analysis indicates up-regulation in the presence of Smad4 
and a positive coefficient indicates down-regulation in the 
presence of Smad4. 
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Figure 32.  Derivation of epithelial-specific Smad4 targets and determination of Wnt 
enrichment.  (A) Schematic depiction of human Smad4-modulated gene expression profiling 
and pathway analysis.  The large black circle represents the human Smad4 gene expression 
profile (FDR<0.05, n=21889 probesets).  The small light gray circle represents the SW480 cell 
line Smad4 gene expression profile (FDR<0.005, fold-change>4, n=1668 probesets).  The 
darker gray overlap represents epithelial-specific Smad4 co-expression targets (n=787 
probesets).  (B) Schematic for determination of Smad4-modulated, Wnt-enriched epithelial-
specific targets for hierarchical and outcome analyses is displayed.  The dark gray circle 
represents epithelial-specific Smad4 co-regulated targets (n=787 probesets) and the light gray 
circle represents annotated Wnt targets (n=285 probesets).  The overlap represents epithelial-
specific Smad4-modulated Wnt target genes (n=32 probesets). 
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Primers used for quantitative real time PCR, RT-PCR and ChIP assays. 
Primer sets were ordered as indicated in Materials and Methods in Chapter III 
and forward and reverse sequences are displayed. 
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